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Abstract 
DNA is nature’s blueprint, holding within it the genetic code that defines the 
structure and function of an organism. A complex network of DNA-binding proteins called 
transcription factors can largely control the flow of information from DNA, so modulating 
the function of transcription factors is a promising approach for treating many diseases. 
Pyrrole-imidazole (Py-Im) polyamides are a class of DNA-binding oligomers, which can 
be synthetically programmed to bind a target sequence of DNA. Due to their unique shape 
complementarity and a series of favorable hydrogen bonding interactions that occur upon 
DNA-binding, Py-Im polyamides can bind to the minor groove of DNA with affinities 
comparable to transcription factors. Previous studies have demonstrated that these cell-
permeable small molecules can enter cell nuclei and disrupt the transcription factor-DNA 
interface, thereby repressing transcription. As the use of Py-Im polyamides has significant 
potential as a type of modular therapeutic platform, the need for polyamides with extremely 
favorable biological properties and high potency will be essential. Described herein, a 
variety of studies have been performed aimed at improving the biological activity of Py-Im 
polyamides. To improve the biological potency and cellular uptake of these compounds, we 
have developed a next-generation class of polyamides bearing aryl-turn moieties, a simple 
structural modification that allows significant improvements in cellular uptake. This 
strategy was also applied to a panel of high-affinity cyclic Py-Im polyamides, again 
demonstrating the remarkable effect minor structural changes can have on biological 
activity. The solubility properties of Py-Im polyamides and use of formulating reagents 
with their treatment have also been examined. Finally, we describe the study of Py-Im 
polyamides as a potential artificial transcription factor. 
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DNA Structure and Function 
 Deoxyribonucleic acid (DNA) is a biological macromolecule that contains genetic 
information encoding for the entire structure and function of all known organisms. Various 
biological characteristics are accounted for by individual genes made up of specific 
sequences of DNA that together provide a blueprint for life, the full set of which is called a 
genome. DNA’s primary structure consists of a backbone of alternating 2-deoxyribose 
sugar units and phosphate residues, which are joined by phosphodiester bonds at the 3’ and 
5’ positions of the sugar. Attached to each sugar at the 1’ position is one of four 
nucleobases: adenine (A), cytosine (C), guanine (G), or thymine (T). As it typically exists 
in nature, double-stranded DNA (dsDNA) contains two antiparallel strands of DNA in a 
double helix, forming a series of specific hydrogen bonding interactions between 
complementary nucleobases: A and T are specific for each other, as are C and G.   
 
Figure 1.1: The 3-D structure of helical dsDNA1 showing the backbone in blue and base pairs in gray, along 
with the minor and major grooves indicated and a set of base pairs highlighted (left), and the specific pairing 
of nucleobases attached to the sugar-phosphate DNA backbone (right). The two hydrogen bonding 
interactions between A and T and the three interactions between C and G are indicated in pink.  
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The Central Dogma of Molecular Biology 
 The term “central dogma” was first coined in 1958 by Walter Crick who later 
described it as dealing with “the detailed residue-by-residue transfer of sequential 
information [and] such information cannot be transferred from protein to either protein or 
nucleic acid.”2 Proteins are a type of biomacromolecule that consist of chains of linked 
amino acids that (depending on the sequence) can perform a variety of functions within 
organisms. Proven over many years, the basic concept behind the central dogma is that 
DNA serves as the genetic code, storing information in the form of genes that eventually 
lead to the production of specific proteins, but proteins can never transmit sequence 
information to lead directly back to the corresponding DNA. Encompassed in this idea are 
the processes of transcription and translation, which together provide the information 
transfer from DNA to protein. Transcription is the process that copies DNA sequence 
information into corresponding ribonucleic acid (RNA) chains. RNA is structurally similar 
to DNA, except for the presence of a 2’ hydroxyl group on the sugar moiety. There are a 
variety of types of RNA that can perform different functions, but in particular messenger 
RNA (mRNA) can allow for the production of proteins. In this process, called translation, 
sequence information is transferred from mRNA into a corresponding protein with a 
specific sequence of amino acids. Because proteins serve so many functions and 
misregulated protein expression is a factor in a variety of diseases, strategies to disrupt the 
pathway from DNA to RNA to protein for specific genes or subsets of genes may be of 
significant therapeutic value. 
 
 
 26 
Transcription Factors and Cellular Signaling 
Transcription factors (TFs) are a type of protein that can control the levels of 
transcription of a given gene, and often sets including multiple genes. This process is 
typically accomplished by non-covalent binding to a specific DNA sequence adjacent to a 
target gene, and either blocking (repression) or promoting (activation) the recruitment of 
RNA polymerase, the main enzyme responsible for transcription. Natural transcription 
factors vary in structure but typically consist of proteins bearing multiple domains that each 
serve specific functions such as a DNA-binding domain (DBD), a transcriptional activation 
domain (TAD), or a signal sensing domain (SSD). Transcription factors can bind to either 
the wider major groove or narrower minor groove of DNA, but in most cases, specific 
DNA-binding occurs via interaction between the DBD and 4-8 DNA nucleotides in a 
sequence specific fashion. These binding events can involve hydrogen bonding, 
electrostatic interactions, or van der Waals interactions with the base pairs or phosphate 
backbone of DNA. Proteins that bind to DNA, such as leucine zippers and zinc fingers, can 
bind as monomers, dimers, or in a combinatorial fashion where multiple DNA-binding 
proteins are required to regulate a certain gene.  
! 
Figure 1.2: Structures of DNA-binding proteins; A) GCN4, a homodimeric leucine zipper; B) NF-κB, a 
heterodimer of p50/p65; c) Androgen Receptor, which includes a ligand binding domain. 
 
B A C 
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Figure 1.3: Structure of the interferon-ß enhanceosome3, an example of combinatorial binding of a variety of 
proteins. This cooperative assembly occurs without any protein-protein contacts. 
 
 Nature has evolved complex networks of protein interactions called signaling 
pathways that can respond to external stimuli or allow for communication between cells. 
These pathways control processes crucial for the proper functioning of an organism, such 
as differentiation, stress response, cell growth, neurological function, metabolism, etc. 
Transcription factors are often major players in cellular signaling, so modulation of 
transcription can often cause major downstream (later in signaling pathway) effects or can 
counteract upstream (earlier in signaling pathway) effects. Therefore, disruption of 
transcription factor function is a potentially powerful strategy for developing therapeutics 
with many possible applications. 
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DNA-Binding Small Molecules 
 In addition to DNA-binding proteins, there are also many known small molecules 
capable of binding to DNA in a sequence specific fashion, most of which have been 
isolated as natural products. There are two major modes of non-covalent small molecule 
DNA-binding: intercalation and groove binding. Intercalation involves planar aromatic 
molecules which lodge between DNA base pairs, taking advantage of ring-stacking 
stabilization interactions with the adjacent nucleobases. In either major or minor groove 
binding, a variety of structures are possible, all of which take advantage of the unique 
electronic and steric environment that exists within the groove and vary with different 
sequences. An example of each binding mode are shown in Figure 1.4: actinomycin D, 
which preferentially binds to DNA by intercalation at 5’-GC-3’ sequences;4 and distamycin 
A, which targets AT tracts of DNA by binding to the minor groove.5 
  
Figure 1.4: Structures of actinomycin D, an intercalator that targets 5’-GC-3’, and distamycin A, a minor 
groove binder that targets 5’-(A,T)5-3’ sequences. 
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Recognition of the DNA Minor Groove 
 In the exposed portion of the minor groove, the plane of the base paired rings is 
perpendicular to the binding molecule, such that one side of the base pairing interaction is 
accessible (while the opposite side is accessible in the major groove). This imparts a unique 
electronic environment depending on the sequence of nucleotides, and a specific pattern 
can therefore be mapped to describe the electronic environment displayed by the minor 
groove of a specific sequence, as in Figure 1.5B. 
 
Figure 1.5: The electronic environment of the minor groove of DNA. A) For A•T base pairs, A displays one 
lone pair while T displays two lone pairs, whereas in C•G base pairs C displays one lone pair while G 
displays one lone pair and one N-H bond from the exocyclic amine. The unique electronic environments for 
each are clear from the corresponding electron density maps. B) The different patterns of lone pairs and N-H 
bonds displayed by a certain sequence can be mapped to provide the unique pattern of electron density for that 
sequence. 
 
 In the case of distamycin, the x-ray crystal structure of its interaction with DNA has 
been studied in detail.6,7 However, it was found that distamycin binds DNA in two different 
stoichiometries: 1:1 binding with DNA or 2:1 distamycin:DNA binding. Interestingly, 
crystal structures revealed hydrogen bond contacts between the amide N-H bonds of 
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distamycin and electron lone pairs of exposed lone pairs from base pairs exposed in the 
minor groove. In the 2:1 binding mode, the distamycin molecules bind in an antiparallel 
fashion, and each of the amide N-H bonds forms a favorable hydrogen bond with a lone 
pair on the same side of the minor groove.  
 
 
Figure 1.6: Recognition of the DNA minor groove by distamycin in A) a 1:1 complex and B) a 2:1 
antiparallel complex. 
 
 This structural information from these crystal structures seem to indicate a 
favorable shape complementarity between distamycin and DNA, allowing for two 
molecules to bind the minor groove of DNA, each with monomeric pyrrole heterocyclic 
amino acids units oriented across from each other such that hydrogen bond interactions 
occur with a single base pair of DNA matched to a single pyrrole monomer unit on each 
molecule of distamycin. 
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Pyrrole-Imidazole Polyamides 
 Based on structure of distamycin, a new class of oligomeric heterocyclic DNA-
binding small molecules called pyrrole-imidazole (Py-Im) polyamides have been 
developed that can be programmed to bind to specific sequences of DNA. In particular, by 
replacing a pyrrole subunit with an imidazole heterocycle, sequences including G•C or 
C•G base pairs can be targeted, and incorporation of a hydroxypyrrole heterocycle can 
distinguish between T•A and A•T base pairs.8,9 A set of pairing rules has been developed 
that allows for programmable targeting specific DNA sequences: N-methylpyrrole/N-
methylimidazole (Py/Im) targets C•G, Im/Py recognizes G•C, 3-hydroxy-N-
methylpyrrole/N-methylpyrrole (Hp/Py) and Py/Hp target T•A and A•T respectively.10  
Finally, Py/Py pairs are degenerate for T•A and A•T. 
 In addition to the expanded range of sequences that can be targeted, a γ-
aminobutyric acid (GABA) “turn” unit has been developed, to form a “hairpin” polyamide 
that provides a favorable entropic effect.11 This structural motif has been shown to provide 
a 100-3600-fold increase in binding affinity for a target DNA sequence relative to the 
corresponding 2:1 motif.12,13 Additionally, a GABA turn unit can allow for the targeting of 
non-palindromic DNA sequences by incorporating unsymmetrical ring pairings. Further 
development of a chiral amino substituted GABA turn allows for binding in a single 
orientation, where a polyamide N- to C- terminus aligns with DNA in a 5’ to 3’ direction, 
known as “forward” binding.14,15  
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Figure 1.7: Recognition of the DNA minor groove by Py-Im polyamides. A) The structure of a Py-Im 
polyamide bound to DNA, showing clear ring stacking and shape complementarity. B) Electronic 
environment created by each base pair in the minor groove. C) Pairing rules for targeting all four base pairs 
with Py-Im polyamides. Ball-and-stick notation (alongside abbreviations) is also defined here, which is used 
as standard nomenclature for Py-Im polyamides. 
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 As seen Figures 1.7 and 1.8, the Im subunit is specific for G nucleotides due to a 
hydrogen bonding interaction between the lone pair of the heterocyclic nitrogen of the Im 
and the N-H bond of the exocyclic amine of guanine. Hp monomers are specific for T 
nucleotides based on an interaction between the O-H bond of Hp (that is sterically 
accommodated by the cleft of the T•A base pair) and the extra lone pair displayed in the 
minor groove by thymine. Finally, the hairpin turn and the “tail” region at the C-terminus 
both target either the A•T or the T•A base pairs adjacent to the ends of the core of 
heterocycles, meaning that 8-heterocycle Py-Im polyamides targets six DNA base pairs. 
 
Figure 1.8: Crystal structure showing the orientation and hydrogen bonding interactions of an Im-Py 
heterocycle pairing adjacent to a G•C base pair.16 The interactions between amide N-H bonds and DNA lone 
pairs are clearly visible, as well as between the lone pair of the heterocyclic nitrogen and the N-H bond of the 
exocyclic amine of guanine. Also indicated are the three hydrogen bonds formed by the G•C base pair. 
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Development of Py-Im Polyamides with Therapeutic Potential 
 For Py-Im polyamides to be viable in a biological context, it is critical that they are 
able to enter live cells, and bind to DNA inside the cell nucleus. Previous cell culture 
studies have indicated that many fluorophore-labeled Py-Im polyamides are able to enter a 
variety of live cell lines, and traffic to the nucleus.17,18 In addition, crystal structures of Py-
Im polyamides bound to nucleosome core particles demonstrated the ability of these 
compounds to bind to DNA in the context of chromatin, causing structural changes in 
nucleosomal DNA without significantly perturbing the structure of the histone octamer.19  
   
Figure 1.9: A) Py-Im polyamides can often enter live cells. In this experiment, a fluorescently labeled (FITC) 
polyamide is added to two live cell lines, each incubated with a nuclear stain (Hoechst 33342, left panels). In 
both cell lines, clear co-localization occurs.20 B) Crystal structure of a nucleosome core particle, showing 
DNA-bound polyamide in blue. 
 
 Py-Im polyamides with isophthalic acid moieties attached at the tail region have 
also shown enhanced cell permeability properties, leading to a class of cell-permeable, 
sequence-specific, and high-affinity DNA-binding small molecules.21 
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Regulation of Gene Expression with Py-Im Polyamides 
 Due to the favorable biological properties of Py-Im polyamides and the power of 
modulating of gene expression for therapeutic purposes, the potential for using polyamides 
to repress or activate transcription is an attractive approach. In addition, the modular 
sequence-specificity of polyamides suggests that polyamides can be tailored to a variety of 
different biological targets for various therapeutic applications. Regulation of transcription 
could occur by two main routes: (1) repression of transcription by interfering with the 
function of existing transcription factors or (2) activation of transcription factor through 
conjugation of a DNA-binding polyamide to a TAD. 
 
 
Figure 1.10: The two routes of modulating transcription. In the case of repression (top), a polyamide targeted 
to the binding site of a transcription factor may be able to interfere with the TF-DNA interaction, limiting the 
ability of the TF to recruit RNA polymerase and initiate transcription. For activation to occur (bottom), an 
activation domain could be attached to a polyamide targeted adjacent to a gene of interest, causing an artificial 
activation of transcription if the polyamide-TAD complex can properly recruit RNA polymerase.  
 
 While the strategy of interfering with the proper functioning of a transcription 
factor is a promising strategy for repression of transcription, there initially remained the 
question of exactly how a Py-Im polyamide could achieve this goal. Because many 
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transcription factors bind to the major groove of DNA, it is not immediately obvious how 
the process of a polyamide disrupting transcription factor function would work. A possible 
model for this to occur is evident when examining the crystal structure of polyamide-DNA 
complexes. 
 
Figure 1.11: The allosteric effect of Py-Im polyamide-DNA binding.16 A) The structure of DNA with a 
narrow minor groove and wide major groove. B) When DNA is in a complex with a polyamide, significant 
widening of the minor groove occurs in order to accommodate the polyamide, causing a concomitant 
narrowing of the major groove. C) In addition to the effect on groove shape and width, the DNA strand 
becomes bent along the helical axis upon polyamide binding. D) An alternate view of the size and shape of the 
major and minor groove before and after polyamide binding. 
A B 
C D 
 37 
 As seen in Figure 1.11, significant deformation of the structure of DNA in the 
vicinity of the polyamide occurs upon binding. It is believed that this allosteric effect is the 
molecular basis for how polyamides binding to the minor groove of DNA can cause a 
disruption of the transcription factor-DNA interface for major groove-binding transcription 
factors. 
One of the initial transcription factors targeted for transcriptional downregulation 
by polyamides was hypoxia inducible factor 1α (HIF-1α), which activates a set of genes in 
response to low oxygen environments by binding to the Hypoxic Response Element (HRE) 
consensus sequence 5’-TACGTG-3’. One of these genes is vascular endothelial growth 
factor (VEGF), which when activated can lead to tumor vascularization. In an induced 
system, a polyamide targeted to the HRE (Figure 1.12A) was demonstrated to repress 
VEGF expression via qRT-PCR.22,23 In contrast, treatment with a mismatch polyamide that 
does not bind the HRE did not significantly affect VEGF expression. On a global scale, 
microarray analysis indicated that the match compound downregulated a subset of genes 
activated by induction of HIF-1α mediated expression. Chromatin immunoprecipitation 
(ChIP) experiments further demonstrated a decrease in occupancy of HIF-1α at the VEGF 
HRE following treatment with the match compound, supporting a sequence-dependent 
mechanism. 
Similar studies were conducted for transcription factors such as: (1) androgen 
receptor,24 which drives the expression of a set of genes crucial in the development and 
progression of prostate cancer (Figure 1.12B), (2) glucocorticoid receptor,25 which is a 
major regulator of inflammatory response (Figure 1.12C), and (3) NF-κB,26  which plays a 
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role in imflammatory response, cell differentiation, and senescence, and its misregulation 
has been implicated in cancer (Figure 1.12D). 
 
Figure 1.12: Various transcription factors that have been targeted with Py-Im polyamides, for which 
reduction of TF-mediated transcription has been demonstrated. In each case, the consensus sequence that was 
targeted is shown, along with the corresponding polyamide. A) Hypoxia inducible factor 1α, B) Androgen 
receptor, C) Glucocorticoid receptor, D) Nuclear factor κB.  
  
  
 
 
 
 
 
 
GILZ
5’-CCTGCActtTGTTCT-3’
GILZ GRE 1
1
3’-GCACGTgaaACAAGA-5’+
+
IPA
5’-CAAACAccgTGTTCA-3’
3’-GTTTGTggcACAAGT-5’
GILZ GRE 2
1
+
+
IPA
2
+
+
IPA
H
N
O
N
H
N
O
N
N
N
H
O NH
O
NH3
N
N
H
O
N
NH
N
O
N
H
N
O
N
H
N
O
N
N
H
O
NHN
O
O-O
H
N
N
1
+
+
IPA
H
N
O
N
N
H
N
O
N
N
H
O NH
O
NH3
N
N
H
O
N
H
N
O
N
H
N
O
N
H
N
O
N
N
H
O
NHN
N
N
O
O-O
H
GRE 2GRE 1 22 bp 2438 bp
5’-WGWWCW-3’
3’-WCWWGW-5’
5’-WGWCGW-3’
3’-WCWGCW-5’
 39 
Py-Im Polyamide-mediated Gene Activation 
 In contrast to repression of TF-mediated transcription, it may also be possible to 
activate specific genes using a Py-Im polyamide. Through the attachment of a 
transcriptional activation domain (TAD) capable of recruiting transcriptional machinery 
(Figure 1.13A), polyamides can be used to activate transcription at target sites. This 
construct is also referred to as an artificial transcription factor (ATF), as it functions like a 
transcription factor and contains similar domains, but can be entirely synthetic. These 
domains consist of a polyamide as the DNA-binding domain, and a synthetic molecule 
capable of recruiting activating transcription. Several polyamide-TAD conjugates have 
previously been demonstrated to upregulate transcription in vitro,27-30 but a lack of efficient 
cellular uptake—likely due to the large molecular weight of these compounds—prevented 
in vivo applications.10,31,32 
 
 
Figure 1.13: The concept of a polyamide based transcriptional activator. A) A small molecule containing 
DBD and TAD domains can bind to DNA (1), recruit transcriptional machinery (2), and allow for the 
assembly of the RNA Polymerase and initiation of transcription (3). B) General structure of a polyamide-TAD 
conjugate, indicating the DBD, linker domain, and TAD. 
 
 
A 
RNA Pol II
Med
Gene is activated1
2
3
TAD
DBD
B 
 40 
Scope of this Work 
 The work presented in this thesis involves various studies aimed at advancing Py-
Im polyamides as a potential class of therapeutics. By making improvements that allow for 
increased biological activity in cancer cell lines, we have developed a more potent class of 
compounds with greatly increased cellular uptake. In Chapter 2, we present a new class of 
Py-Im polyamides bearing modifications to the γ-aminobutyric acid turn unit, with 
unprecedented levels of cytotoxicity in cell culture. We used confocal microscopy and flow 
cytometry to qualitatively and quantitatively assess levels of nuclear concentration, which 
strongly suggest that this effect was based on a significant increase in levels of nuclear 
uptake. We found that a simple modification to include an aryl-turn moiety can potentiate 
the biological effects of a Py-Im polyamide by up to two orders of magnitude. In Chapter 3, 
we develop an improved synthetic route that allows a practical method for unsymmetrical 
modifications to be made at the turn units of cyclic Py-Im polyamides. We then designed a 
panel of cyclic compounds to study the effects of a variety of substitutions that included 
aryl-turn technology, and found surprising results that further emphasize the dramatic effect 
that small structural changes can have on biological activity. In Chapter 4, we examine the 
aggregation propensity of a diverse library of Py-Im polyamides, finding that the solubility 
of polyamides does not seem to correlate with biological activity. We also investigate the 
effects of solubilizing agents, and find that this strategy can improve polyamide solubility 
and allow for improved injection conditions in mice. Finally, in Chapter 5 we develop a 
class of Py-Im polyamides conjugated to isoxazolidine moieties, and investigate their 
potential as artificial transcription factors. 
 
 41 
References 
 
1. Drew, H. R.; Wing, R. M.; Takano, T.; Broka, C.; Tanaka, S.; Itakura, K.; Dickerson, 
R. E. Structure of a B-DNA dodecamer - conformation and dynamics. Proc. Natl. Acad. 
Sci. USA 1981, 78, 2179-2183. 
2. Crick, F., Central dogma of molecular biology. Nature 1970, 227, 561. 
3. Panne, D.; Maniatis, T.; Harrison, S. C., An atomic model of the interferon-beta 
enhanceosome. Cell 2007, 129 (6), 1111-1123. 
4. Kamitori, S.; Takusagawa, F., Multiple binding modes of anticancer drug 
actinomycin-D - X-ray, molecular modeling, and spectroscopic studies of 
d(GAAGCTTC)2-actinomycin D complexes and its host DNA. J. Am. Chem. Soc. 1994, 
116, 4154-4165.  
5. Coll, M.; Frederick, C. A.; Wang, A. H. J.; Rich, A., A bifurcated hydrogen-bonded 
conformation in the d(A·T) base pairs of the DNA dodecamer d(CGCAAATTTGCG) 
and its complex with distamycin. Proc. Natl. Acad. Sci. USA 1987, 84, 8385-8389. 
6. Mitra, S. N.; Wahl, M. C.; Sundaralingam, M., Structure of the side-by-side binding of 
distamycin to d(GTATATAC)(2). Acta Crystallogr. Sect. D 1999, 55, 602-609.  
7. Pelton, J. G.; Wemmer, D. E., Structural characterization of a 2-1 distamycin 
A·d(CGCAAATTGGC) complex by two-dimensional NMR. Proc. Natl. Acad. Sci. USA 
1989, 86, 5723-5727. 
8. White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P. B., Recognition of 
the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature 
1998, 391, 468-471. 
9. Kielkopf, C. L.; White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P. B.; 
Rees, D. C., A structural basis for recognition of A·T and T·A base pairs in the minor 
groove of B-DNA. Science 1998, 282, 111-115. 
10. Dervan, P. B.; Edelson, B. S., Recognition of the DNA minor groove by pyrrole-
imidazole polyamides. Curr. Opin. Struct. Biol. 2003, 13, 284-299. 
11. Mrksich, M.; Parks, M. E.; Dervan, P. B., Hairpin peptide motif - a new class of 
oligopeptides for sequence-specific recognition in the minor-groove of double-helical 
DNA. J. Am. Chem. Soc. 1994, 116, 7983-7988. 
12. Trauger, J. W.; Baird, E. E.; Dervan, P. B., Recognition of DNA by designed ligands 
at subnanomolar concentrations. Nature 1996, 382, 559-561. 
13. Herman, D. M.; Turner, J. M.; Baird, E. E.; Dervan, P. B., Cycle polyamide motif for 
recognition of the minor groove of DNA. J. Am. Chem. Soc. 1999, 121, 1121-1129. 
 
 42 
 
14. White, S.; Baird, E. E.; Dervan, P. B., Orientation preferences of pyrrole-imidazole 
polyamides in the minor groove of DNA. J. Am. Chem. Soc. 1997, 119, 8756-8765. 
15. Herman, D. M.; Baird, E. E.; Dervan, P. B., Stereochemical control of the DNA 
binding affinity, sequence specificity, and orientation preference of chiral hairpin 
polyamides in the minor groove. J. Am. Chem. Soc. 1998, 120, 1382-1391. 
16. Chenoweth, D. M.; Dervan, P. B., Allosteric modulation of DNA by small molecules. 
Proc. Natl. Acad. Sci. USA 2009, 106, 13175-13179. 
17. Edelson, B. S.; Best, T. P.; Olenyuk, B.; Nickols, N. G.; Doss, R. M.; Foister, S.; 
Heckel, A.; Dervan, P. B., Influence of structural variation on nuclear localization of 
DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res. 2004, 32, 2802-
2818. 
18. Belitsky, J. M.; Nguyen, D. H.; Wurtz, N. R.; Dervan, P. B., Solid-phase synthesis of 
DNA binding polyamides on oxime resin. Bioorg. Med. Chem. 2002, 10, 2767-2774. 
19. Suto, R. K.; Edayathumangalam, R. S.; White, C. L.; Melander, C.; Gottesfeld, J. M.; 
Dervan, P. B.; Luger, K., Crystal structures of nucleosome core particles in complex with 
minor groove DNA-binding ligands. J. Mol. Biol. 2003, 326, 371-380. 
20. Best, T. P.; Edelson, B. S.; Nickols, N. G.; Dervan, P. B., Nuclear localization of 
pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc. Natl. Acad. Sci. 
USA 2003, 100, 12063-12068. 
21. Nickols, N. G.; Jacobs, C. S.; Farkas, M. E.; Dervan, P. B., Improved nuclear 
localization of DNA-binding polyamides. Nucleic Acids Res. 2007, 35, 363-370. 
22. Olenyuk, B. Z.; Zhang, G. J.; Klco, J. M.; Nickols, N. G.; Kaelin, W. G.; Dervan, P. 
B., Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia 
response element antagonist. Proc. Natl. Acad. Sci. USA 2004, 101, 16768-16773. 
23. Nickols, N. G.; Jacobs, C. S.; Farkas, M. E.; Dervan, P. B., Modulating hypoxia-
inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem. Biol. 2007, 2, 
561-571. 
24. Nickols, N. G.; Dervan, P. B., Suppression of androgen receptor-mediated gene 
expression by a sequence-specific DNA-binding polyamide. Proc. Natl. Acad. Sci. USA 
2007, 104, 10418-10423. 
25. Muzikar, K. A.; Nickols, N. G.; Dervan, P. B., Repression of DNA-binding 
dependent glucocorticoid receptor-mediated gene expression. Proc. Natl. Acad. Sci. USA 
2009, 106, 16598-16603. 
 
 43 
 
26. Raskatov, J. A.; Meier, J. L.; Puckett, J. W.; Yang, F.; Ramakrishnan, P.; Dervan, P. 
B., Modulation of NF-kappaB-dependent gene transcription using programmable DNA 
minor groove binders. Proc. Natl. Acad. Sci. USA 2012, 109, 1023-1028. 
27. Mapp, A. K.; Ansari, A. Z.; Ptashne, M.; Dervan, P. B., Activation of gene expression 
by small molecule transcription factors. Proc. Natl. Acad. Sci. USA 2000, 97, 3930-3935. 
 
28. Ansari, A. Z.; Mapp, A. K.; Nguyen, D. H.; Dervan, P. B.; Ptashne, M., Towards a 
minimal motif for artificial transcriptional activators. Chem. Biol. 2001, 8, 583-592. 
29. Arora, P. S.; Ansari, A. Z.; Best, T. P.; Ptashne, M.; Dervan, P. B., Design of artificial 
transcriptional activators with rigid poly-L-proline linkers. J. Am. Chem. Soc. 2002, 124, 
13067-13071. 
30. Kwonj, Y.; Arndt, H. D.; Qian, M.; Choi, Y.; Kawazoe, Y.; Dervan, P. B.; Uesugi, M., 
Small molecule transcription factor mimic. J. Am. Chem. Soc. 2004, 126, 15940-15941.  
31. Best, T. P.; Edelson, B. S.; Nickols, N. G.; Dervan, P. B., Nuclear localization of 
pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc. Natl. Acad. Sci. 
USA 2003, 100, 12063-12068.  
32. Nickols, N. G.; Jacobs, C. S.; Farkas, M. E.; Dervan, P. B., Improved nuclear 
localization of DNA-binding polyamides. Nucleic Acids Res. 2007, 35, 363-370. !
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
 
 
 
 
 
 
Enhancing the Cellular Uptake of Pyrrole-Imidazole 
Polyamides Through Next-Generation Aryl Turns 
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Abstract 
 
 
 Pyrrole–imidazole (Py–Im) hairpin polyamides are a class of programmable, 
sequence-specific DNA binding oligomers capable of disrupting protein–DNA interactions 
and modulating gene expression in living cells. Methods to control the cellular uptake and 
nuclear localization of these compounds are essential to their application as molecular 
probes or therapeutic agents. Here, we explore modifications of the hairpin γ-aminobutyric 
acid turn unit as a means to enhance cellular uptake and biological activity. Remarkably, 
introduction of a simple aryl group at the turn potentiates the biological effects of a 
polyamide targeting the sequence 5′-WGWWCW-3′ (W#=#A/T) by up to two orders of 
magnitude. Confocal microscopy and quantitative flow cytometry analysis suggest this 
enhanced potency is due to increased nuclear uptake. Finally, we explore the generality of 
this approach and find that aryl-turn modifications enhance the uptake of all polyamides 
tested, while having a variable effect on the upper limit of polyamide nuclear accumulation. 
Overall this provides a step forward for controlling the intracellular concentration of Py–Im 
polyamides that will prove valuable for future applications in which biological potency is 
essential. 
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Introduction  
 Hairpin pyrrole-imidazole (Py-Im) polyamides are a class of heterocyclic amino 
acid oligomers that can be programmed to bind a wide repertoire of DNA sequences with 
high affinity and specificity.1,2 Sequence-selective recognition of the minor groove of 
DNA is achieved through side-by-side stacked ring pairings: Im/Py distinguishes G·C 
from C·G, while Py/Py is degenerate for T·A and A·T. In recent years our group has 
focused on the biological evaluation of eight-ring polyamides arranged in a hairpin 
configuration through a γ-aminobutyric acid linker (Figure 2.1).3,4 These compounds are 
of modest (~1300 Da) molecular weight and recognize 6 base pairs (bp) of DNA, similar 
to the size of many eukaryotic transcription factor binding sites.5 When applied to living 
cells, hairpin polyamides can disrupt protein-DNA interactions and modulate the 
expression of genes induced by many transcription factors, including the ligand-activated 
nuclear receptors glucocorticoid receptor (GR) and androgen receptor (AR).6-10 However, 
one persistent challenge encountered when applying Py-Im polyamides to new biological 
systems is cellular uptake. Previous studies have shown that the nuclear localization of 
fluorescently labelled polyamides can be influenced by several variables including 
molecular weight, modifications to the C-terminal moiety, and composition of Py/Im 
content.11-13 In particular, Py-Im polyamides incorporating multiple (>2-3) N-
methylimidazole subunits show reduced nuclear localization, limiting the ability to target 
GC rich sequences in vivo.14 Therefore, new solutions for enhanced uptake are important 
for advancing Py-Im polyamides as probes of transcription factor binding and, 
potentially, as therapeutic agents. 
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 While a large amount of work has been done one the effect of C-terminal 
modifications on polyamide nuclear localization,13,15 relatively few studies have explored 
the impact of modifications to the γ-aminobutyric acid (GABA) turn moiety on biological 
activity. The incorporation of a chiral (R)-α-amino substituent on the GABA turn 
enforces polyamide binding in a N-terminusC-terminus orientation with respect to the 
5’3’ direction of the adjacent DNA strand.16  
 
Figure 2.1: Schematic diagram of eight-ring Py–Im polyamides targeting the sequence 5’ -WGWWCW-3’ 
(W=A/T). Dashed lines indicate hydrogen bonds between the polyamide and DNA base pairs. The γ-
aminobutyric acid turn unit enforces an antiparallel hairpin configuration, and codes for W.16 Substitution 
of the chiral turn functionality can have substantial effects on DNA-binding and biological activity. 
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 More recently, we introduced hairpin polyamides bearing (R)-β-amino GABA 
turns which show increased DNA-binding affinity and, importantly for the purposes of 
this study, a negligible decrease in DNA-binding affinity upon acylation (Figure 2.1).16 
Structural studies suggest this is due to their unique stereochemical presentation of the 
chiral β-amino moiety, which is directed up and out of the minor groove floor, thereby 
providing a chemical handle for introduction of functionality at the turn position.17 
Furthermore, biological evaluation of a β-acetylated polyamide targeted to the consensus 
androgen response element (ARE) half site 5’-WGWWCW-3’ (W = A/T) showed 
inhibition of prostate specific antigen (PSA) gene expression at 10-fold lower 
concentrations relative to polyamides bearing unsubstituted β-amino turns, illustrating the 
ability of turn substitution to potentiate gene regulatory effects.18   
 Guided by these results, we explored modifications of the Py-Im polyamide 
hairpin γ-aminobutyric acid turn unit as a means to enhance uptake and biological 
activity. Our strategy applied cytotoxicity analysis at an extended time point as an 
effective assay for identifying biologically active polyamides from small focused 
libraries. This led to the discovery that for a hairpin polyamide targeting the DNA 
sequence 5’-WGWWCW-3’ (W = A/T), simple conversion of the β-amino turn to a β-
benzamide turn led to a 100-fold increase in gene regulatory activity. To better 
understand the mechanism of this phenomenon, fluorescent analogues of β-amino and β-
aryl polyamides were synthesized and analyzed by confocal microscopy and quantitative 
flow cytometry. Our results suggest the enhanced potency of β-aryl polyamides is due to 
increased nuclear uptake of these compounds.  
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Figure 2.2: Based on a simple structural modification, pyrrole-imidazole polyamides have been developed 
with increased cellular uptake. This class of compounds can traffic to cell nuclei and access chromatin, 
imparting gene regulatory effects at lower concentrations.  
 
 Finally, we explore the generality of this modification and find that aryl-turn 
substitution capably enhances the uptake of other polyamides cores, but has a variable 
effect on the upper limits of polyamide nuclear accumulation. Overall this provides a new 
direction for controlling the intracellular concentration of Py-Im polyamides that will 
prove essential for future applications in which biological potency is required. 
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Results and Discussion 
 
Synthesis, DNA-Binding, and Cytotoxicity of β-aryl Polyamides 
 Following an unanticipated observation that a hairpin polyamide conjugated to an 
aryl group at the β-amino position showed greater activity in cell culture, we synthesized 
a small panel of β-aryl substituted polyamides (4-12) targeting the sequence 5’-
WGWWCW-3’ and benchmark their DNA-binding affinities and biological activity 
against unsubstituted parent (1), β-amino (2), and β-acetylated (3) GABA turns in the 
A549 human lung carcinoma cell line (Figure 2.3). We used cytotoxicity at 96 hours as a 
proxy for uptake following the observation that polyamide uptake, gene regulatory 
activity, and cytotoxicity are often highly correlated.13 Thermal denaturation analysis of a 
DNA duplex of the sequence 5’-TTGCTGTTCTGCAA-3’ (polyamide match site in 
bold) shows all polyamides containing a β-amino GABA group (2-14) similarly increase 
the melting temperature by ~13-15 °C, suggesting no substantial energetic penalty for 
appendage of the bulky β-aryl groups (Figure 2.3). Cytotoxicity analyses demonstrate 
that β-amino GABA incorporating polyamide 2 (IC50 = 3.155 µM) is considerably more 
cytotoxic than its unsubstituted counterpart 1 (IC50 >30 µM). While this trend mirrors the 
relative duplex stabilization of these molecules (ΔTm 1 = 8.8 °C; ΔTm 2 = 13.3 °C), 
simple N-acetylation of the β-amino turn (3) results in another order of magnitude 
increase in growth inhibition while not greatly affecting binding affinity (ΔTm 3 = 13.2 
°C). Replacement of the acetyl unit of 3 with a benzoyl functionality (4) results in 
approximately another order of magnitude increase in cytotoxicity (IC50 = 35 nM), again 
without concomitant change in the duplex stabilizing ability of this minor groove binder. 
Within the aryl series (4-12) several trends are seen, including increased cytotoxicity of 
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p-substituted benzoic acids (compare 9 and 10) and a preference for electron-
withdrawing groups at the p-position (compare 6 and 7). Remarkably, significantly 
increasing the steric bulk of the β-aryl turn, as in polyamides 8 and 11, does not greatly 
affect either DNA-binding or cytotoxicity, arguing against interaction of the β-aryl turn 
with a small pocket of a specific protein partner as a mechanism of cytotoxicity.  
 
Figure 2.3: Biological activity and DNA-binding of β-substituted hairpin polyamides. Cytotoxicity 
analyses were conducted 96 hr after polyamide treatment in the A549 lung carcinoma cell line. IC50 values 
represent the mean of three biological replicates. ΔTm denotes the shift in melting temperature following 
polyamide treatment for the 5’-WGWWCW-3’ duplex DNA sequence shown.  
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 Since previous studies have noted that polyamide activity can be strongly 
influenced by cell type,12 we tested the generality of the increased cytotoxicity of 4 and 9 
in LNCaP prostate cancer, MCF-7 breast cancer, and HCT-116 colon cancer cell lines. 
All three cell lines showed a similar increase in potency for β-aryl compared to β-amino 
polyamides as was observed in A549 cells (Table 2.1). 
 
Table 2.1: Cytotoxicity of β-amino (2) and β-aryl (4, 9) polyamides targeting the sequence 5’-
WGWWCW-3’ towards alternative cancer cell lines. Growth inhibition values represent the mean and 
standard deviation of three biological replicates. 
 
Suppression of Nuclear-Receptor Mediated Gene Expression by β-Aryl Polyamides 
 A549 lung epithelial cells have been widely applied as a model for inflammatory 
gene expression mediated by the transcription factor glucocorticoid receptor (GR).23-25 
GR is a member of larger family of nuclear receptors that utilize activation by small 
molecule ligands in order to affect release from cytoplasmic inhibitory complexes, after 
which they traffic to the nucleus, multimerize with their cognate protein partners, and 
activate (or repress) transcription (Figure 2.4A). Hairpin polyamides have been 
previously shown to inhibit nuclear receptor-DNA interactions in cell culture, making 
them promising agents for mechanistic studies of nuclear receptor-DNA binding and 
therapeutic modulation of nuclear receptor activity in diseases such as prostate cancer.  
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Figure 2.4: Inhibition of nuclear-receptor mediated gene expression by β-aryl polyamides. (a) General 
schematic of nuclear receptor-mediated gene expression and polyamide inhibition of the protein-DNA 
interface. (b) Effect of β-turn polyamides 2 and 4 on dexamethasone (DEX)-induced GILZ gene expression 
as measured by qRT-PCR analysis. I = DEX-induced. NI = non-induced. Polyamide 2 concentrations: 100, 
1000, 10,000 nM, polyamide 4 concentrations: 1, 10, 100 nM. (c) Effect of β-substituted polyamides 2 and 
4 on dihydrotestosterone (DHT)-induced PSA gene expression as measured by qRT-PCR analysis. 
Polyamide 2 concentrations: 100, 1000, 10,000 nM, polyamide 4 concentrations: 1, 10, 100 nM. I = 
induced. NI = not induced.  
 
 Polyamides 1-12 target the 5’-WGWWCW-3’ sequence found in the consensus 
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increased activity of β-aryl polyamides might be extended to gene regulatory studies, we 
analyzed the effects of β-aryl polyamide 4 and parent polyamide 2 on endogenous GR-
mediated transcription in A549 cells. Following 48 hours treatment with 2, 4, or vehicle 
DMSO, A549 cells were induced with dexamethasone (Dex) before isolation of total 
RNA and analysis by qRT-PCR. As seen in Figure 2.4B, β-aryl polyamide 4 blunts GR-
driven transcription of the canonical GR-regulated gene GILZ in a dose-dependent 
fashion.  
 Remarkably, inhibition of gene expression by 4 occurs at polyamide 
concentrations 100x lower than parent compound 2. Similar results are seen for 
expression of FKBP5, another prototypical GR target (Figure 2.5). 
 
 
Figure 2.5: Inhibition of nuclear-receptor mediated gene expression by β-aryl polyamides. (a) Effect of β-
turn polyamides 2 and 4 on dexamethasone-induced FKBP5 gene expression as measured by qRT-PCR 
analysis. I = induced. NI = non-induced. Polyamide 2 concentrations: 100, 1000, 10,000 nM, polyamide 4 
concentrations: 1, 10, 10 nM. (b) Effect of β-turn polyamides 2 and 4 on dihydrotestosterone-induced 
FKBP5 gene expression as measured by qRT-PCR analysis. Polyamide 2 concentrations: 100, 1000, 10,000 
nM, polyamide 4 concentrations: 1, 10, 10 nM. I = induced. NI = not induced.  
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 Notably, these effects are not expected to be due to cytotoxicity, as these 
experiments utilize a fivefold higher cell plating density than cytotoxicity analyses and 
are normalized to a housekeeping gene (GUSB) that remains stable to polyamide 
treatment (Figure 2.6).  
 
 
Figure 2.6: Time courses for (a) cytotoxicity analysis, (b) dexamethasone-induced gene expression studies, 
(c) dihydrotestosterone-induced gene expression studies, (d) flow cytometric analysis of uptake of 
polyamide-FITC conjugates, (e) confocal microscopy analysis of uptake of polyamide-FITC conjugates. 
 
 Time course experiments show substantial inhibition of dexamethasone-induced 
transcription as early as 12 hours after polyamide treatment, far prior to the onset of 
cytotoxicity (Figure 2.7).  
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Figure 2.7: Time course analysis of polyamide-mediated inhibition of dexamethasone-induced gene 
expression. (a) Effect of β-turn polyamides 2 and 4 on dexamethasone (DEX)-induced GILZ gene 
expression as measured by qRT-PCR analysis. I = DEX-induced. NI = non-induced. Polyamide 2 
concentration: 10,000 nM, polyamide 4 concentration: 100 nM. These concentrations of 2 and 4 were 
chosen because they show approximately equivalent inhibition of GR-mediate gene expression at 48 hr. (b) 
Identical time course analysis of polyamide inhibition of FKBP5 gene expression over time. 
 
 Since the sequence targeted by 4, 5’-WGWWCW-3’, is also found in the 
androgen response element (ARE), we next tested whether 4 showed similarly enhanced 
inhibition of androgen receptor (AR) regulated gene expression.7 LNCaP prostate cancer 
cells were exposed to polyamides 2 or 4 for 48 hours prior to induction with the AR-
activating ligand 4,5α-dihydrotestosterone (DHT). Quantitative PCR analysis of reverse-
transcribed mRNA shows a drastic decrease in transcription of the known AR target gene 
prostate specific antigen (PSA, also known as KLK3) following exposure to 4 (Figure 
2.4C). Once again, this inhibition is greater than that observed when parent compound 2 
is applied at 100x greater concentrations, reducing PSA mRNA to below basal (non-
induced) levels. These results highlight the activity of β-aryl polyamides as potent 
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antagonists of nuclear receptor-mediated gene expression in living cells. 
 
The Effect of β-Aryl Substitution on Polyamide Uptake by Quantitative Fluorescence 
Analysis 
 Hypothetically, the increased biological activity of β-aryl turn polyamides could 
be attributed to either 1) improved ability to impede protein-DNA interactions, 2) 
increased uptake, or 3) reduced efflux. The former seemed unlikely, given that our initial 
structure-activity analysis showed no correlation between steric bulk of the β-aryl turn, 
which would be expected to affect interaction of groove-binding proteins, and 
cytotoxicity (Figure 2.3). Therefore, to examine cellular uptake in a systematic and direct 
fashion we synthesized fluorescent analogues of polyamides 2 and 4 and analyzed their 
accumulation by confocal microscopy and flow cytometry.11,26 Polyamide-FITC 
conjugates 13 and 14 show similar trends in terms of biological activity compared to 
parent compounds, although the observed gap in cytotoxicities is decreased from ~ 100x 
to ~10x (Figure 2.8).  
 
Figure 2.8: Relative cytotoxicity of fluorescent analogues 13 and 14 in A549 cells. Cytotoxicities of the 
parent compounds 2 and 4 are found in Figure 2.3. 
 
 Following addition to growth media, polyamides 13 and 14 penetrate the 
membrane and localize to the nucleus of A549 cells, as verified by co-localization with 
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the well-known DNA stain Hoechst (Figure 2.9A). However, flow cytometry analysis 
reveals quantitative differences in the kinetics and degree of uptake. Cells treated with 
100 nM β-aryl polyamide 14 demonstrate a rapid increase in fluorescence intensity 
between 0-12 hours, compared to much slower accumulation of β-amino polyamide 13 
dosed under identical conditions (Figure 2.9B).  
 
Figure 2.9: Quantitative fluorescence analysis of β-turn substitution on Py-Im polyamide nuclear uptake. 
(a) Nuclear localization of β-aryl polyamide 13, as verified by co-localization with Hoechst 33342. (b) 
Influence of incubation time on fluorescence for A549 cells treated with 100 nM polyamide 13 or 14. X-
axis: relative median fluorescence (FL1: FITC channel); Y-axis: hours of polyamide treatment. (c) 
Influence of dosage concentration on nuclear accumulation of polyamides. Polyamide 13 concentration: 
100 nM, 1000 nM, 10,000 nM. Polyamide 14 concentration: 100 nM, 1000 nM. 
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labelling of ~ 88% of A549 cells after 6 hr, while cells treated with 100 nM 13 show 
labelling of only ~5% of cells over the same time period (Figure 2.10).  
 
 
Figure 2.10: Percentage of cells labelled as a function of time exposed to β-turn polyamides β-aryl 13-20 
(100 nM). (a) Bar graph depicting relative percentage of cells fluorescently labelled by β-amino 
polyamides 13 and 17 compared to their β-aryl analogues 14 and 18. (b) Complete data for all polyamide 
cores analyzed in this study. Percentage of cells labelled is calculated relative to control cells treated with 
vehicle DMSO. 
 
 In order to gain a more quantitative view of the fluorescence increase, we 
calculated the nuclear concentrations of fluorescent polyamides 13 and 14 through 
comparison to fluorescent beads functionalized with known amounts of the FITC 
fluorophore.14,26 Using this methodology, at 48 hours we observe a >4x greater 
accumulation of 14 than 13 in A549 nuclei when dosed at identical concentrations (100 
nM). However, these concentrations can be shifted by increasing polyamide 
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concentration, as 10x greater dosage concentrations result in a ~3x increase in polyamide 
concentration values over 48 hours (Figure 2.9C). Notably, this is not due merely due to 
decreased cell growth, as analysis of cell count and viability prior to flow cytometry 
revealed no differences between treated samples. Finally, to differentiate uptake and 
efflux, we compared the effect of verapamil on uptake of β-aryl and β-amino polyamides. 
Verapamil is an inhibitor of the p-glycoprotein transporter that has previously been 
implicated in cellular efflux of polyamides.27 If β-aryl polyamide 4 is attaining higher 
concentrations through reduced efflux, verapamil treatment should have little or no affect 
on intracellular polyamide concentration, whereas if β-aryl polyamide 4 is attaining 
higher concentrations through enhanced uptake, verapamil will have additive effect on 
nuclear accumulation. Our results are consistent with the latter mechanism, as we 
observed similarly higher fluorescent labelling by both 2 and 4 in A549 cells co-treated 
with a non-toxic (10 µM) dose of verapamil (Figure 2.11). Overall these findings have 
two implications: 1) β-aryl turns can significantly increase the rate of polyamide uptake 
at sub-micromolar concentrations and 2) polyamide cytotoxicity and cellular uptake are 
well correlated, as the 10x increase in cytotoxicity of 14 relative to 13 is mirrored by its 
accumulation in cells at 10x lower concentrations. 
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Figure 2.11: Analysis of β-aryl (14) and β-amino (13) polyamide efflux. (a) Adherent A549 cells were 
incubated with 100 nM 13 or 14 in the presence or absence of verapamil (10 µM) for 48 hr and analyzed by 
flow cytometry. Both polyamides show similar increases in uptake. All samples were analyzed in the same 
biological experiment. Cellular fluorescence reported as arbitrary units. (a) Adherent A549 cells were 
incubated with 1000 nM 13 or 14 in the presence or absence of verapamil (10 µM) for 24 hr and analyzed 
by flow cytometry. Both polyamides show similar increases in uptake. (c) Washout study of polyamides. 
A549 cells were treated with 13 or 14 for 24 hr, at which point polyamides were removed and cells were 
grown in fresh media for 0, 24, or 48 hr followed by FACS analysis. Both compounds show similar 
profiles, suggesting efflux or dilution by cell growth proceeds similarly for each. 
 
Exploring the Utility of β-Aryl Substitution on Alternative Polyamide Cores 
 Finally, we examined the ability of β-aryl turns to influence the uptake of 
polyamide cores targeting alternative sequence motifs. We synthesized fluorescent β-
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5’-WGWCGW-3’ (17-18), and 5’-WGCGCW-3’ (19-20). Compound 15 is a high affinity 
binder of the 5’-ATACGT-3’ sequence found within the hypoxia response element 
(HRE) of the VEGF enhancer,6 while compounds 17-20 probe the ability of β-aryl turns 
to facilitate the uptake of polyamides with increased N-methylimidazole content, a 
known negative determinant of polyamide nuclear localization.12,14 Next, uptake was 
verified by confocal microscopy (Figure 2.12). 
 
Figure 2.12: Confocal microscopy analysis of β-aryl polyamide nuclear localization. Adherent A549 cells 
were treated with 1µM β-aryl polyamide-FITC conjugates (14/16/18/20) for 16 hr, and counterstained with 
Hoechst 33342 (nuclear stain) and Mitotracker Red CM-H2Ros (mitochondrial stain) just prior to imaging. 
Top left: polyamide-FITC (λex = 488 nm λem = 505-530 nm). Top right: Hoechst (λex = 750 nm [2-photon] 
λem = 390-465 nm). Bottom left: Mitotracker (λex = 543 nm λem = 565-615 nm). Bottom right: three-color 
overlay. 
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 Each compound was further analyzed for time and concentration-dependent 
uptake by quantitative flow cytometry (Figures 2.13 and 2.14). When added to media at 
100 nM, time-course experiments demonstrate that polyamide-FITC conjugates 15-18 
rapidly accumulate in A549 cells (Figure 2.13). Analysis of Im-rich polyamide 19-20 at 
100 nM was less informative, as these compounds required dosing at 1000 nM to label a 
significant percentage of treated cells (Figure 2.10). 
 
Figure 2.13: Time course analysis of uptake of polyamide-FITC conjugates incorporating diverse DNA 
sequence-recognition elements. (a) Cellular concentration of polyamide-FITC conjugates 13-20 as a 
function of time incubated with A549 cells. Polyamide structures are represented as ball and stick models 
according the shorthand code: closed circle, Im monomer; open circle, Py monomer; diamond, β-alanine; 
square, 3-chlorothiophene 2-carboxylic acid. Complete structures can be found in Supplementary Data. 
Cellular concentration calculated from flow cytometry data as described in materials and methods. (b) Data 
displayed in tabular form with standard deviations. Core = DNA sequence targeted by the hairpin 
polyamide core heterocylic ring pairs. Turn = identity of β-turn modification. 
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 Under these treatment conditions (100 nM 15-18; 1000 nM 19-20) each β-aryl 
polyamide shows increased cellular uptake relative to its β-amino counterpart, 
demonstrating the general utility of this modification in promoting increased uptake 
(Figure 2.14). 
 
Figure 2.14: Influence of polyamide dosage on cellular concentration at 48 hr. (a) Graphical depiction of 
relative cellular concentrations of polyamides analyzed in this study. β-amino polyamides 13, 15, 17, and 
19 were dosed at 100, 1000, and 10,000 nM respectively (left to right). β-aryl polyamides 14, 16, 18, and 
20 were dosed at 100 and 1000 nM respectively (left to right). Attempts to dose β-aryl compounds at higher 
concentrations were hindered by insolubility. Cellular concentration calculated from flow cytometry data as 
described in materials and methods. (b) Data displayed in tabular form with standard deviations. Core = 
DNA sequence targeted by the hairpin polyamide core heterocylic ring pairs. Turn = identity of β-turn 
modification. 
 This enhanced uptake is accompanied by a large increase in the cytotoxicity of 
non-fluorescent analogues of Im-rich polyamides 18 and 20, but surprisingly not 5’-
WTWCGW-3’ targeting polyamide 16 (Figure 2.15).  
NH+3FITC NH
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FITC FITC
NH+3 FITC NH
O
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NH+3 FITC NH
O
FITC
NH+3 FITC NH
O
13 14 15 16 17 18 19 20
Polyamide core turn 100 nM 1000 nM 10,000 nM
13 GWWC amine 37.6 (± 5.1) 318.5 (± 44.3) 1282 (± 107.7)
14 GWWC benzamide 211.3 (± 31.4) 936.5 (± 51.3) -
15 TWCG amine 110.2 (± 19.5) 674.4 (± 126.7) 820.8 (± 151.7)
16 TWCG benzamide 291.5 (± 17.6) 374.4 (± 71.1) -
17 GWCG amine 69.0 (± 7.6) 344.9 (± 65.6) 558.5 (± 87.9)
18 GWCG benzamide 231.4 (± 12.1) 385 (± 40.4) -
19 GCGC amine 16.1 (± 5.3) 68.5 (± 10.4) 480.2 (± 61.3)
20 GCGC benzamide 22.8 (± 0.7) 183.4 (± 7.9) -
*compounds incubated for 48 hr at concentration listed in column heading; calculated cellular
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Figure 2.15. Cytotoxicity of β-aryl polyamide cores conjugated to C-terminal isophthalic acid (IPA) tails 
in A549 cells. Complete structures are given in Scheme S2.4. 
 
 Once again flow cytometric analysis proved informative in explaining this 
unexpected observation, as A549 cells dosed at increasing concentrations (100 nM–10 
µM) of 15-16 show concentration-dependent accumulation of parent polyamide 15, while 
β-aryl polyamide 16 shows relatively equivalent uptake at both 100 nM and 1000 nM 
(Figure 2.14). This is consistent with the small, but constant, inhibitory effect polyamide 
15 has on HIF1-α-mediated transcription, as judged by qRT-PCR analysis of VEGF gene 
expression (Figure 2.16).  
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Figure 2.16. Inhibition of hypoxia-induced gene expression by β-turn polyamides targeted to the hypoxia 
response element (HRE) of the vascular endothelial growth factor (VEGF) locus. The effect of β-
substituted polyamides 21 and 22 on desferoxamine (DFO)-induced VEGF gene expression was analyzed 
by qRT-PCR analysis. I = DFO induced. NI = non-induced. Polyamide 21 concentrations: 100, 1000, 
10,000 nM. Polyamide 22 concentrations: 10, 100, 1000 nM.  
 
 Therefore, while our studies show β-aryl turns provide a generally applicable 
approach to increase the uptake of polyamides at reduced concentrations, this 
modification can have a variable consequence on the upper limits of polyamide nuclear 
accumulation that may be required for biological effects. 
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Conclusions 
 Chemical approaches for controlling gene expression at the protein-DNA 
interface require efficient nuclear delivery of gene regulatory agents. Thus far, 
comprehensive efforts to define structure-uptake relationships for hairpin polyamides in 
cell culture have largely focused on the optimization of the C-terminus. Insights from 
these studies are reflected in our use of polyamides modified with a C-terminal 
isophthalic acid modification for gene regulation and cytotoxicity studies (1-12, 21-26), 
with the higher molecular weight FITC reserved for direct analysis of polyamide uptake 
(14-20).12,15 Here we explore integration of an additional uptake determinant at the 
hairpin polyamide β-aminobutyric acid turn. Introduction of functionality at the 
polyamide turn position has previously been most thoroughly explored in the design of 
covalent sequence-selective DNA alkylating agents.28,29 Our findings here represent an 
initial inquiry into the effect of turn modification on noncovalent sequence-selective 
DNA-binding agents, and have lead to the discovery of a polyamide (4) that exhibits 
excellent affinity for DNA and nanomolar inhibition of dexamethasone and DHT-induced 
gene expression in human cancer cells. This molecule represents one of the most 
biologically potent members of this compound-class (eight-ring hairpin polyamides) 
identified to date. 
 The second phase of this study examined the mechanism and generality of β-aryl 
turn modification as a vehicle for increasing polyamide potency using fluorescent 
polyamide conjugates and quantitative flow cytometry analysis. The power of this 
approach lies in its relatively simple calibration and ability to sample a large number of 
cells for any given condition. Our findings indicate the β-aryl turn of 14 aids polyamide 
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uptake, allowing rapid permeation and nuclear accumulation as compared to β-amino-
modified 13. When extended to hairpin polyamides with alternative heterocycle 
composition and DNA-binding preferences (15-20), uptake of polyamide-FITC 
conjugates was well-correlated with cytotoxicity and gene regulatory effects, implicating 
membrane permeability as a primary determinant of the biological activity for this class 
of molecules. However, while informative, these methods are not without caveats. First, 
the calculated nuclear concentrations cannot be taken as absolute values, as they do not 
take into account the known fluorescence enhancements exhibited by polyamide-FITC 
conjugates upon binding to DNA,30 subcellular localization, fluorescein photostabilty, or 
differences in the optical properties of cells as compared to fluorochrome-coated beads. 
Second, fluorescein modification can significantly alter the biological properties of 
hairpin polyamides (compare the IC50 of 4 with 14; Figure 2.8). Integration of a low 
molecular weight reporter into the hairpin polyamide scaffold is therefore attractive from 
the standpoint of streamlining activity and uptake assays. This approach may benefit 
from recent incorporation of click chemistry methods into many flow cytometry 
workflows.31,32 
 It is interesting to speculate as to the mechanism by which β-aryl turns expedite 
polyamide uptake. Studies of oligonucleotide-based therapies have shown that 
modification of these agents with highly lipophilic moieties, such as cholesterol, can 
facilitate association with the cell membrane and endocytosis.33,34 It is possible a similar 
effect mediates the delivery of β-aryl polyamides. Also interesting is the lack of nuclear 
accumulation of β-aryl polyamide 16 at higher concentrations. The finding that β-aryl 
modification promotes increased uptake at 100 nM but not 1000 nM suggests this may 
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result from a physical phenomena such as insolubility (due to aggregation) at the higher 
concentration. In general, β-aryl polyamides show decreased solubility relative to β-
amino compounds owing to their reduced charge at physiological pH.  
 Other than delivery, perhaps the most important future challenge lies in 
developing new methods to define the concentration-dependent effects of Py-Im 
polyamides on gene expression in living cells. Analytical techniques such as MPE 
footprinting and affinity cleavage have proven essential to the design of sequence-
selective DNA-binding agents,35,36 and reveal dose-dependent binding patterns that can 
be used to directly guide applications in vitro.37,38 Quantitative fluorescence analysis of 
polyamide uptake, as performed here, combined with recently developed high-throughput 
sequencing strategies for analysis of protein-DNA binding39,40 and gene expression39 
represent promising approaches to similarly footprint polyamide-induced perturbations 
and binding events in vivo, and thereby define the relationship between nuclear 
concentration and gene regulatory effects. 
 Overall, these findings highlight hairpin turn modification as a promising new 
strategy for intracellular delivery of Py-Im polyamides. In terms of applications, the 
increased potency of these analogues should prove immediately useful for testing in 
animal models, where the ability to work at lower concentrations will help overcome 
technical challenges of polyamide solubility and formulation. The amenability of the β-
aryl turn to substitution also raises the possibility of using it as a selective handle to 
optimize polyamide pharmacokinetic properties, such as plasma protein binding, through 
attachment of pendant chemical functionalities. Finally, β-aryl turns may prove useful for 
the delivery of molecular probes using polyamides as tethered DNA-binding domains 
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into living cells. The relevance of such strategies is highlighted by the numerous studies 
which have used polyamides to target the activity of alkylating agents,28 chromatin 
remodelling enzymes,41 and transcriptional activation domains42-43 to subsets of genomic 
loci. Future work will focus on characterizing the mechanism of β-aryl polyamide uptake 
and applying this technology to the manipulation of protein-DNA interactions in living 
systems. 
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Materials and Methods 
Reagents and Equipment 
 Anhydrous N,N-dimethylformamide (DMF), diisopropylethylamine (DIEA), 
triethylsilane (Et3SiH), trifluoroacetic acid (CF3CO2H [peptide synthesis grade]), 
isophthalic acid, and (±)-verapamil hydrochloride were purchased from Sigma-Aldrich. 
Fluorescein isothiocyanate (FITC, Isomer I) was purchased from Invitrogen. Kaiser oxime 
resin (LL, 200-400 mesh) and benzotriazole-1-yl-oxy-trispyrrolidinophosphonium 
hexafluorophosphate (PyBOP) were from Novabiochem. N-β-Cbz-N-γ-Boc-D-3,4-
diaminobutyric acid [Z-D-β-Dab(Boc)-OH] was purchased from Sigma Aldrich (product 
code 28206). All Boc-protected N-methylpyrrole and N-methylimidazole monomers and 
dimers for polyamide synthesis were prepared according to the published protocols.44-45 
Bulk grade solvents were purchased from Fisher Scientific. Centrifugation was performed 
in a Beckman Coulter bench-top centrifuge (Allegra 21R) equipped with a Beckman 
swing-out rotor (model S4180). Preparative HPLC purification was performed on an 
Agilent 1200 Series instrument equipped with a Phenomenex Gemini preparative column 
(250 x 21.2 mm, 5µm) with the mobile phase consisting of a gradient of acetonitrile 
(MeCN) in 0.1% CF3CO2H (aqueous). Polyamide synthesis was monitored by analytical 
HPLC, with analysis conducted on a Beckman Gold instrument equipped with a 
Phenomenex Gemini analytical column (250 x 4.6 mm, 5µm), a diode array detector, and 
the mobile phase consisting of a gradient of MeCN in 0.1% CF3CO2H (aqueous). 
Polyamide concentrations were measured by UV analysis on a Hewlett-Packard model 
8453 diode array spectrophotometer in distilled and deionized water (ddH2O) with a molar 
extinction coefficient (ε) of 69,500 M-1cm-1 at λmax of 310 nm.  
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Synthesis of Polyamides 
 
 All polyamide cores were synthesized by manual solid-phase synthesis on Kaiser 
oxime resin (Novabiochem) according to the previously published protocol.19 Polyamides 
were cleaved from resin by aminolysis with 3,3’-diamino-N-methyldipropylamine for 3 
hr at 55°C. Repeated cycles of precipitation and washing with diethyl ether were used to 
remove excess 3,3’-diamino-N-methyldipropylamine from polyamides prior to 
purification by reverse phase HPLC.20 The purified polyamide cores were modified at the 
C-terminal tail position by isophthalic acid (IPA) or fluorescein-5-isothiocyanate (FITC 
isomer I; Invitrogen) as previously described.15 Polyamides incorporating the β-Cbz-γ-
aminobutyric acid turns were subjected to repeated cycles of precipitation and washing 
with diethyl ether to remove excess reagents, resuspended in 9:1 CF3COOH/TFMSA (0.9 
mL, 5 min) to remove the benzyl carbamate group,21 and purified by HPLC to afford 
polyamides bearing a β-amino group at the turn. These compounds were coupled to the 
designated acids by PyBOP and subjected to a final step of HPLC purification to yield β-
aryl turn conjugates. Purity of all compounds was verified by analytical HPLC and 
matrix-assisted, LASER desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry. 
 
General Synthetic Procedure for Conjugation of β-Aryl Turn 
 A solution of benzoic acid (2.4 mg, 0.02 mmol) and PyBOP (10.4 mg, 0.02 mmol) 
in DIEA (14 µL, 0.2 mmol) and DMF (0.4 mL) was stirred at 23°C for 1 hr. Separately, 
polyamide 2 (800 nmol) was dissolved in DMF (0.1 mL) and slowly added to the pre-
activated isophthalic acid solution. The reaction was allowed to stand at 23°C for 1 hr and 
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monitored by analytical HPLC. Upon completion, Et2O (45 mL) was added and the 
reaction was vortexed thoroughly, resulting in formation of a brownish white precipitate 
that was isolated by centrifugation (~ 4500 rpm).46 After removal of the organic layer, the 
residual solid was dissolved in DMF (0.5 mL) with ultrasonication, and diluted with 20% 
MeCN in 0.1% CF3COOH (4.5 mL). Purification by reverse-phase HPLC followed by 
lyophilization provided β-aryl polyamide 4 (0.082 mmol, 91%). MS (MALDI-TOF) calc’d 
for C72H81N22O13 [M+H]+ 1461.6, found 1461.9. 
 
Polyamide Characterization Data 
 
1 MS (MALDI-TOF) calc’d for C65H76N21O12 [M+H]+ 1342.6, found 1589.8. 
2 MS (MALDI-TOF) calc’d for C65H77N22O12 [M+H]+ 1357.6, found 1357.8. 
3 MS (MALDI-TOF) calc’d for C67H79N22O13 [M+H]+ 1399.6, found 1399.9. 
4 MS (MALDI-TOF) calc’d for C72H81N22O12 [M+H]+ 1461.6, found 1461.9. 
5 MS (MALDI-TOF) calc’d for C71H80N23O13 [M+H]+ 1462.6, found 1462.7. 
6 MS (MALDI-TOF) calc’d for C72H80N23O15 [M+H]+ 1506.6, found 1506.5. 
7 MS (MALDI-TOF) calc’d for C72H82N23O13 [M+H]+ 1476.6, found 1476.2. 
8 MS (MALDI-TOF) calc’d for C78H85N22O13 [M+H]+ 1537.7, found 1537.5. 
9 MS (MALDI-TOF) calc’d for C73H81N22O15 [M+H]+ 1505.6, found 1505.8. 
10 MS (MALDI-TOF) calc’d for C73H81N22O15 [M+H]+ 1505.6, found 1505.8. 
11 MS (MALDI-TOF) calc’d for C78H93N24O14 [M+H]+ 1589.7, found 1589.8. 
12 MS (MALDI-TOF) calc’d for C78H93N24O14 [M+H]+ 1589.7, found 1589.8. 
13 MS (MALDI-TOF) calc’d for C78H83N23O14S [M+H]+ 1597.6, found 1598.0. 
14 MS (MALDI-TOF) calc’d for C85H87N23O15S [M+H]+ 1701.6, found 1701.8. 
15 MS (MALDI-TOF) calc’d for C77H80N22O14S2Cl1 [M+H]+ 1635.5, found 1635.6. 
16 MS (MALDI-TOF) calc’d for C84H83N22O15S2Cl1 [M+H]+ 1738.6, found 1738.3. 
17 MS (MALDI-TOF) calc’d for C77H80N24O14S1 [M+H]+ 1596.6, found 1596.8. 
18 MS (MALDI-TOF) calc’d for C84H86N24O15S1 [M+H]+ 1702.6, found 1702.8. 
19 MS (MALDI-TOF) calc’d for C70H80N23O14S1 [M+H]+ 1498.6, found 1498.9. 
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20 MS (MALDI-TOF) calc’d for C77H83N23O15S1 [M+H]+ 1601.6, found 1601.7. 
21 MS (MALDI-TOF) calc’d for C64H73N21O12S1Cl1 [M+H]+ 1394.5, found 1394.6. 
22 MS (MALDI-TOF) calc’d for C71H76N21O13S1Cl1 [M+H]+ 1497.5, found 1497.7. 
23 MS (MALDI-TOF) calc’d for C64H74N23O12 [M+H]+ 1356.6, found 1356.8. 
24 MS (MALDI-TOF) calc’d for C71H77N23O13 [M+H]+ 1459.6, found 1459.6. 
25 MS (MALDI-TOF) calc’d for C57H73N22O12 [M+H]+ 1257.6, found 1257.5. 
26 MS (MALDI-TOF) calc’d for C64H76N22O13 [M+H]+ 1360.6, found 1360.8. 
 
Synthetic Schemes 
 
 
Scheme S2.1: Monomers, dimers, and general scheme for solid-phase synthesis of polyamides analyzed in 
this study. 
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Scheme S2.2: Scheme for solution-phase derivatization of polyamides and conjugation of β-aryl turns. 
 
 
Scheme S2.3: Complete structures of polyamides 21-26. 
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Scheme S2.4: Scheme and complete chemical structures for fluorescent polyamides 14-20.  
1. PyBOP, DIEA,
    FITC isomer I
2. TFMSA, TFA (9:1)
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Cell Culture 
 All cell lines were purchased from ATCC (Manassas, VA) and maintained in the 
following media: A549 cells (F-12K); LNCaP (RPMI 1640); HCT-116 (McCoy’s 5a 
Medium Modified); MCF-7 (Eagle’s Minimum Essential Medium). All media were 
supplemented with 10% FBS and cultured at 37°C under 5% CO2. 
 
Sulforhodamine B Assay of Polyamide Cytotoxicity 
 IC50 values for cytotoxicity were determined in 96-well microplates using the 
sulforhodamine B colorimetric assay for cellular protein content as previously 
described.22 All polyamide stock solutions were prepared in neat DMSO and dosed to 
give a final concentration of ≤ 0.3% DMSO. Briefly, cell lines were plated in 100 µL of 
the defined media at the following densities: A549 (1000 cells/well); LNCaP (5000 
cells/well), HCT-116 (750 cells/well), MCF-7 (3000 cells/well). After 24 hr, polyamides 
were added to adhered cells in 100 µL of media by serial dilution. Quadruplicate wells 
were used for each polyamide concentration. After 72 hr, the medium was replaced with 
100 µL fresh medium, and cells were allowed to recover for 24 hr. Following recovery, 
cells were fixed with 100 µL 10% trichloroacetic acid solution, washed, stained, and 
dried as described. For 48 and 72 hr polyamide treatments, the procedure was followed as 
above with A549 cells plated at 3000 and 2000 cells per well, respectively. After 
solubilization of the bound dye in 10 mM Tris (pH 8), the absorbance was measured at 
490 nm on a Victor microplate reader (PerkinElmer). The data are charted as a 
percentage of untreated controls, corrected for background absorbance. IC50 is defined as 
the concentration that inhibits 50% of control cell growth. These values were determined 
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by non-linear least-squares regression fit to Y= A + (B-A)/(1+10^((Log EC50-X)*H, 
where A=max., B=min., and H=Hill Slope. All calculations were performed using Prism 
4 (GraphPad) software. Three independent trials were averaged; stated IC50 values 
represent the mean and standard deviation.  
 
Thermal Melting Temperature Analysis 
 Melting temperature analysis was performed on a Varian Cary 100 
spectrophotometer equipped with a thermo-controlled cell holder possessing a cell path 
length of 1 cm. An aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 10 mM 
MgCl2 and 5 mM CaCl2 at pH 7.0 was used as analysis buffer. Oligonucleotides (0.1 mM 
stock solutions dissolved in 10 mM Tris-Cl, 0.1 mM EDTA, pH 8.0) were purchased 
from Integrated DNA Technologies. DNA duplexes and hairpin polyamides were mixed 
to a final concentration of 2 µM and 2.4 µM, respectively, for each experiment. Prior to 
analysis, samples were heated to 90°C and cooled to a starting temperature of 25°C with 
a heating rate of 5°C/min for each ramp. Denaturation profiles were recorded at λ = 260 
nm from 25°C to 90°C with a heating rate of 0.5°C/min. The reported melting 
temperatures were defined as the maximum of the first derivative of the denaturation 
profile, and represent the average of four measurements. 
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Quantitative Real-Time Polymerase Chain Reaction (qrt-PCR) Analysis of Nuclear 
Receptor-Mediated Gene Expression 
 To analyze the effects of polyamide-treatment on dexamethasone-induced gene 
expression, A549 cells were plated in 24-well plates at a density of 15–25 x 103 cells per 
well (30–50 x 103 cells/ml).8 After 24 hr the medium was replaced by F-12K containing 
10% charcoal-stripped FBS, and polyamides were added to the specified concentrations 
(1-10,000 nM). Cells were incubated with polyamides for 12, 24, or 48 hr, followed by 
induction with dexamethasone (100 nM). After 6 hr cells were harvested and mRNA was 
isolated (RNEasy 96 kit - Qiagen) and reverse transcribed (Transcriptor First Strand 
cDNA Synthesis kit – Roche). Quantitative real-time PCR was performed with FastStart 
Universal SYBR Green Master Mix (Roche) on an ABI 7300 qPCR instrument (Applied 
Biosystems) following the manufacturer’s protocol. A similar protocol was utilized to 
measure 4,5α-dihydrotestosterone (DHT)-induced gene expression in LNCaP cells, with 
the following modifications: (1) the initial plating density was 20–30 x 103 cells per well 
(40–60 x 103 cells/ml), (2) cells were incubated with polyamides for 48 hr, (3) cells were 
induced with DHT (10 nM) for 16 hr.7 In both cases, cDNA corresponding to the genes 
of interest was measured relative to β-glucuronidase as an endogenous control. Primer 
sequences are provided in the Supplementary Data. 
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Confocal Microscopy Analysis 
 For microscopy experiments, A549 cells in F-12K medium were plated into 
culture dishes equipped with glass bottoms for direct imaging (MatTek) at a density of 20 
x 103 cells per dish (100 x 103 cells/mL). Cells were grown in the glass-bottom dishes for 
24 hr. Medium was then removed and replaced with 200 µL of fresh medium 
supplemented with FITC-labelled polyamides (1 µM) in DMSO (final concentration 
0.1%). Cells were incubated at 37°C for 16 hr, followed by removal of media, gentle 
washing with 100 µL PBS, and addition of fresh medium immediately prior to imaging. 
For colocalization experiments, 15 µM Hoechst 33342 (0.5 mM stock in ddH2O) and 1 
µM Mitotracker Red CM-H2XRos (1 mM stock in DMSO) were added 2 hr prior to 
imaging. For time-course experiments, cells were imaged directly after polyamide 
addition using an environmentally-controlled microscopy chamber (37 °C, 5 % CO2). 
Imaging was performed at the Caltech Beckman Imaging Center using a Zeiss LSM 510 
Meta NLO 2-photon inverted laser scanning microscope equipped with a 40x oil-
immersion objective lens. Polyamide–fluorescein conjugates and Mitotracker were 
imaged in multi-track mode using 488 nm and 543 nm laser excitation with a pinhole of 
375 µm and standard filter sets for fluorescein and rhodamine respectively. Hoechst was 
imaged using 800 nm two-photon excitation with an HFT KP680 dichroic and a 390-465 
nm bandpass filter with a fully open pinhole. All images were analyzed using Zeiss LSM 
software. 
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Flow Cytometry Analysis. 
 For flow cytometry experiments A549 cells were plated in 6-well plates at a 
density of 500 x 103 cells per well (133 x 103 cells/ml), and allowed to adhere for 16-24 
hr before treatment with polyamide-FITC conjugates (100-10,000 nM). Cells were grown 
for 6, 12, 24, or 48 hr, the medium removed, washed with cold PBS, and trypsinized for 5 
min at 37 ° C. The trypsinized cells were combined with the cell culture supernatant and 
wash solution, and centrifuged for 5 min at 300 x g. This pellet was resuspended, washed 
with cold PBS, pelleted for 5 min at 300 x g and resuspended in 800 µL Hank’s Balanced 
Salt Solution (2.5 mg/mL BSA, 10 mM HEPES, pH 7.0, no Mg2+, no Ca2+, no phenol 
red). Cell viability was checked with trypan blue stain and found to be ≥ 90-95% in all 
cases. Live cells were then diluted to a concentration of 5 x 105 cells/mL pipetted through 
a 40 µm cell strainer (BD Falcon) into 5 mL polystyrene round-bottom tubes (BD 
Falcon). Just prior to analysis, cells were stained for viability using 7-amino-actinomycin 
D (7-AAD; eBioscience). Analyses were performed on a BD Bioscience FACSCalibur 
instrument at the Caltech Flow Cytometry Cell Sorting Facility using standard filter sets 
for fluorescein and 7-AAD. SPHERO Rainbow Calibration Particles (6 peaks, 3.0-3.4 
µm; Spherotech) were used as calibration standards. For each condition 10,000 cells were 
analyzed. Fluorescence values are representative of the relative median fluorescence 
(RMF) intensity of the main population, gated for viability based on 7-AAD dye 
exclusion. Comparison of RMFs of polyamide-labelled cells with SPHERO Rainbow 
Calibration Particles was used to calculate molecules of equivalent fluorescein per cell, 
which was converted to a nuclear concentration based on modelling the A549 nucleus as 
a cylinder with radius 10 µm and height 5 µm to give a calculated nuclear volume of 1 x 
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10-12 L (estimates based on confocal microscopy). All data were analyzed using FlowJo 
v8.8.2 (TreeStar) and indicate the average and standard deviation of two trials. 
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Abstract 
 
Cyclic Py-Im polyamides containing two GABA turn units exhibit enhanced DNA 
binding affinity, but extensive studies of their biological properties have been hindered due 
to synthetic inaccessibility. A facile modular approach towards cyclic polyamides has been 
developed via microwave-assisted solid-phase synthesis of hairpin amino acid oligomer 
intermediates followed by macrocyclization. A focused library of cyclic polyamides 1-7 
targeted to the androgen response element (ARE) and the estrogen response element (ERE) 
were synthesized in 12-17% overall yield. The Fmoc protection strategy also allows for 
selective modifications on the GABA turn units that have been shown to improve cellular 
uptake properties. The DNA binding affinities of a library of cyclic polyamides were 
measured by DNA thermal denaturation assays and compared to the corresponding hairpin 
polyamides. Fluorescein-labeled cyclic polyamides have been synthesized and imaged via 
confocal microscopy in A549 and T47D cell lines. The IC50 values of compounds 1-7 and 
9-11 were determined, revealing remarkably varying levels of cytotoxicity. 
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Introduction  
The selective modulation of eukaryotic gene expression by small molecules may 
have important implications in the field of chemical biology and human medicine. 
Pyrrole-imidazole polyamides are a class of synthetic ligands that can be programmed to 
bind the minor groove of specific DNA sequences.1 Antiparallel, side-by-side N-
methylpyrrole (Py) and N-methylimidazole (Im) carboxamides (Im/Py) pairs distinguish 
G·C from C·G base pairs, N-methyl-3-hydroxypyrrole (Hp)/Py shows specificity for T·A 
over A·T, whereas Py/Py pairs are specific for both T·A and A·T.2-5 By linking two 
strands of these heterocyclic oligomers via a γ-amino butyric acid (GABA) turn unit, 
hairpin Py-Im polyamides can be programmed to bind a large library of DNA sequences 
with affinities comparable to natural DNA-binding proteins.6-8 Hairpin polyamides have 
been shown to localize to the nuclei of living cells, and regulate endogenous gene 
expression by disrupting protein/DNA interfaces.9-17 Cyclic polyamides containing a 
second GABA turn unit exhibit further enhanced DNA binding properties.18-21 We have 
recently demonstrated their gene regulatory effects on AR-activated gene expression in 
prostate cancer models.22 
This discovery has opened a new area of research towards transcriptional 
regulation with small molecules, but the relative synthetic inaccessibility of cyclic 
polyamides has remained a bottleneck for examining libraries of structural variants that 
would modulate affinity, cell uptake and biological activity. Initial solid-phase methods 
were low yielding, and required substantial pre-modifications of the PAM resin.18-20 
While the solution-phase synthesis of cyclic polyamides remains useful in large-scale 
target-oriented synthesis, it has limited practicality towards libraries for screening 
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biological activities.22 The recent report by Morinaga et al. offers a modular approach to 
achieve cyclic polyamides by intramolecular coupling of a cysteine and a chloroacetyl 
residue, but the modification of the optimal three-carbon GABA turn into a sulfur-
containing four-atom linker compromises its DNA binding affinity and may alter its 
biological properties.23 
We report here a solid-phase polyamide synthesis of a key hairpin amino acid 
oligomer intermediate, which followed by intramolecular cyclization, affords cyclic 
polyamides 1-8 in good yields. The polyamides were synthesized step-wise on 2-
chlorotrityl resin. The modular approach led to rapid access of a focused library of cyclic 
polyamides 1-7 with various core sequences and turn unit modifications. The utilization 
of Fmoc chemistry allowed for differentially protected turn units, which were modified 
selectively to complement existing cellular imaging and cell uptake enhancement 
technologies.24 We examined the DNA binding properties and cytotoxicity profiles of 
compounds 1-11, and the cellular localization of cyclic polyamides 12-14 by fluorescence 
microscopy.  
 
Figure 3.1: The basic strategy for synthesis of differentially protected cyclic Py-Im polyamides. 
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Results and Discussion 
 
Microwave-Assisted Solid-Phase Synthesis 
Due to previously observed decomposition of the conjugated C-terminal free 
carboxylic acid in polyamide intermediates, 2-chlorotrityl-chloride (2-Cl-Trt-Cl) resin was 
chosen for its mild synthesis and cleavage conditions. Polyamide synthesis on this resin has 
been previously reported by Aldrich-Wright and co-workers, but a resin-bound β-alanine 
linker was used in both instances, and a new loading procedure was therefore needed.25,26 
2-Cl-Trt-Cl resin was first loaded with the Fmoc-protected Py monomer in N,N-
dimethylformamide (DMF) and capped with methanol. Resin substitution levels were 
determined by the Fmoc test and confirmed by weighing the dry mass of the loaded resin. 
Fmoc deprotection was achieved using a 50% piperidine in DMF solution. In light of the 
recent improvements in both efficiency and yield, the couplings were performed under 
microwave-assisted conditions using the desired PyBOP-activated monomers.27  
 
Resin-Bound 
Nucleophile 
Deprotection 
Timesa 
Coupling Timesb (min) 
Py Im GABA/β-Ala 
Py 3 x 10min 20 20 20 
Im 3 x 10min IRc 30 30 
GABA/β-Ala 2 x 5min 20 20 20 
 
Table 3.1 Standard Fmoc deprotection and microwave-assisted coupling times for solid-phase polyamide 
synthesis. aAll deprotections were performed in 50% piperidine in DMF. bAll coupling reactions were 
conducted under microwave-assisted conditions at 50 oC with a 0.3M solution of the activated monomers (3 
eq. monomer acid, 3 eq. PyBOP, 8 eq. DIEA, DMF). cFmocPyOH coupling onto resin with N-terminal Im 
was incomplete even at 60oC for up to 1h. Synthesis of polyamide sequences that require this linkage should 
use the FmocPyImOH dimer instead, demonstrated later in the synthesis of 8. 
 
Initial syntheses performed at 60oC led to premature cleavage of intermediates off 
the 2-Cl-Trt resin, and 50oC couplings were therefore preferable.  The challenging Im to Py 
coupling required an FmocPyImOH dimer, which was obtained via an optimized procedure 
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by Weltzer and Wemmer.28 The deprotection and coupling conditions are detailed in Table 
3.1. This 2-step deprotection-coupling procedure was repeated until the desired polyamide 
sequence was achieved. To build the small library of polyamides in a modular fashion, the 
resin was split into different batches at corresponding steps for further derivatization.  Upon 
completion, the N-terminal Fmoc-protected polyamide oligomer was cleaved from the 
resin with 30% hexafluoroisopropanol (HFIP) in dichloromethane (DCM), concentrated in 
vacuo, and the resulting residue was subjected to a 20% piperidine solution to remove the 
Fmoc group. Direct cleavage of the free-amine polyamide oligomer was attempted, but 
found to be ineffective due to poor solubility of the zwitterion intermediate in the cleavage 
solution. After purification by high-performance liquid chromatography (HPLC), the 
desired polyamide intermediates 18-24 were obtained in 31-40% yields. 
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Scheme 3.1: Microwave-assisted synthesis of cyclic polyamides 1-7. 1All PyBOP-mediated coupling 
conditions were performed under microwave-assisted conditions (see Table 3.1). 2Reagents and conditions: (i) 
50% piperidine, DMF; (ii) FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, DMF; (iv) FmocPyOH, 
PyBOP, DIEA, DMF; (v) 50% piperidine, DMF; (vi) FmocImOH, PyBOP, DIEA, DMF; (vii) 50% 
piperidine, DMF; (viii) Z-β-Dab(Fmoc)-OH (for 1-6) or Boc-β-Dab(Fmoc)-OH (for 7), PyBOP, DIEA, DMF; 
(ix) 50% piperidine, DMF; (x) FmocPyOH, PyBOP, DIEA, DMF; (xi) 50% piperidine, DMF; (xii) 
FmocPyOH, PyBOP, DIEA, DMF; (xiii) 50% piperidine, DMF; (xiv) FmocPyOH (for 1-3) or FmocImOH 
(for 4-7), PyBOP, DIEA, DMF; (xv) 50% piperidine, DMF; (xvi) FmocImOH, PyBOP, DIEA, DMF; (xvii) 
50% piperidine, DMF; (xviii) Z-β-Dab(Fmoc)-OH (for 1 & 4 & 7) or Fmoc-GABA-OH (for 2 & 5) or Boc-β-
Dab(Fmoc)-OH (for 3 & 6), PyBOP, DIEA, DMF; (xix) 30% HFIP, DCM; (xx) 20% piperidine, DMF; (xxi) 
DPPA, DIEA, DMF; (xxii) 10% TFMSA, TFA (for 1, 2, 4 & 5) or TFA (for  3, 6 & 7).  
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DPPA-Mediated Macrocyclization 
The polyamide macrocyclization step was achieved by a DPPA-mediated ring-
closing reaction between the N-terminal amino group and the C-terminal carboxylic acid. 
This method was first employed by Cho et al. in the synthesis of cyclic polyamides.18,29,30 
In order to obtain a general work-up procedure applicable to polyamides of various 
lipophilicities, diisopropylethylamine (DIEA) was used as the base in place of sodium 
bicarbonate (NaHCO3) in the original conditions.31 Deprotection of the turn units with 
trifluoromethanesulfonic acid (TFMSA) or trifluoroacetic acid (TFA), followed by HPLC 
purification, afforded polyamides 1-7 in 37-43% yields over 2 steps.  
 
Table 3.2: Summary Table of MALDI-TOF Data and Synthetic Yields for Cyclic Polyamides 1−8 and 
Intermediates 18−25. 
 
Selective Derivatization of Cyclic Polyamide Turn Units 
 By taking advantage of the Fmoc protection scheme, the two GABA β-amino 
groups in 3 were differentially protected. This is further highlighted in 6 and 7, which 
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share the same asymmetric polyamide core targeted to the 5’-WGGWCW-3’ sequence, 
and allowed for the selective conjugation of a benzoic acid moiety on a single turn unit in 
polyamides 9-11 that has been recently developed to enhance the cellular localization 
properties of hairpin polyamides.24  
 
Scheme 3.2: Preparation of cyclic polyamides 9-11. Reagents and conditions: (i) BzOH, PyBOP, DIEA, 
DMF; (ii) 10% TFMSA, TFA. 
 
 Mono-substituted benzyl carbamate (Cbz) polyamides 3, 6 and 7 were chosen as 
targets based on unpublished results indicating Cbz-functionalized polyamides are 
biologically active (Supp. Fig. S16). Cyclic polyamides 12-14 with a fluorescein dye 
were synthesized in a similar fashion, and imaged in live cells via fluorescence 
microscopy. Furthermore, both the solubility and the pharmacokinetic profiles of cyclic 
polyamides can be highly dependent on subtle structural modifications, and this method 
allows for the modular synthesis of these structural variants in an efficient manner.31-33 
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Scheme 3.3: Preparation of FITC-labeled cyclic polyamides 12-14. Reagents and conditions: (i) FITC, DIEA, 
DMF; (ii) 10% TFMSA, TFA. 
 
Synthesis of Cyclic and Hairpin Polyamides with C-terminal Imidazole Units 
 Previously established solid-phase polyamide synthesis methods have been 
generally limited to sequences beginning with a pyrrole monomer.34,35 Solid-phase 
synthesis of polyamides starting with imidazole units on the commonly used Kaiser oxime 
resin have been low yielding, mainly attributed to the sensitivity of the oxime-imidazole 
linkage that lead to premature cleavage of resin-bound intermediates. The addition of an 
aliphatic linker (e.g. Boc-β-Ala-PAM resin) circumvents this issue, but previous studies on 
hairpin polyamides with C-terminal β-alanine motifs have shown reduced cellular uptake 
properties and thus diminished gene regulatory effects of these products.9 Using the 
microwave-assisted conditions reported above, cyclic polyamide 8 targeted to the 5’-
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WCGWGW-3’ sequence found in E-Box binding sites have been synthesized in 13% yield 
overall. 
 
Scheme 3.4: Preparation of cyclic polyamide 8. All PyBOP-mediated coupling conditions were performed 
under microwave-assisted conditions (see Table 3.1). Reagents and conditions: (i) 50% piperidine, DMF; (ii) 
FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, DMF; (iv) FmocPyOH, PyBOP, DIEA, DMF; (v) 
50% piperidine, DMF; (vi) Z-β-Dab(Fmoc)-OH, PyBOP, DIEA, DMF; (vii) 50% piperidine, DMF; (viii) 
FmocImOH, PyBOP, DIEA, DMF; (ix) 50% piperidine, DMF; (x) Fmoc-β-Ala-OH, PyBOP, DIEA, DMF; 
(xi) 50% piperidine, DMF; (xii) FmocPyImOH, PyBOP, DIEA, DMF; (xiii) 50% piperidine, DMF; (xiv) Z-β-
Dab(Fmoc)-OH, PyBOP, DIEA, DMF; (xv) 30% HFIP, DCM; (xvi) 20% piperidine, DMF; (xvii) DPPA, 
DIEA, DMF; (xviii) 10% TFMSA, TFA. 
 
Initial attempts starting with FmocImOH-loaded resin resulted in undesired 
cleavage during subsequent steps, and so syntheses began with loading of the 
FmocPyImOH dimer onto 2-chlorotrityl resin. After deprotection-coupling of the 
corresponding monomer units, followed by resin cleavage and Fmoc removal, polyamide 
 98 
intermediate 25 was isolated by HPLC purification in 34% yield. DPPA-mediated 
cyclization of 25, followed by Cbz deprotection afforded cyclic polyamide 8 in 39% yield 
over 2 steps.  
Hairpin polyamide 17 was synthesized in a similar stepwise manner to afford the 
Im-capped, C-terminal acid intermediate, which was then coupled to a 3,3’-diamino-N-
methyldipropylamine linker, followed by isophthalic acid conjugation, Boc deprotection, 
and isolation in 24% yield over 16 steps (Scheme 3.5).  This is a step forward which allows 
for the synthesis of both cyclic and non-β-alanine-linked hairpin polyamides with 
sequences beginning with an imidazole unit, further expanding the scope of targetable 
DNA sequences and inhibition of transcription factor-mediated gene expression by Py-Im 
polyamides.  
 
Scheme 3.5: Preparation of hairpin polyamide 17. All PyBOP-mediated coupling conditions were performed 
under microwave-assisted conditions (see Table 3.1). Reagents and conditions: (i) 50% piperidine, DMF; (ii) 
FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, DMF; (iv) FmocPyOH, PyBOP, DIEA, DMF; (v) 
50% piperidine, DMF; (vi) Boc-b-Dab(Fmoc)-OH, PyBOP, DIEA, DMF; (vii) 50% piperidine, DMF; (viii) 
FmocImOH, PyBOP, DIEA, DMF; (ix) 50% piperidine, DMF; (x) Fmoc-β-Ala-OH, PyBOP, DIEA, DMF; 
(xi) 50% piperidine, DMF; (xii) PyImOH, PyBOP, DIEA, DMF; (xiii) 30% HFIP, DCM; (xiv) 3,3’-diamino-
N-methyldipropylamine, PyBOP, DMF; (xv) Isophthalic acid, PyBOP, DIEA, DMF; (xvi) TFA. 
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Thermal Stabilization of DNA Duplexes by Polyamides 
Py-Im polyamide-DNA binding affinities and specificities have historically been 
measured by quantitative DNase I footprinting assays.36 As previously reported, however, 
cyclic polyamides have exceptionally high DNA binding affinities that exceed the detection 
limit of this experiment (i.e. Ka ≥ 2 x 1010 M-1).22,37,38 The DNA binding affinities of cyclic 
polyamides 1-14 have been rank ordered by magnitude of DNA thermal stabilization 
(ΔTm), and compared to the corresponding hairpin polyamides 14-16. Spectroscopic 
measurements were performed on 12-mer DNA duplexes with sequences 5’-
CGATGTTCAAGC-3’, 5’-CGATGGTCAAGC-3’, and 5’-CGATCGTGAAGC-3’, each 
containing a match binding site for the corresponding polyamides.  
Consistent with the findings of Chenoweth et al, the ΔTm value for bis-amino cyclic 
polyamide 1 (ΔTm = 26.1oC) was calculated to be significantly higher than that of hairpin 
polyamide 15 (ΔTm = 22.0oC).22 So while 15 has an established binding affinity to the 
match androgen response element (ARE) half-site (5’-WGWWCW-3’) in the 
subnanomolar range, cyclic polyamide 1 provides even greater stabilization to such DNA 
duplexes. Mono-unsubstituted cyclic polyamide 2 provides less DNA stabilization 
compared to 1 (ΔTm = 20.4oC), which is likely due to the loss of a positive charge and thus 
the loss of favorable electrostatic interactions with the negatively-charged DNA backbone. 
Perhaps more surprising is the high ΔTm values retained by mono-protected cyclic 
polyamides 3 (ΔTm = 27.3oC) and 9 (ΔTm = 28.0oC), each containing a lone free amino 
group and net +1 charge.  As shown in Figure 3.2, the benzoyl (Bz) group in 9 projects 
straight down the minor groove, avoiding unfavorable steric interactions with the groove 
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wall, and may offer insight into the high degree of DNA stabilization by 3 and 9 
comparable to the bis-amino cycle 1.  
 
 
 
 
 
Figure 3.2 (Left) Stick model and (right) space-filling model of benzoyl-substituted turn along the DNA 
minor groove from three different angles (A-C). Based on published crystal structure by Chenoweth et al 
(PDB ID: 3OMJ).  
 
A 
B 
C 
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Fluorescein-conjugate 12 (ΔTm = 21.8oC) has a DNA binding affinity lower than 3 
and 9, perhaps due to increased steric clashes from the larger substitution group and 
unfavorable electrostatic interactions from the negatively-charged fluorescein group, but 
still binds DNA at a similar level to 15.  
 
Table 3.3: Tm Values for Polyamide Library. 
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The magnitude of stabilization provided by cyclic polyamides 4-7, 10-11, and 13-
14 targeted to estrogen response element (ERE) half-sites (5’-WGGWCW-3’) follows a 
similar pattern to the aforementioned ARE-targeting series. Mono-unsubstituted cycle 5 
(ΔTm = 18.6oC) stabilizes the duplex at a comparable level to hairpin polyamide 16 (ΔTm = 
16.7oC), whereas bis-amino compound 4 (ΔTm = 23.2oC) has a higher ΔTm value. The 
mono-Cbz cycles 6 (ΔTm = 23.6oC) and 7 (ΔTm = 24.3oC), mono-Bz substituted 10 (ΔTm = 
26.0oC) and 11 (ΔTm = 25.1oC), and mono-fluorescein conjugates 13 (ΔTm = 22.2oC) and 
14 (ΔTm = 21.0oC) each bind DNA similar to 4.  
Cyclic polyamide 8 (ΔTm = 13.4oC) binds the match 5’-WCGWGW-3’ sequence at 
an elevated level compared to hairpin 17 (ΔTm = 6.6oC), which may prove important 
towards targeting oncogenic transcription factors such as c-Myc that act through binding 
canonical E-Box (5’-CACGTG-3’) sequences.  
 
Sulforhodamine B Cytotoxicity Assay for Compounds 1-11 
The cytotoxicities of compounds 1-11 were assessed in A549 human lung 
carcinoma and T47D human breast cancer cell lines (Tables 3.4 & 3.5).  The cyclic 
polyamides targeted to the 5’-WGWWCW-3’ sequence generally exhibit a higher level of 
cytotoxicity than the 5’-WGGWCW-3’series, which is consistent with the trends observed 
in the DNA thermal denaturation analysis and confocal microscopy studies. Detailed 
inspection of the IC50 values within the series of compounds and across the cell lines, 
however, offers some unanticipated insights into the different biological properties of these 
minor structural variants. 
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Bis-amino cycle 1, which has previously been shown to be biologically active, did 
not display any significant level of cytotoxicity in either cell line (IC50 > 30 µM). Mono-
unsubstituted compound 2 (IC50 = 4.9 µM) and mono-Bz 9 (IC50 = 1.0 µM) were 
comparably cytotoxic to hairpin polyamide 15 (IC50 = 3.1 µM) in A549 cells, but an order 
of magnitude more cytotoxic (IC50 = 74 nM & 79 nM, respectively) than 15 (IC50 = 710 
nM) in T47D cells. The mono-Cbz cycle 3 was consistently the most cytotoxic compound 
in both A549 (IC50 = 160 nM) and T47D (IC50 = 25 nM) cell lines. 
 
Table 3.4: SRB cytotoxicity data on compounds 1-3, 9, and 15, in A549 and T47D cells, 72 hr incubation. 
 
For the 5’-WGGWCW-3’ targeting polyamides, the only compound that exhibited 
an IC50 value lower than 30 µM in A549 cells was the mono-Cbz compound 6 (IC50 = 1.9 
µM). In T47D cells, consistent with the 5’-WGWWCW-3’ series, bis-amino cycle 4 (IC50 > 
30 µM) was found to be not significantly cytotoxic and 6 (IC50 = 460 nM) was the most 
cytotoxic compound. Mono-unsubstituted cycle 5 (IC50 = 0.82 µM) again shares a 
comparable level of cytotoxicity with the reference hairpin 16 (IC50 = 1.1 µM), whereas 
mono-Bz compounds 10 (IC50 = 13.3 µM) and 11 (IC50 = 7.5 µM) are both an order of 
magnitude less cytotoxic.  
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Table 3.5: SRB cytotoxicity data on compounds 4-7, 10-11, and 16, in A549 and T47D cells, 72 hr 
incubation. 
 
Perhaps most interestingly, mono-Cbz compound 7 did not exhibit observable 
levels of cytotoxicity (IC50 > 30 µM) in either A549 or T47D cells. Considering that 7 is a 
regioisomer of 6, where the Cbz group is simply swapped onto the other turn, and that 7 
only differs from 3 by a single –CH to -N substitution, it is rather surprising that 7 is more 
than 15- to 65- fold less cytotoxic than 6 and at least 180- to 1200- fold less cytotoxic than 
3 in the two examined cell lines. Given the comparable DNA stabilization properties 
between 6 and 7, and their common core sequence, we would not have predicted this vast 
discrepancy in cytotoxicity.  
This study has demonstrated the large and somewhat unpredictable effects in 
biological activity induced by small structural variations of cyclic polyamides. Based on 
our preliminary work, the aggregation and pharmacokinetic properties of polyamides also 
vary greatly depending on structural modifications.31-33 All this combines to highlight the 
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importance of a fast and reliable method to generate focused libraries of cyclic polyamides 
for future research. 
 
Confocal Microscopy of Cyclic Polyamide-Fluorescein Conjugates 12-14 
To directly examine the cellular localization of cyclic polyamides, fluorescein 
conjugates 12-14 were synthesized and visualized in living cells via confocal microscopy 
(Figs. 2 & 3). The selective conjugation of a single fluorescein molecule not only helped 
retain a free amino group for solubility purposes, but also allowed for the qualitative 
comparison of the two fluorescein conjugates 13 and 14 that share the same asymmetric 
polyamide core. 
In each of the cases examined, cyclic polyamides 12-14 appear to permeate through 
the cellular membrane and localize in the cell nucleus, which was confirmed by the co-
localization with Hoechst 33258 DNA stain. For ease of qualitatively assessing compound 
uptake, all A549 images were taken at a 660 fluorescence gain level, and all T47D images 
were taken at 600 fluorescence gain.  Comparing Figures 3.3 and 3.4, the fluorescence 
levels of compounds 12-14 in T47D cells are all significantly higher than in A549, and this 
is only further amplified by this difference in gain levels.  
Compound 12 matched to the 5’-WGWWCW-3’ sequence exhibits the highest 
level of nuclear localization in both cell lines. Among the two 5’-WGGWCW-3’ targeting 
cycles, polyamide 14 qualitatively appears to have a relatively higher fluorescence signal in 
the cell nuclei in both A549 and T47D cells. This may help explain the cytotoxicity data 
reported above, where compounds 6 and 11 with Cbz and Bz substitutions on the same side 
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as the fluorescein in 14 consistently display larger biological effects than 7 and 10, which 
are more structurally similar to cyclic polyamide 13.  
 
Figure 3.3: Confocal microscopy of cyclic polyamide-fluorescein conjugates 12 (top), 13 (middle), and 14 
(bottom) in A549 cells. In order to confirm nuclear localization, the fluorescence panel (left) was compared 
with Hoechst 33258 staining (middle) and overlay (right).  
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Figure 3.4: Confocal microscopy of cyclic polyamide-fluorescein conjugates 12 (top), 13 (middle), and 14 
(bottom) in T47D cells. In order to confirm nuclear localization, the fluorescence panel (left) was compared 
with Hoechst 33258 staining (middle) and overlay (right). 
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Conclusions 
We have described a modular solid-phase synthesis method, which, when 
combined with an established DPPA-mediated macrocyclization step, afforded cyclic 
polyamides in a high-yielding and time-efficient manner. Using this method, we have 
overcome previous limitations and synthesized both cyclic and hairpin polyamides that 
start with an imidazole unit. The binding affinities of all synthesized cycles have been 
assessed by DNA thermal denaturation assays and compare favorably to hairpin 
polyamides that bind their match DNA sequences at subnanomolar concentrations. 
Furthermore, the protection strategy of our method allows for selective modification of the 
GABA turn units, which we have used to rapidly generate a focused library of compounds. 
The cytotoxicity and uptake analysis of the cyclic polyamides revealed unexpected 
properties that further highlight the need for an efficient method to synthesize structural 
variants of cyclic polyamides for future studies.   
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Materials and Methods 
Reagents and Equipment 
2-Chlorotrityl chloride (2-Cl-Trt-Cl) resin was purchased from Bachem. 
FmocPyOH and FmocImOH monomers were purchased from Wako. PyBOP was 
purchased from NovaBioChem. Boc-β-Dab(Fmoc)-OH was purchased from Peptides 
International. All DNA oligomers were purchased HPLC purified from Integrated DNA 
Technologies. Cell culture media was purchased from Gibco. Fetal bovine serum was 
purchased from Omega Scientific. Microwave-assisted coupling reactions were conducted 
on a Biotage Initiatior Eight synthesizer.  
 
Polyamide Quantification 
 Polyamide concentrations were measured in 20% MeCN in 0.1% (v/v) aqueous 
TFA using an approximated extinction coefficient of 69 200 M-1 cm-1 at λmax near 310 nm, 
unless otherwise specified.32, 36 
 
Monomer Loading onto 2-Cl-Trt Resin 
Prior to manual microwave-assisted synthesis, 2-Cl-Trt-Cl resin (1.0 g, 1.59 
mmol/g) was first loaded by mixing with 576 mg (1.59 mmol, 1 eq.) of FmocPyOH 
monomer, followed by addition of 6 mL dimethylformamide (DMF) and 1.38 mL 
diisopropylethylamine (DIEA) (7.59 mmol, 5 eq.). The suspended mixture was stirred for 
18 hr, then capped by addition of 1 mL methanol (MeOH) and stirred for 1 hr.  The orange-
colored, loaded resin was then collected on a fritted peptide synthesis vessel, washed with 
DMF (2x), MeOH (2x), DMF (2x), MeOH (2x), and diethyl ether (Et2O). (Owing to the 
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sensitivity of the 2-Cl-Trt resin towards hydrolysis/methanolysis, this final Et2O wash was 
found to be essential and all loaded resin was sealed and stored at -20oC.) The loading 
efficiency was quantitated via the Fmoc test, and confirmed by measuring the mass of the 
dried resin. Typical monomer loading was calculated to be 0.4-0.8 mmol/g. 
 
Microwave-Assisted Solid-Phase Synthesis (18-24) 
All solid-phase polyamide coupling reactions were performed manually on a 
Biotage Initiator Eight microwave synthesizer on a 200-500 mg scale of loaded resin. Prior 
to each monomer coupling reaction, the N-terminal Fmoc group was first removed in a 
piperidine solution. The Fmoc deprotections were performed in a fritted peptide synthesis 
vessel at room temperature, and the specific conditions for each N-terminal monomer are 
as follows: 
N-Fmoc-Pyrrole / Imidazole: (a) swell resin in DCM; (b) wash with DMF; (c) add 50% 
piperidine in DMF; (d) shake suspension for 10 min; (e) wash with DMF; (f) repeat steps a-
e twice.  
N-Fmoc-GABA / β-Alanine: (a) swell resin in DCM; (b) wash with DMF; (c) add 50% 
piperidine in DMF; (d) shake suspension for 5 min; (e) wash with DMF; (f) repeat steps a-e 
once. 
Following Fmoc removal, the resin was de-swelled in MeOH, washed with Et2O, 
dried in vacuo, and transferred to a microwave synthesis vessel as a dry powder. The 
corresponding monomer acid (3 eq.) was activated with PyBOP (3 eq.) and DIEA (6 eq.) in 
DMF (0.3M concentration of monomer), and added to the resin.  The coupling reactions 
were then set up in the microwave reactor at 50°C for the time durations described in Table 
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3.1. After the listed microwave-assisted coupling times, the reaction mixture was filtered 
into a peptide synthesis vessel, and the collected resin was washed with DMF (3x), MeOH 
(3x), Et2O, and dried in vacuo. To ensure completion of each deprotection and coupling 
step, analytical HPLC spectra were taken by cleaving a small resin sample in 30% 
hexafluoroisopropanol (HFIP) in DCM.  
The polyamide core was synthesized on 2-Cl-Trt resin in an iterative manner by 
repeating the deprotection-coupling procedures described above using the corresponding 
monomeric units. Upon completion of the sequence, 100-200 mg of the resin was 
suspended in 1 mL 30% HFIP in DCM and stirred for 1 hr to yield the crude N-terminal 
Fmoc-protected polyamide intermediate. The reaction mixture was then run through a 
cotton filter to remove the resin, and the filtrate was concentrated in vacuo. The residual oil 
was resuspended in 5 mL of a 1:1 MeOH:DCM mixture, and reconcentrated in vacuo to 
give an off-white/beige solid. To remove the N-terminal Fmoc group, the solid was 
redissolved in 800µL DMF, followed by addition of 200 µL piperidine, and the solution 
was stirred for 30 min. Upon confirmation of complete deprotection by analytical HPLC, 
the solution was added to 4 mL 30% MeCN in 0.1% aqueous TFA. The precipitated 9-
methylenefluorene side product was then removed by centrifugation, and washed twice 
with 2 mL 30% MeCN in 0.1% aqueous TFA. The combined aqueous solution was 
purified by reverse-phase HPLC and lyophilized to dryness to yield pre-cyclic polyamide 
intermediates 18-24.  All dried samples of 18-24 were stored at -20oC prior to DPPA-
mediated macrocyclization.  
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Synthetic yields and MALDI-TOF Characterization Data for 18-24:  
(18): 12.6 µmol recovered (38.0 µmol theoretical, 33% yield). MALDI-TOF [M + H]+ 
calc’d for C70H77N22O15+ = 1465.4, observed = 1465.9. 
(19):  15.2 µmol recovered (38.0 µmol theoretical, 40% yield). MALDI-TOF [M + H]+ 
calc’d for C62H70N21O13+ = 1316.5, observed = 1316.9.  
(20):  12.8 µmol recovered (38 µmol theoretical, 34% yield). MALDI-TOF [M + Na]+ 
calc’d for C67H79N22NaO15+ = 1453.6, observed = 1453.9.  
(21):  15.1 µmol recovered (49 µmol theoretical, 31% yield). MALDI-TOF [M + H]+ calc’d 
for C69H76N23O15+ = 1466.5, observed = 1466.9.  
(22):  17.2 µmol recovered (51 µmol theoretical, 34% yield). MALDI-TOF [M + H]+ calc’d 
for C61H69N22O13+ = 1317.5, observed = 1317.2.  
(23):  16.2 µmol recovered (51 µmol theoretical, 32% yield). MALDI-TOF [M + Na]+ 
calc’d for C66H77N23NaO15+ = 1454.5, observed = 1455.0. 
(24):  8.2 µmol recovered (25 µmol theoretical, 33% yield). MALDI-TOF [M + Na]+ calc’d 
for C66H78N23NaO15+ = 1454.5, observed = 1454.9. 
 
DPPA-mediated Macrocyclization (1-7)  
The macrocyclization reactions were run on a 2 µmol to 16 µmol scale. 
Intermediates 18-24 were first dissolved in DMF (0.25 mM) in a round-bottom flask 
equipped with a magnetic stir bar, followed by addition of DIEA (200 eq.), and purged 
with argon for 15 min. Diphenylphosporyl azide (DPPA) (50 eq.) was then added to the 
reaction mixture in a drop wise manner, while rapidly stirring. Upon full addition of the 
DPPA, the solution was allowed to react and stirred at room temperature for 16-20 hr. After 
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confirmation of reaction completion by analytical HPLC, the reaction mixture was 
concentrated in vacuo, and the resulting oil residue was dissolved in 3 mL MeCN and 
transferred to a 15 mL Falcon Tube. The MeCN was then removed with air flow and 3 mL 
0.1% aqueous TFA was added to the remaining oil layer to yield an off-white suspension, 
which was isolated via centrifugation and lyophilized to dryness.  
For reactions starting with 18, 19, 21, and 22, the lyophilized residue was submitted 
to 1 mL 10% trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in 
LN2, and thawed by layering 1 mL DMF. For reactions starting with 20, 23, and 24, the 
lyophilized residue was submitted to 1 mL neat TFA, stirred for 15 min, frozen in LN2, and 
thawed by layering 1 mL DMF. All the thawed solutions were then diluted with 6 mL 0.1% 
aqueous TFA, purified by reverse-phase HPLC and lyophilized to dryness to yield cyclic 
polyamides 1-7.  
 
Synthetic yields and MALDI-TOF characterization data for 1-7: 
(1):  4.5 µmol recovered (12.9 µmol theoretical, 35% yield). MALDI-TOF [M + H]+ calc’d 
for C54H63N22O10+ = 1179.5, observed = 1179.9. 
(2):  0.84 µmol recovered (2.0 µmol theoretical, 42% yield). MALDI-TOF [M + H]+ calc’d 
for C54H62N21O10+ = 1164.5, observed = 1164.6. 
(3):  3.2 µmol recovered (6.7 µmol theoretical, 47% yield). MALDI-TOF [M + H]+ calc’d 
for C62H69N22O12+ = 1313.6, observed = 1314.0. 
(4):  3.1 µmol recovered (8.0 µmol theoretical, 39% yield). MALDI-TOF [M + H]+ calc’d 
for C53H62N23O10+ = 1180.5, observed = 1180.9. 
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(5):  0.96 µmol recovered (2.0 µmol theoretical, 48% yield). MALDI-TOF [M + H]+ calc’d 
for C53H61N22O10+ = 1165.5, observed = 1165.5. 
(6):  3.7 µmol recovered (10.0 µmol theoretical, 37% yield). MALDI-TOF [M + H]+ calc’d 
for C61H68N23O12+ = 1314.5, observed = 1314.5. 
(7):  2.2 µmol recovered (5.7 µmol theoretical, 38% yield). MALDI-TOF [M + H]+ calc’d 
for C61H68N23O12+ = 1314.5, observed = 1314.8. 
 
Selective Conjugation of Benzoic Acid Derivatives (9-11)  
A solution of benzoic acid (3.0 mg, 0.025 mmol, 25 eq.) and PyBOP (13 mg, 0.025 
mmol, 25 eq.) in DMF (0.5 mL) and DIEA (44 µL, 0.25 mmol, 250 eq.) was stirred at 
room temperature for 10 min. The activated solution was then added to 3 (1.0 µmol) and 
stirred for 3 hr. After confirmation of complete reaction by analytical HPLC, 12 mL cold 
Et2O was added to the reaction mixture and cooled at -20oC for 16 hr. The precipitate was 
then isolated by centrifugation and allowed to air dry. The resulting residue was submitted 
to 1mL 10% trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in 
LN2, and thawed by layering 1 mL DMF. The thawed solution was then diluted with 6 mL 
0.1% aqueous TFA, purified by reverse-phase HPLC and lyophilized to dryness to yield 
cyclic polyamides 9 (684 nmol, 68% yield).  Using the same procedure described above, 
starting with 6 (1.60 µmol) and 7 (750 nmol), yielded mono-benzoyl substituted cyclic 
polyamides 10 (1.05 µmol, 67% yield) and 11 (367 nmol, 49% yield), respectively.  
(9): MALDI-TOF [M + H]+ calc’d for C61H67N22O11+ = 1283.5, observed = 1284.1. 
(10): MALDI-TOF [M + H]+ calc’d for C60H66N23O11+ = 1284.5, observed = 1284.5. 
(11): MALDI-TOF [M + H]+ calc’d for C60H66N23O11+ = 1284.5, observed = 1284.9. 
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Synthesis of Cyclic Polyamide-Fluorescein Conjugates (12-14) 
A solution of fluorescein isothiocyanate (FITC) (2.7 mg, 7.0 µmol, 25 eq.) in DMF 
(0.2 mL) and DIEA (12 µL, 0.07 mmol, 250 eq.) was added to 3 (0.28 µmol) and stirred for 
2 hr. After confirmation of complete reaction by analytical HPLC, 12 mL cold Et2O was 
added to the reaction mixture and cooled at -20oC for 16 hr. The precipitate was then 
isolated by centrifugation and allowed to air dry. The resulting residue was submitted to 1 
mL 10% trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in LN2, 
and thawed by layering 1 mL DMF. The thawed solution was then diluted with 6 mL 0.1% 
aqueous TFA, purified by reverse-phase HPLC and lyophilized to dryness to yield cyclic 
polyamide 12 (65 nmol, 23% yield). Using the same procedure described above, starting 
with 6 (0.40 µmol) and 7 (0.40 µmol), yielded cyclic polyamide-fluorescein conjugated 13 
(345 nmol, 86% yield) and 14 (118 nmol, 29% yield), respectively. 
(12): ESI-MS [M + H]+ calc’d for C75H74N23O15S+ = 1568.6, observed = 1568.3. 
(13): ESI-MS [M + H]+ calc’d for C74H73N24O15S+ =  1569.5, observed = 1569.2. 
(14): ESI-MS [M + H]+ calc’d for C74H73N24O15S+ = 1569.5, observed = 1569.3. 
 
Synthesis of Cyclic Polyamide Targeted to 5’-WCGWGW-3’ Sequence (8) 
2-Cl-Trt-Cl resin (200 mg, 1.59 mmol/g) was first loaded with FmocPyImOH 
dimer (96 mg, 0.20 mmol), which was obtained from published procedures.13 Experimental 
details were analogous to the monomer loading protocol reported above. The obtained 
Fmoc-Py-Im-(2-Cl-Trt) resin (265 mg, 0.59 mmol/g) was subjected to the previously 
described microwave-assisted solid-phase synthesis conditions to build the corresponding 
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polyamide sequence. A quarter of the resin (0.15 µmol theoretical) was then cleaved and 
purified by reverse-phase HPLC to yield pre-cyclic polyamide intermediate 25 as an off-
white powder (13.3 µmol, 34% yield). The isolated 25 (2.0 µmol) was subjected to DPPA-
mediated macrocyclization conditions analogous to that for compounds 1-7, with the Cbz 
groups removed with 10% TFMSA in TFA, and purified by reverse-phase HPLC to afford 
cyclic polyamide 8 (773 nmol, 39% yield). 
(25): MALDI-TOF [M – CO2 + H]+ calc’d for C65H675N22O13+ = 1371.6, observed = 
1371.7. 
(8): MALDI-TOF [M + H]+ calc’d for C61H67N22O11+ = 1129.5, observed = 1130.0 
 
Synthesis of Hairpin Polyamide Targeted to 5’-WCGWGW-3’ Sequence (17) 
Fmoc-Py-Im-(2-Cl-Trt) resin, obtained via the same procedure as for 8, was 
subjected to the previously described microwave-assisted solid-phase synthesis conditions 
to build the corresponding polyamide sequence with an N-terminal PyImOH cap. The resin 
(70 mg, 0.039 mmol) was then suspended in 2 mL 30% HFIP in DCM, stirred for 1 hr, 
filtered, washed, and concentrated to afford the crude C-terminal free acid. The residue was 
then dissolved in DMF (1.8 mL) and added drop wise to a pre-activated solution of 3,3’-
diamino-N-methyldipropylamine (252 µL, 1.56 mmol, 40 eq.) and PyBOP (40 mg, 0.078 
mmol, 2 eq.) in DMF (6.0 mL). After stirring for 1 hr and confirmation of complete 
conjugation by HPLC, the crude product was isolated by Et2O precipitation, air dried, 
redissolved in 8 mL 15% MeCN: 0.1% aqueous TFA, and purified by reverse-phase HPLC 
to yield polyamide intermediate 26 as an off-white powder (11.8 µmol, 30% yield).  
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The isolated 26 (3.1 µmol) was dissolved in DMF (200 µL) and added drop wise to 
a pre-activated solution of isophthalic acid (12 mg, 0.072 mmol) and PyBOP (5 mg, 
9µmol) in DMF (800 µL) and DIEA (13 µL). After stirring for 1 hr and confirmation of 
complete conjugation by HPLC, the reaction mixture was then precipitated in Et2O, 
isolated by centrifugation, and air-dried. The remaining residue was then subjected to 500 
µL neat TFA, stirred for 15 min, frozen in LN2, thawed by addition of 1 mL DMF, diluted 
with 6 mL 0.1% aqueous TFA, and purified by reverse-phase HPLC to afford cyclic 
polyamide 8 (3.1 nmol, 86% yield). (Note: Extinction coefficient for compounds 26 and 17 
were established as 40,000 M-1 cm-1 at λmax = 302nm.) 
(26): MALDI-TOF [M + H]+ calc’d for C58H79N22O11+ = 1259.6, observed = 1260.1. 
(17): MALDI-TOF [M + H]+ calc’d for C61H75N22O12+ = 1307.6, observed = 1307.8. 
 
Thermal Denaturation Analysis 
Melting temperature analysis was performed on a Varian Cary 100 
spectrophotometer equipped with a thermo-controlled cell holder possessing a cell path 
length of 1 cm. A degassed aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 10 
mM MgCl2, and 5 mM CaCl2 at pH 7.0 was used as analysis buffer. DNA duplexes and 
polyamides were mixed in 1:1 stoichiometry to a final concentration of 2 µM for each 
experiment. Prior to analysis, samples were heated to 95°C and cooled to a starting 
temperature of 25°C with a heating rate of 5°C/min for each ramp. Denaturation profiles 
were recorded at λ = 260 nm from 25 to 95°C with a heating rate of 0.5 °C/min. The 
reported melting temperatures were defined as the maximum of the first derivative of the 
denaturation profile. 
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Cell Culture 
Cell lines were cultured at 37°C under 5% CO2 using standard cell culture and 
sterile techniques. Cell medium was supplemented with 10% fetal bovine serum. Ham's F-
12K (Kaighn's) medium was used for A549 cells, and RPMI 1640 was used for T47D cells. 
 
Confocal Microscopy  
For each experiment, cells were plated in 200 µL of the proper medium onto glass-
bottom cell culture plates at a density of 1$×$105 (A549) cells/mL, or 1.5$×$105 cells/mL 
(T47D). Cells were grown for 24 hr, and media was replaced with fresh media containing 
polyamide to give a final DMSO concentration of 0.1%. Next, cells were incubated for 16 
hr, followed by removal of media, washing, and addition of fresh media. Hoechst 33258 
was added 2 hr prior to imaging. Imaging was performed at the Caltech Beckman Imaging 
Center using a Zeiss LSM 510 Meta NLO 2-photon inverted laser scanning microscope 
equipped with a 40x oil-immersion objective lens. Polyamide–fluorescein conjugates 12-14 
were imaged in multi-track mode using 488 nm laser excitation at 15% output with a 
pinhole of 375$µm and a standard fluorescein filter set. Hoechst was imaged using 800$nm 
two-photon excitation with an HFT KP680 dichroic and a 390- to 465-nm bandpass filter 
with a fully open pinhole. All images were analyzed using Zeiss LSM Zen software. 
 
Sulforhodamine B Cytotoxicity Assay 
For cytotoxicity assays, cell lines were plated in 96-well cell culture plates in 100 
µL media at a density of 1$×$104 cells/mL (A549), or 5$×$104 cells/mL (T47D). IC50 values 
were determined using the sulforhodamine B (SRB) colorimetric assay as previously 
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described.39 Cells were grown for 24 hr, before polyamides in 100 µL media were added in 
serial dilution, in quadruplicate for each concentration. After incubation for 72 hr, cell 
media was replaced with 100 µL fresh media, and cells were allowed to recover for an 
additional 24 hr. Cells were then fixed by adding 100 µL of 10% trichloroacetic acid 
directly to each well and stored at 4°C for 1 hr, before being washed, dried, stained with 
100 µL 0.057% SRB solution per well for 30 min, and washed and dried again as 
described. After solubilizing the bound dye with 200 µL of 10 mM Tris (pH 10.5) per well, 
absorbance at 490nm was measured on a PerkinElmer Victor microplate reader. The data 
are charted as a percentage of untreated controls, corrected for background absorbance. 
IC50 is defined as the concentration that inhibits 50% of control cell growth. These values 
were determined by non-linear least-squares regression fit to Y$=$A$+$(B$−$A)/(1+10^((Log 
EC50$−$X)$×$H)), where A$=$max., B$=$min. and H$=$Hill Slope. All calculations were 
performed using Prism 4 (GraphPad) software. Stated IC50 values represent the mean and 
standard deviation of three independent biological replicates. 
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Figure S3.1: Confocal microscopy analysis of 12-14 in A549 cells with included bright field images. 
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Figure S3.2: Confocal microscopy analysis of 12-14 in T47D cells with included bright field images. 
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Figure S3.3: In previous unpublished results, the cytotoxicity of compound S1 in A549 cells was examined 
using the same Sulforhodamine B assay described in the text. The IC50 was determined to be 0.003µM ± 
0.002µM. 
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Abstract 
 
 To optimize the biological activity of pyrrole–imidazole polyamide DNA-binding 
molecules, we characterized the aggregation propensity of these compounds through 
dynamic light scattering and fractional solubility analysis. Nearly all studied polyamides 
were found to form measurable particles 50–500 nm in size under biologically relevant 
conditions, while HPLC-based analyses revealed solubility trends in both core sequences 
and peripheral substituents that did not correlate with overall ionic charge. The solubility of 
both hairpin and cyclic polyamides was increased upon addition of carbohydrate 
solubilizing agents, in particular, 2-hydroxypropyl-β-cyclodextrin (HpβCD). In mice, the 
use of HpβCD allowed for improved injection conditions and subsequent investigations of 
the availability of polyamides in mouse plasma to human cells. The results of these studies 
will influence the further design of Py-Im polyamides and facilitate their study in animal 
models. 
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Introduction  
N-methylpyrrole (Py) and N-methylimidazole (Im) polyamides are heterocycle-
based oligomers that bind the minor groove of DNA in a sequence-specific manner.1-3 
Investigations of Py-Im polyamide biological properties have demonstrated that these 
compounds are cell permeable,3-5 localize to the nucleus,3-5 and display transcriptional 
inhibition, likely through an allosteric mechanism by disrupting the transcription factor-
DNA interface.6,7 This compression may be responsible for the observed reduction in 
transcription factor occupancy upon polyamide-DNA complexation.8-10 Gene regulation 
properties have been illustrated in cell culture models targeting transcription factors 
androgen receptor (AR),8 glucocorticoid receptor (GR),10 hypoxia inducible factor 
(HIF),9,11 nuclear factor kappaB (NF-κB),12 AURKA/AURKB,13 and TGF-β.14,15 We have 
investigated the utility of Py-Im polyamides in organismal models through in vitro 
ADMET studies,16 real-time biodistribution monitoring methods,17 and, most recently, the 
development of mouse pharmacokinetic and toxicity profiles.18 Recent efforts to develop 
more potent polyamides, however, have been hindered by poor solubility.19 These 
observations raise concerns about the likely aggregation of Py-Im polyamides. If 
aggregation is an issue, how does particle size correlate with structural features such as 
size, charge, shape, turn substitution, and Py/Im composition of the oligomer? 
Recent studies of the aggregation of small molecule drug candidates through 
dynamic light scattering (DLS) and detergent-based assays have highlighted the 
importance of such considerations in drug design.20-23 Indeed, a screen of over 70,000 
potential drug candidates by Shoichet and co-workers found that 95% of the initial hits 
acted as aggregate-based inhibitors.24 At the same time, several currently approved drugs 
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can be classified as aggregate-based inhibitors25 and in some cases aggregate particle size 
may be linked to pharmaceutical efficacy.23,26,27 We thus decided to investigate this 
important pharmacokinetic parameter and its relationship to the biological activity of Py-
Im polyamides. As our laboratory explores the efficacy of polyamides in animal disease 
models, there becomes a pressing need to characterize the aggregation and solubility 
properties of these compounds as well as to investigate the use of formulating reagents to 
solubilize polyamides at the high concentrations required for animal injections. 
 
Figure 4.1: The use of solubilizing agents can disrupt the aggregation of polyamides and allow increased 
solubility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
130 
Results and Discussion 
Selection of a Panel of Polyamides 
 We selected two libraries of Py-Im hairpin polyamides, 1-6 and 7-11, targeting 
the AR/GR consensus sequence 5’-WGWWCW-3’ (W = A/T)8,28 or the NF-κB 
consensus sequence 5’-WGGWWW-3’, respectively (Figure 4.2).12  
 
Figure 4.2 Chemical structures of hairpin polyamide library along with the corresponding circle-stick 
models and target DNA sequences. Legend: Black circle = Im; white circle = Py; semi-circle = γ-
aminobutyric acid unit with dashed (R, β) or wedge (R, α) substituents; hexagon = isophthalic acid / IPA; 
rectangle = fluorescein / FITC; W = A/T bases.  
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 These two different heterocyclic cores were diversified with a variety of 
substituents at the 4-aminobutyric acid (GABA) turn positions (R1, R2) and the C-
terminal tail position (R3). Substituents at these positions are known to affect DNA 
binding and biological activities.19,29,30 In addition, the employment of cyclic polyamide 
architectures has resulted in increased DNA binding affinities and selectivities31 as well 
as improved efficacy against AR-regulated genes.28 Taken in context with our recent 
finding of increased murine toxicity of cyclic polyamides,18 we decided to also 
investigate the properties of cycles 12-14 (Figure 4.3). All Py-Im polyamides were 
synthesized according to previously published solid-phase procedures.12,18,19,32 
 
Figure 4.3:  Chemical structures of cyclic polyamide library along with the corresponding circle-stick 
model and target DNA sequence. Legend: black circle = Im; white circle = Py; semi-circle = γ-
aminobutyric acid unit with dashed (R, β) substituents; W = A/T bases. 
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Dynamic Light Scattering 
The aggregation propensity of Py-Im polyamides was investigated through 
dynamic light scattering (DLS). Compounds 1-14 were studied at 1, 4, and 10 µM 
concentrations in a 0.1% DMSO/PBS solution in order to approximate the DMSO 
concentration and salt content present in cell culture experiments. Stock solutions 
(1000x) of each polyamide in DMSO were rapidly mixed with PBS, and the scattered 
light intensity was measured over the course of 10 minutes. The minimum concentration 
at which each compound was found to give a significant signal intensity (3x the buffer 
signal as per manufacturer guidelines), along with the respective particle sizes derived 
from a cumulant fit of the autocorrelation functions, are listed in Table 4.1.33 Hairpin 
polyamides generally formed particles with radii of 70-200 nm at 4 µM concentration. 
One notable trend is that the benzamide substituted compounds (4 and 10) formed 
measurable particles at lower concentrations (1 µM vs. 4 µM) than their free amine 
counterparts (2 and 8).  Polyamides containing fluorescein substituents (5 and 6) formed 
significantly larger particles when compared to the isophthalic acid conjugates (2 and 4), 
and compound 11 precipitated from the solution before particle size could be determined. 
Interestingly, cyclic polyamides 12-14 formed larger particles than the hairpin 
polyamides, with the bis-β-amino substituted cycle 13 forming the largest particles in this 
data set. Similar results were observed for a number of additional polyamides (Table 
S4.1), except for compounds containing three or four consecutive imidazole rings (17, 
18), which formed particles too large to be accurately measured (radii > 1 µM). 
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Table 4.1: Estimated radii of polyamide aggregate particles at the concentration of minimum signal in 
0.1% DMSO/PBS at 25 °C. aRadii derived from a cumulant fit of the average autocorrelation functions 
collected over 10 min. Errors represent standard deviation of at least three independent measurements. 
bRadius could not be determined due to rapid precipitation of the compound at 1 µM concentration. 
 
Fractional Solubility Analysis  
Next, the macroscopic solubility properties of these compounds were investigated 
by measuring the concentration of selected Py-Im polyamides in the soluble fraction of 
solutions with similar maximum concentrations (4 µM, Figure 4.4). Each compound was 
added as a 1000x (4 mM) stock in DMSO to PBS in accord with the light scattering 
experiments. Solutions were sonicated and then allowed to equilibrate for 2 hours at room 
temperature before aggregates were removed through centrifugation. In order to measure 
the concentration of polyamide in the supernatant, a plot of HPLC peak area vs. 
concentration was generated using polyamide 7 with detection at 310 nm, the wavelength 
at which each compound was quantified (Figure S4.1).  
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Figure 4.4: Calculated soluble concentration of select polyamides in 0.1% DMSO/PBS at 25°C. Maximum 
concentration estimated at 4 µM (dotted line) based on quantitation of starting material in 0.1% 
DMSO/water. Resultant concentrations determined by HPLC peak area at 310 nm detection after 
comparison with a standard curve (see SI.).  Error bars represent standard deviation of at least three 
independent measurements. 
In general, the 5’-WGWWCW-3’-targeted hairpin polyamides (1-4) were found 
to be more soluble than their 5’-WGGWWW-3’-targeted counterparts (7-10). Within 
each set of polyamide hairpin cores, a relationship between turn substituents and 
solubility was observed. Polyamides with β-amine turns (2, 8) were found to be more 
soluble than those compounds with α-amine-substituted turns (1, 7), and the former 
compounds were further solubilized upon acetylation (3, 9). Increased solubility upon 
incorporation of acetylated turn units was also observed in the cyclic architecture (13 vs. 
14). The benzamide-substituted compounds (4, 10) and the bis-β-amine substituted cycle 
14 were found to be the least soluble, in good agreement with the light scattering 
measurements. Interestingly, none of the studied polyamides were fully soluble under 
these conditions. 
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Addition of Formulating Reagents 
We thus decided to investigate the ability of known formulating reagents, in 
particular cyclodextrins (CDs),34 to decrease aggregation and/or precipitation among the 
less soluble hairpin polyamides 7-10 (Figure 4.5). 2-Hydroxypropyl-β-cyclodextrin 
(HpβCD) was chosen initially due to its high water solubility and low animal toxicity.35 
Using procedures identical to the solubility analyses, peak areas of Py-Im polyamides in 
the presence of 0, 5, or 50 mM HpβCD were measured. A cyclodextrin-dependent 
increase of soluble polyamide concentration was observed for all compounds studied, 
with compounds 7 and 8 near the maximum expected concentration in solutions of 50 
mM HpβCD (Figure 4.5A). Impressively, 50 mM HpβCD increased the concentration of 
the least soluble derivative (benzamide-substituted polyamide 10) over 50-fold.  
Surprisingly, the soluble concentration observed for polyamide 9 was significantly 
higher than expected based on the quantitation of the corresponding DMSO stock 
solution. This result likely derives from aggregation and/or precipitation of compound 9 
upon dilution of the polyamide in water before the absorbance is measured, resulting in 
an underestimation of the stock concentration. We further probed the specificity of these 
effects by studying the solubilization of polyamide 7 by other carbohydrate formulating 
reagents, namely α-CD, γ-CD, hydroxypropyl methylcellulose (hypromellose), and 
dextrose (Figure S4.2). The three cyclodextrin derivatives were studied at 5 mM 
concentrations while hypromellose, a linear substituted glucose polymer, and dextrose, 
the glucose monomer, were normalized for total sugar content against 5 mM HpβCD. In 
addition to HpβCD, polyamide 7 was solubilized by γ-CD and hypromellose (Figure 
4.5B). 
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Figure 4.5: A) Calculated soluble concentration of polyamides 7 - 10 in 0.1% DMSO/PBS containing 0, 5, 
or 50 mM HPβCD at 25°C. B) Calculated soluble concentration of polyamides 7 and 12 in 0.1% 
DMSO/PBS containing: 5 mM α-, Hpβ-, γ-cyclodextrin (α , β , γ , respectively); 6 mg/mL hypromellose 
(HM); 35 mM dextrose (DX). Maximum concentration estimated at 4 µM (dotted line) based on 
quantitation of starting material in 0.1% DMSO/water. Resultant concentrations determined by HPLC peak 
area (λ = 310 nm) after comparison with a standard curve (see SI). Error bars represent standard deviation 
of at least three independent measurements. 
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Polyamide 12, which would seem less likely to form an inclusion complex with 
cyclodextrin due to its cyclic form, was screened against the same formulating agents. 
HpβCD and hypromellose also solubilized cyclic compound 12. Notably, neither 
polyamide displayed an increased solubility in the monomer (dextrose) solution. 
 
Mouse Model Experiments 
The utility of these results was further probed in an animal model system. Our 
laboratory recently found that high blood levels of polyamide 7 can be achieved in mice 
following an intraperitoneal (IP) injection of 120 nmol compound in a vehicle of 20% 
DMSO/PBS (600 µM concentration, Figure 4.6A).18 Using HpβCD, the DMSO content 
could be reduced to 1% with no loss in solubility. IP injections of 120 nmol polyamide 7 
in a 1% DMSO/80 mM HpβCD / PBS vehicle and the subsequent blood collection were 
performed under identical conditions to those previously reported. After blood collection, 
the plasma was isolated through centrifugation and the bulk proteins removed through 
methanol precipitation. The supernatant was then mixed with dilute aqueous 
trifluoroacetic acid (TFA) and a reference compound in acetonitrile was added. The 
injection vehicle containing HpβCD yielded circulating polyamide concentrations 
comparable to those previously reported (Figure 4.6B). In both cases, polyamide 
concentrations of 13-14 µM were detected in mouse plasma 1.5 hours after injection, 
with no polyamide detected after 24 hours. Furthermore, FITC-labeled compound 11, 
which formed a precipitate in 20% DMSO/PBS solutions, was fully solubilized upon 
addition of HpβCD (80 mM), allowing the compound to be injected into mice.  
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Figure 4.6: HPLC traces of mouse plasma isolated from four mice at three time points after injection with 
120 nmol polyamide 7 in two different vehicles: 20% PBS / DMSO (A) and 1% DMSO/80 mM HPβCD / 
PBS (B). 
Slightly reduced plasma concentrations of compound 11 were observed as 
compared to compound 7, which may indicate reduced bioavailability of the FITC-
modified polyamide (Figure 4.7A). We then sought to investigate the availability of the 
circulating polyamide to human cells by taking advantage of the nuclear staining 
generally observed with FITC-polyamide conjugates. Plasma samples isolated from mice 
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injected with compound 11 were added to A549 (human lung cancer) cells 16 hours prior 
to imaging live cells with confocal microscopy. In cells treated with plasma collected at 
1.5 hours post-injection, strong nuclear fluorescent signals were observed (Figure 4.7B). 
Greatly reduced levels were observed with plasma isolated 4.5 hours post-injection, and 
no significant signal was observed with the addition of the 24 hours plasma sample 
(Figure 4.8). 
 
Figure 4.7: A) HPLC traces of mouse plasma isolated from four mice at three time points after injection 
with 120 nmol polyamide 11 in 20% DMSO/80 mM HPβCD / PBS.  B) Confocal image of A549 cells after 
16 hr incubation with mouse plasma isolated 1.5 hr after injection with polyamide 11. 
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Figure 4.8: Confocal images of A549 cells after 16 hr incubation with mouse plasma isolated 90 min, 270 
min, and 24 hr after injection with polyamide 11.  Images have been analyzed with identical intensity, 
brightness, and contrast settings to allow a direct comparison.  Left: Fluorescence channel; Middle: Bright 
field image; Right: Overlay. 
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Conclusions 
Dynamic light scattering measurements revealed that both hairpin and cyclic 
polyamides form measurable particles between 5 and 500 nm in size at biologically 
relevant concentrations (Table 4.1). Particle size was observed to be dependent on both 
cyclic vs. hairpin architecture and the terminal (tail) substituent. Interestingly, particles of 
similar size were observed for all polyamides containing an isophthalic acid (IPA) at the 
C-terminus despite the differing activities of these compounds in cell culture.  These 
results support a mechanism of polyamide activity in which aggregation may not be a key 
factor.   
Another interesting observation is that neither aggregation nor solubility is 
affected by the overall ionic charge of the polyamide.  While organic compounds with 
ionizable groups are generally expected to be more soluble in aqueous salt solutions, 
neither light scattering nor solubility analyses revealed such a dependence.  Indeed, 
hairpins and cycles in which the GABA amino turn units were modified with acetyl 
groups were found to be the most soluble.  
At first glance, the lack of solubility observed for some polyamides is surprising 
as similar concentrations are commonly used in cell culture experiments, often without 
evidence of aggregation or precipitation.  However, the experimental conditions required 
for the solubility experiments are a limited comparison to those in cell culture. For 
example, cell media generally contain a variety of small molecule and protein nutrients, 
and cell cultures are kept at higher temperatures  (37 °C vs. 25 °C).  In addition, the 
soluble fraction isolated by centrifugation is not necessarily representative of the 
available polyamide concentration during a typical cell incubation period (48-72 h), 
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particularly if aggregation is a dynamic process.  We note that similar solubility problems 
have been reported by Sugiyama and co-workers, who enhanced the biological activity of 
seco-CBI polyamide conjugates through PEGylation36 or liposomal formulations.37 
We were able to mitigate the problem of polyamide solubility through the addition 
of carbohydrate formulating reagents, in particular HpβCD. As cyclodextrins are 
generally thought to form discrete inclusion complexes with small organic molecules,35,38 
we postulated that the linear conformation of hairpin polyamides may be well solubilized 
by such additives.  Indeed, the solubilization of polyamide 7 by the larger cyclodextrins 
(β and γ) is consistent with the formation of possible cyclodextrin inclusion complexes,39 
which in this case may result from interactions with the isophthalic acid unit at the C-
terminus or the N-methylimidazole group at the N-terminus.  Such interactions would not 
be expected, however, between cyclodextrins and cyclic polyamide 12.  Interestingly, 
solubilization of compound 12 was observed with HpβCD but not the other cyclodextrin 
derivatives.  The lack of solubilization with γCD would be consistent with a model in 
which the interactions between HpβCD and cycle 12 rely more on the hydroxypropyl 
substituents unique to HpβCD, perhaps through additional hydrogen bonding 
interactions, rather than encapsulation.  While both the linear 7 and cyclic 12 polyamide 
compounds were solubilized by hypromellose, presumably through encapsulation within 
the polymer matrix, it is notable that no significant solubilization was observed with the 
dextrose monomer.  This latter observation may indicate the importance of an ordered 
carbohydrate structure, such as that available with cyclodextrins and hypromellose, for 
efficient polyamide solubilization. Further studies are necessary, however, before 
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conclusions can be drawn regarding the interactions between Py-Im polyamides and 
carbohydrate derivatives, and such investigations fall outside the scope of this work.   
Further evidence of the utility of HpβCD as a formulating reagent was gathered in 
mouse experiments.  First, we demonstrated that the HpβCD vehicle did not significantly 
affect circulating levels of polyamide 7.  On the other hand, the fluorescently labeled 
derivative 11 was only sufficiently soluble in HpβCD solutions.  As a result, hairpin 11 
could be injected into mice using this vehicle.  This tagged compound was of particular 
interest due to the high plasma protein binding levels (>99%) that had been previously 
reported for Py-Im polyamides during ADMET studies.28 Evidence of nuclear uptake was 
observed in A549 cells following incubation with plasma from hairpin 11-treated mice, 
thus demonstrating the availability of circulating polyamides to human cancer cells.  
In summary, these studies have provided evidence that the aggregation propensity 
of Py-Im polyamides likely does not contribute to biological activity and may not be a 
critical concern in pharmacokinetic analyses.  Solubility experiments revealed important 
trends, such as the increased solubility achieved by acetylation of the GABA amino turn 
unit, which will impact the design of next generation polyamides.  Furthermore, the 
identification of an effective delivery vehicle will allow for the in vivo study of otherwise 
inaccessible Py-Im polyamides. These studies represent a valuable contribution to the 
field of small molecule transcriptional inhibitors and their ultimate utility as tools for 
perturbing gene expression networks in vivo. 
 
 
 
  
144 
Materials and Methods 
Synthesis of Hairpin Py-Im Polyamides (1-11, 15-32) 
The synthesis of Py-Im polyamides has been extensively described in previous 
work5,12,19,29,32 and is summarized as follows: Reagents were purchased from Sigma-
Aldrich or Novabiochem.  Py-Im cores were synthesized on Kaiser oxime resin using 
Boc-based chemistry, cleaved using 3,3’-diamino-N-methyldipropylamine, and purified 
by reverse phase preparative HPLC.  The C-terminal amine was then derivatized with 
either isophthalic acid (IPA) or fluorescein isothiocyanate (FITC) and the crude 
intermediate isolated through ether precipitation.  The GABA turn protecting groups (α-
NHBoc or β-NHCBz) were removed under acidic conditions.  If applicable, the crude 
intermediate was again isolated through ether precipitation and further derivatized at the 
GABA turn amine with either acetic anhydride or PyBOP-activated benzoic acid.  Final 
products were purified through reverse phase HPLC and the identity confirmed through 
matrix-assisted laser desorption ionization – time-of-flight (MALDI-TOF) mass 
spectrometry.  The synthesis and characterization of compounds 1;10 2-6;19 7, 11;12 15, 
25-3219 were in line with literature reports.  Results from MALDI-TOF characterization 
for compounds 8-10, 12-14, and 16-24 are available (Table S4.2). 
 
Synthesis of Cyclic Py-Im Polyamides (12-14)   
The synthesis and characterization of polyamides 12 and 13 have been previously 
described.18 In brief, the heterocyclic cores of these polyamides were synthesized on 
Kaiser oxime resin as above, except that a terminal GABA turn unit (Boc-GABA-OH or 
(R)-4-(Boc-amino)-3-(Z-amino)butyric acid) was added.  Following deprotection of the 
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terminal Boc unit, the core was cleaved from the resin with DBU / H2O and the resulting 
acid purified by reverse phase HPLC.  The precursor acid was then cyclized using 
diphenylphosphorylazide under basic conditions.  The crude intermediate was isolated 
through ether precipitation and the Cbz group(s) removed as above.  Polyamides 12 and 
13 were then isolated through reverse phase preparative HPLC.  Polyamide 14 was 
synthesized by reaction of 13 with acetic anhydride under basic conditions and then 
purified by reverse phase HPLC. Results from MALDI-TOF characterization for 
compound 14 are available (Table S4.2). 
 
Polyamide Quantification 
Polyamide concentrations were measured by UV-absorption analysis on an 
Agilent 8453 diode array spectrophotometer in distilled and deionized water containing 
up to 0.1% DMSO using a molar extinction coefficient (ε) of 69,500 M-1cm-1 at 310 nm. 
 
Dynamic Light Scattering 
DMSO and PBS were passed through a 0.02 µM syringe filter (Whatman) 
immediately prior to use.  Stock solutions of each polyamide in DMSO were quantified 
as above and the purity determined by HPLC to be greater than 95%.  Solutions of 1, 4, 
and 10 mM in DMSO were prepared and then centrifuged for 15 min at 16 x  g to 
remove particulates.  Immediately before measurement, 0.5 µL of the DMSO stock was 
added to 500 µL of PBS in a microcentrifuge tube.  The solution was mixed briefly with a 
pipette tip and transferred to a disposable plastic cuvette (Fisher).  Measurements were 
performed on a Wyatt Dynapro Nanostar instrument using a 659 nm / 100 mW laser at 
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100% power and a 90 degree detection angle at 25°C.  Acquisition times of 10-15 sec 
were collected over 10 minutes and analyzed using the cumulant fit tool in the Dynamics 
(6.11.1.3) software with PBS as the referenced solvent.  Acquisitions in which the 
baseline value of the fit was greater than ± 0.1 were omitted and the remaining traces 
averaged.  Measurements in which the intensity (cts/s) was less than 3x the buffer signal 
intensity were considered below the detection limit.  
 
Solubility Analysis 
Stock solutions of each polyamide in DMSO were quantified as above and the 
purity checked by HPLC.  Solutions of 4 mM stock were prepared in DMSO.  Polyamide 
(0.5 µL) was added to 500 µL PBS in a microcentrifuge tube, and the solution was 
immediately vortexed and placed in a sonicating water bath at 25°C for 20 min.  The 
tubes were then removed from the bath and allowed to equilibrate for 2 hr at room 
temperature.  Samples were centrifuged for 20 min at 16 xg and 100 µL of the 
supernatant removed for HPLC analysis. Analytical HPLC analysis was conducted on a 
Beckman Gold instrument equipped with a Phenomenex Gemini analytical column (250 
x 4.6 mm, 5µm) and a diode array detector (Mobile phase: 10-80% CH3CN in 0.1% 
CF3CO2H (aqueous) over 17.5 min; Flow rate: 1.50 mL / min; Injection volume: 40 µL). 
Peaks were detected and integrated at 310 nm absorbance using the Karat32 software.  
Sample concentrations were determined through comparison to a standard curve of 
concentration vs. peak area that was generated using compound 7 (Figure S1).  
Solubilization by formulating agents proceeded similarly except that the DMSO stock 
solutions were added to PBS containing 5 or 50 mM HpβCD, 5 mM αCD, 5 mM γCD, 
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35 mM dextrose, or 6.00 mg / mL hypromellose (approximately 35 mM relative glucose 
units based on reported substitution for Aldrich lot #128k0214v). 
 
Animal Experiments 
Murine experiments were performed as described previously.18 In brief, C57bl/6 
mice (8 to 12 weeks of age, Jackson Laboratory) were injected intraperitoneally with 200 
µL of a PBS solution containing: a) 120 nmol compound 7, 20% DMSO; b) 120 nmol 
compound 7, 1% DMSO, 80 mM HpβCD; or c) 120 nmol compound 11, 20% DMSO, 80 
mM HpβCD. Blood was collected from anesthetized animals (2-5% isoflurane) by retro-
orbital withdrawal. Immediately after the third blood draw, animals were euthanized by 
asphyxiation in a CO2 chamber (2 atm).  
Plasma was isolated by centrifugation of the collected blood. The samples from 
the four replicate mice were combined at 5 µL / sample, yielding 20 µL combined plasma 
that was then treated with 40 µL CH3OH, vortexed, and centrifuged. Fifty µL of the 
supernatant were combined with one equivalent of the HPLC loading solution (4:1 water/ 
CH3CN, 0.08 % CF3CO2H) containing Boc-Py-OMe (methyl 4-((tert-
butoxycarbonyl)amino)-1-methyl-pyrrole-2-carboxylate) as an internal spike-in control. 
Analytical HPLC analyses were conducted with a Phenomenex Kinetex C18 analytical 
column (100 × 4.6 mm, 2.6 µm, 100 Å) and a diode array detector (Mobile phase: 5-60% 
CH3CN in 0.1% (v/v) aqueous CF3CO2H over 12.5 min; Flow rate: 2.0 mL / min; 
Injection volume: 40 µL).  Peaks were detected and integrated at 310 nm absorbance, and 
sample concentrations were determined through comparison to the previously published 
standard curve for this column.18 
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Confocal Microscopy 
For confocal microscopy experiments, A549 cells in F-12K medium 
supplemented with 10% FBS (1 mL, 100k cells / mL) were applied to culture dishes 
equipped with glass bottoms for direct imaging (MatTek). Cells were allowed to adhere 
for 18 hr in a 5% CO2 atmosphere at 37 °C. The medium was then removed and replaced 
with 200 µl of fresh medium supplemented with 20 µL of plasma collected 1.5, 4.5, or 24 
hr after injection of compound 11. After an additional 16 hr incubation period, 100 µL of 
untreated medium was added to each slide prior to imaging. Imaging was performed at 
the Caltech Beckman Imaging Center using a Zeiss LSM 5 Pascal inverted laser scanning 
microscope equipped with a 63x oil-immersion objective lens. Fluorescence and visible-
light images were obtained using standard filter sets for fluorescein and analyzed using 
Zeiss LSM software. 
 
 
Figure S4.1. Plot of concentration vs. peak area plot derived from HPLC traces of compound 7 at 310 nm.  
Points were fit to a first order polynomial using the Prism software program (dotted line).  
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Figure S4.2. Structures of carbohydrate solubilizing agents. 
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Table S4.1: Estimated radii of polyamide aggregate particles at the concentration of minimum signal in 
0.1% DMSO/PBS at 25 °C. a. Radii derived from a cumulant fit of the average autocorrelation functions 
Collected over 10 min. b. Compounds formed particles with radii too large to be accurately determined 
with this method (radius > 1 µM). 
Conc 
(!M) Average Std. Dev. Average Std. Dev.
0.1% DMSO / PBS - - - - 2.2E+05 7.9E+04
15 4 157 33 4.6E+06 2.0E+06
16 4 128 11 5.1E+06 2.2E+06
17 4 > 1000b - 3.5E+06 1.2E+06
18 4 > 1000b - 4.8E+06 1.2E+06
19 4 90 20 1.5E+06 9.3E+05
20 10 111 13 1.0E+06 7.4E+05
21 4 108 2 6.1E+06 3.1E+06
22 4 123 8 6.0E+06 4.5E+04
23 4 189 2 7.9E+06 2.4E+05
24 10 100 12 8.7E+05 1.3E+05
25 1 344 41 4.4E+06 1.4E+05
26 1 112 8 8.7E+06 2.3E+05
27 1 119 10 7.7E+06 5.3E+05
28 1 132 5 2.4E+06 6.8E+05
29 1 100 1 1.9E+06 1.9E+05
30 4 101 4 5.8E+06 1.6E+06
31 10 120 7 9.9E+05 2.9E+05
32 10 99 2 7.7E+05 3.6E+04
Radius (nm)a Intensity (cts/s)
IPA +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
IPA + +
++FITC
+ NH
O
FITC
IPA + NH
O
IPA + NH
O
IPA + NH
O
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 Technique Formula Calculated Mass 
Measured 
Mass (m/z) 
8 MALDI-TOF C65H77N22O12 [M+H]+ 1357.6 1357.8 
9 MALDI-TOF C67H79N22O13 [M+H]+ 1399.6 1399.8 
10 MALDI-TOF C72H81N22O13 [M+H]+ 1461.6 1461.8 
14 MALDI-TOF C58H67N22O12 [M+H]+ 1263.5 1263.9 
16 MALDI-TOF C66H78N21O12 [M+H]+ 1356.6 1356.6 
17 MALDI-TOF C64H76N23O12 [M+H]+ 1358.6 1358.8 
18 MALDI-TOF C63H75N24O12 [M+H]+ 1359.6 1360.0 
19 MALDI-TOF C66H78N21O12 [M+H]+ 1356.6 1356.8 
20 MALDI-TOF C62H76N21O12 [M+H]+ 1306.6 1306.9 
21 MALDI-TOF C62H76N21O12 [M+H]+ 1306.6 1307.3 
22 MALDI-TOF C65H77N22O12 [M+H]+ 1357.6 1357.8 
23 MALDI-TOF C65H77N22O12 [M+H]+ 1357.6 1358.0 
24 MALDI-TOF C62H76N21O12 [M+H]+ 1306.6 1306.9 
Table S4.2. Mass spectroscopy results for unpublished compounds 8-10, 12-14, 16-24. 
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Abstract 
Pyrrole-Imidazole hairpin polyamides are a cell-permeable class of DNA-binding 
small molecules that are able to access chromatin and disrupt the transcription factor-DNA 
binding interface, thereby downregulating endogenous gene expression in human 
carcinoma cell lines. Conversely, several polyamide-peptide conjugates have been shown 
to upregulate transcription in vitro, with the polyamide mimicking the DNA-binding 
domain of a transcription factor and the peptide functioning as the transcriptional activation 
domain (TAD). Recently, isoxazolidine structures have been used as synthetic TADS, and 
an isoxazolidine-transcription factor conjugate has yielded an 80-fold induction of gene 
transcription in HeLa cells. Using a small molecule approach, hairpin polyamides may be 
utilized to replace the transcription factor-DNA binding domain, yielding polyamide-
isoxazolidine conjugates for gene activation studies. Solution-phase polyamide synthesis 
methods have been developed to generate gram-scale quantities of polyamides, enabling 
the synthesis of several polyamide-isoxazolidine conjugates. These compounds have been 
studied using various cell-culture assays for their ability to selectively activate 
transcription. In all of the studies herein, no significant levels of upregulation were 
observed. 
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Introduction 
 
Transcriptional regulation is an important strategy for the modulation of cellular 
signaling pathways, and molecules that can activate or repress transcription are of 
therapeutic value.1-2 Pyrrole-imidazole (Py-Im) hairpin polyamides are a class of sequence-
specific DNA-binding small molecules with affinities comparable to transcription factors.3 
Previous studies have shown that polyamides readily enter living cells, traffic to the 
nucleus, and downregulate endogenous gene expression through disruption of the 
DNA/transcription factor interface.4-11 Likewise, polyamide-based upregulation of gene 
expression is also possible, although the process is somewhat more complicated.  
Natural transcription factors can bind to either the wider major groove or narrower 
minor groove of DNA. These binding events can involve hydrogen bonding, electrostatic 
interactions, or van der Waals interactions with the base pairs or phosphate backbone of 
DNA. Proteins that bind to DNA, such as leucine zippers and zinc fingers, can bind as 
monomers, dimers, or in a combinatorial fashion where multiple DNA-binding proteins are 
required to regulate a certain gene. In addition to the DNA-binding domain (DBD), natural 
transcription factors generally contain other structural elements for purposes such as 
ligand-binding and transcriptional activation. In order to create an artificial transcription 
factor (ATF) to upregulate transcription, it will be essential to include structural motifs that 
mimic these domains, particularly the DBD and TAD. 
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Figure 5.1: Structures of DNA-binding proteins; A) GCN4, a homodimeric leucine zipper; B) NF-κB, a 
heterodimer of p50/p65; C) Interferon-ß enhanceosome, an example of combinatorial binding.12 
TADs are structural motifs capable of recruiting and positioning RNA Polymerase 
II for gene transcription, when localized to specific DNA binding sites. By attaching a 
TAD to a Py-Im polyamide, it may be possible to selectively activate transcription. In this 
scenario, the polyamide serves to localize the TAD to a specific sequence in the promoter 
region of a target gene, thereby directing the assembly of the transcriptional machinery and 
enabling transcription. In order to allow the activation domain enough conformational 
flexibility for optimal recruitment of the transcriptional machinery, a stable and flexible 
linker region is necessary to connect the polyamide to the activation domain. 
B A 
C 
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Figure 5.2: Modes of polyamide-based gene regulation. A) Activation: a polyamide attached to a TAD binds 
to the DNA , the TAD recruits the transcriptional machinery , which allows assembly of the RNA 
polymerase II holoenzyme , leading to transcription. B) Polyamide can displace natural transcription 
factors, leading to a downregulation in transcription. 
 
Several polyamide-peptide conjugates have been reported that are capable of 
upregulating transcription in vitro, in which the polyamide mimics the DBD of a 
transcription factor, and is linked to a peptide known to function as a TAD.13-15 A 
polyamide conjugated to a synthetic activation domain, wrenchnolol, was also 
demonstrated to induce transcription in vitro.16 A lack of efficient cellular uptake, likely 
due to the large molecular weight of these compounds—which often exceeded 4 kDa—
prevented in vivo applications.5,17,18 More recently, a polyamide conjugated to a lower 
molecular weight synthetic peptoid activation domain showed 5-fold induction of a 
luciferase reporter in HeLa cells, the first reported ATF that is cell permeable.19 
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Figure 5.3: An example of a polyamide attached to a peptide activation domain (YPWM) that recruits Exd (a 
member of the HOX family of transcription factors).  
 
A recent example of a low molecular weight, synthetic TAD is the isoxazolidine 
structure developed by Mapp and coworkers (Figure 5.4A).20  The transcriptionally active 
isoxazolidine derivative contains moieties that mimic amino acids (specifically 
phenylalanine, leucine, and serine) found in natural transcription factors, and is 
amphipathic, which has been reported as an important feature in TADs.1,21 
 
A B             
 
Figure 5.4: Synthetic activation domains. A) Isoxazolidine; B) Wrenchnolol. 
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Rowe et al. conjugated an isoxazolidine compound to an OxDex steroid—which 
binds to the glucocorticoid receptor (GR). Gal4, a natural transcription factor, was fused to 
the functional portion of the GR, which served as the DBD. Transfection of a plasmid 
containing five Gal4 binding sites upstream of a firefly luciferase reporter gene allowed for 
the monitoring of transcription in vivo.  
 
 
 
A                                                             B        B) 
Figure 5.5: a) Structures of active (i) and inactive (ii) isoxazolidine TADs. b) In vivo luciferase assay; 80-fold 
activation at 1.0 µM. Adapted from Rowe et al. 
 
As seen in Figure 5.5, amphipathic i containing an alcohol group was found to 
function as a TAD, whereas hydrophobic ii containing an olefin does not. This system 
utilizing isoxazolidine construct i showed an 80-fold induction in HeLa cells over the 
control construct ii.22  The transcriptional activity of i was shown to be comparable to 
natural peptides used by cells for activation of transcription, making it one of the most 
active TADs to date. This, combined with its low molecular weight and synthetic 
accessibility, indicate the great potential for polyamide-isoxazolidine conjugates to function 
as ATFs. 
By directly linking a polyamide to the isoxazolidine TAD, this complicated DBD 
system can be avoided. The use of a polyamide may be advantageous over DBDs similar to 
the Gal4/GR/OxDex construct, in that polyamides bind DNA with comparable affinity, and 
can be programmed to bind many sequences. Therefore, the range of possible targets for 
N O
H
NHO OxDex
N O
H
N OxDex
i ii
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gene activation using polyamides as DBDs is greatly expanded. Py/Im polyamides have 
also been shown to readily traffic to the nucleus of living cells and modulate endogenous 
gene expression without the need for lipophilic transfection agents required with other 
methods.  
 
Figure 5.6: General structure of a polyamide-isoxazolidine conjugate, indicating the DBD, linker domain, and 
TAD. 
 
 The polyamide-mediated upregulation of genes has met with limited success in the 
past, partly due to the small number of molecules that function as general activation 
domains.1  In addition, the complication of adding molecular weight to an already large 
molecule can lead to a decrease in cellular uptake, thereby obstructing in vivo applications. 
Isoxazolidines appear to function as highly active general activation domains, and are 
relatively low in molecular weight and synthetically accessible. With recent strategies 
developed in the Dervan lab17,23 that have been demonstrated to increase cellular uptake, 
polyamide-isoxazolidine conjugates would seem to have a great potential for 
transcriptional activation.  
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In order to compare results for polyamide-isoxazolidine conjugates to previous 
isoxazolidine studies, the promoter region containing Gal4 binding sites upstream of the 
firefly luciferase gene in the plasmid (pG5luc) was targeted. There are five Gal4 binding 
sites in the promoter, each containing a 5’-WGWWCW-3’ sequence, a convenient target 
site for the polyamides shown in Figure 5.7. The geometry of the designed polyamides, in 
which the isoxazolidine group is conjugated to an (R)-β-amino-γ-turn, was chosen based on 
recent work in the Dervan laboratory indicating that substituents at this turn are better 
tolerated and have a relatively small effect on the binding affinity of the polyamide.23  The 
length of the linker will be varied to determine whether this has any significant effect on 
gene activation. 
 
Figure 5.7: Targeting the pG5luc promoter region. There are five binding sites in this promoter, and each 
contains a 5’-WGWWCW-3’ (W=A/T) region (top). The proposed general structure of the polyamide-
isoxazolidine conjugates is shown (bottom). 
   
In collaboration with Ryan Casey from Professsor Anna Mapp’s laboratory 
(University of Michigan), a library of six polyamide-isoxazolidine derivatives was chosen. 
pG5luc Promoter Region: 
  1 GGTACCGAGT TTCTAGACGG AGTACTGTCC TCCGAGCGGA GTACTGTCCT      
 51 CCGACTCGAG CGGAGTACTG TCCTCCGATC GGAGTACTGT CCTCCGCGAA    
101 TTCCGGAGTA CTGTCCTCCG AAGACGCTAG CGGGGGGCTA TAAAAGGGGG   
151 TGGGGGCGTT CGTCCTCACT CT 
 
General Structure: 
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Initially, Mr. Casey began work synthesizing the compounds listed below, which he would 
later send to Caltech. 
 
Figure 5.8: Isoxazolidine compounds sent from the Mapp laboratory. Three of these compounds are active 
(left), and three control compounds are inactive (right). 
 
As seen in Figure 5.8, milligram-scale samples of these compounds were sent to 
Caltech, including three active TADs, with alcohol moieties, and three inactive control 
compounds, of varying linker lengths. These compounds can be directly coupled (after t-
Boc deprotection for RJC-6-1 and RJC-6-3) to a polyamide bearing a carboxylic acid as 
discussed below. Unfortunately, it was determined that the compound labeled RJC-6-8 
was not the correct compound. The proposed library of polyamide-isoxazolidine conjugates 
is shown in Figure 5.9. 
Active TAD Control 
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Figure 5.9: Proposed library of polyamide-isoxazolidine conjugates. 
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Results and Discussion 
 
Solid-phase Polyamide Synthesis 
 Prior to receiving the isoxazolidine compounds, solid-phase synthesis (SPS)24,25 
methods were employed to generate sufficient quantities of the unsubstituted polyamide, 
such that the necessary steps to prepare this polyamide for conjugation with isoxazolidines 
could be worked out. 
     
Figure 5.10: t-Boc-solid phase synthesis of an eight-ring hairpin polyamide attached to oxime resin, 5. 
 
 This synthesis employed t-Boc-SPS with Kaiser Oxime resin, and involved 
successive PyBOP couplings (or the use of preactivated heterocycles) and TFA 
deprotections. Each reaction was monitored by the cleavage and analytical HPLC of a 
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small sample of resin to verify reaction completion. Next, the resin was cleaved with 3,3’-
diamino-N-methyl-dipropylamine, as seen in Figure 5.11. 
 
 
Figure 5.11: Cleavage of polyamide from oxime resin; coupling of mono-tert-butyl protected isophthalic 
acid. 
 
After preparatory HPLC purification to yield polyamide 6, PyBOP coupling of 
mono-tert-butyl isophthalic acid afforded 1.5µmol of polyamide 7. This tert-butyl ester 
protecting group was used to later allow regioselective amide coupling of isoxazolidines to 
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a carboxylic acid-functionalized amino turn. Next, palladium-catalyzed transfer 
hydrogenation afforded free amine 8, in low yield. Succinylation of the amine then 
afforded the corresponding carboxylic acid 9 in moderate yield, which could be coupled 
directly to the amino-substituted isoxazolidine compounds. 
 
Figure 5.12: Synthesis of carboxylic-acid derivatized polyamide. Conditions: a) Pd(OAc)2, H4NHCO2, 
DMF/H2O, r.t., 16h, 27%; b) Succinic Anhydride, DIEA, DMF, r.t., 1 hr, 77%. 
  
 However, the yield of these reactions (21% over two steps) was very low, despite 
attempts at optimization. After the isoxazolidines were received, a nanomole-scale 
(20nmol) isoxazolidine coupling reaction was attempted, but the miniscule amount of 
remaining material after work-up and purification made analytical characterization 
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difficult. These results indicated that further optimization would be necessary in order to 
preserve valuable material, especially considering two additional steps—an isoxazolidine 
coupling and subsequent tert-butyl ester deprotection—would be required to afford the 
desired structure. This indicated that a large quantity of polyamide 7 would be necessary to 
synthesize reasonable quantities (~500 nmol) of the six polyamide-isoxazolidine 
conjugates.  
 
Solution-phase Polyamide Scale-up 
 As a way to generate a significant quantity of polyamide for isoxazolidine coupling 
reactions, a solution-phase route was considered. 
 
Figure 5.13: Retrosynthesis of polyamide 7. The tail piece 10 can be coupled to polyamide core 11, which is 
generated from tetramer 12, and pentamer 13 (which contains a hairpin turn unit). 
 
Retrosynthetically, two key amide bond disconnections were envisioned, as seen in 
Figure 5.13. Polyamide 7 was first disconnected from its tail (10) and polyamide core (11) 
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pieces. The polyamide core was further disconnected from its precursors 12 and 13. 
Therefore, compounds 10, 12, and 13 were the initial synthetic targets. 
In order to synthesize the tail region 10, the amide coupling of commercially 
available triamine 16 with mono-tert-butyl isophthalic acid 15 was proposed. While 15 is 
commercially available, it is relatively expensive. Other methods to synthesize 15 were 
attempted, involving the conversion of commercially available isophthalic acid to its mono-
tert-butyl protected form 15, without much success. However, a literature search also 
revealed the synthesis of 15 from commercially available isophthaloyl dichloride 14.26  
This reaction was incorporated to yield 15 in moderate yield, but with extremely 
inexpensive starting materials. This route allowed the synthesis of large quantities (16 
grams) of 15. Next, DCC-mediated coupling of triamine 16 to carboxylic acid 15 afforded 
building block 10 in moderate yield. 
 
Figure 5.14: Synthesis of 10. Conditions: a) tert-butanol, pyridine, THF, 81°C, 6 hr; b) H2O, pyridine, THF, 
81°C, 6 hr, 52% over two steps; c) DCC, HOBt, DCM, r.t., 1 hr; d) 16, DCM, r.t., 4 hr, 47% over two steps. 
 
Beginning with trimer 20, which can be readily synthesized in two steps from 
Dervan Laboratory stock compounds 17 and 18, the synthesis of tetramer 12 was 
completed in two steps by coupling of an activated imidazole unit to 20, followed by 
saponification. Tetramer 23 was also synthesized from trimer 20 in two steps through an 
activated ester coupling of a bifunctional imidazole derivative, followed by acidic 
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deprotection of the N-tert-butoxycarbonyl (Boc) protecting group. PyBOP coupling of an 
(R)-β-amino-γ-turn to 23 followed by acidic Boc-deprotection yielded pentamer 13.  
   
 
Figure 5.15: Synthesis of 12 and 13 from trimer 20. Conditions: a) DIEA, DMF, r.t, 16h, 91%; b) 4.0M HCl 
in 1,4-Dioxane, r.t., 18h, 97%; c) Im-CCl3, DIEA, DMF, r.t., 16h, 87%; d) 1N NaOH, H2O, 1,4-Dioxane, 50°, 
6h, 98%; e) Boc-Im-COOH, HBTU, DIEA, DMF, r.t., 16h, 81%; f) 2.0M HCl in Et2O, 1,4-Dioxane, r.t., 3h, 
97%; g) Z-ß-Dab(Boc)-OH, PyBOP, DIEA, DMF, r.t., 16h, 78%; h) 2.0M HCl in Et2O, 1,4-Dioxane, r.t., 3h, 
99%. 
 
With polyamide precursors 10, 12, and 13 synthesized in gram-scale quantities 
(0.5-1.0 grams of each compound), polyamide 7 was synthesized in 3 steps: PyBOP 
coupling of 12 and 13 to yield the polyamide core ethyl ester 25, saponification to afford 
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carboxylic acid 11, and PyBOP coupling of 11 with tail unit 10, as illustrated in Figure 
5.16. 
 
 
Figure 5.16: Synthesis of Polyamide 7. Conditions: a) 12, PyBOP, DIEA, DMF, r.t., 16h, 76%; b) 1N NaOH, 
H2O, 1,4-Dioxane, r.t., 15h, 86%; c) 10, PyBOP, DIEA, DMF, r.t., 2h, 94%.  
 
 Using this solution-phase synthesis route, it was possible to synthesize over 350mg 
(over 200 µmol) of 7, with more synthetic precursors available if necessary. While this 
route necessitated chromatography steps and required some optimization, it is anticipated 
that future syntheses of this nature would be more straightforward and less laborious, 
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allowing synthesis of large quantities of polyamide where previous solid-phase methods 
would be inadequate. Indeed, Chenoweth et al. from the Dervan laboratory have since 
developed a high-yielding chromatography-free route for gram-scale solution phase 
synthesis of a polyamide.27 
 
Synthesis of Polyamide-Isoxazolidine Conjugates 
 With a large quantity of polyamide 7 available, the next step was derivatization of 
the polyamide for coupling with the isoxazolidine compounds. Initially, this required 
deprotection of the Cbz-protected amino turn. Due to the tert-butyl protecting group on the 
polyamide tail, catalytic transfer hydrogenation was chosen as the optimal chemoselective 
transformation.28-30 At first, the use of palladium(II) acetate as a catalyst along with 
ammonium formate (as a source of hydrogen) was attempted, as mentioned above. 
However, among the various conditions tested, heating was necessary for full conversion 
and decomposition was always a major drawback, leading to poor yields. Palladium on 
carbon (Pd/C) was also attempted as a hydrogenation catalyst, and this reaction afforded 
amino compound 8 with less decomposition. Despite indications that this was a clean 
reaction, yields were consistently low after filtration and purification. It was found that with 
too much Pd/C catalyst, yields were lower. It is speculated that some polyamide becomes 
bound—perhaps irreversibly—to the catalyst, leading to a loss of product. Additionally, it 
was found that the standard method of filtering Pd/C, using celite, was also a major reason 
for lost material. Optimization of reaction conditions and purification methods proved 
crucial, and eventually a high yielding procedure was developed.  
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Figure 5.17: Synthesis of acid-functionalized polyamide 9. Conditions: a) Pd/C, H4NHCO2, H2O, 1,4-
Dioxane, 60°, 12 hours; b) Succinic Anhydride, DMF, DIEA, r.t., 30min, 87% over two steps. 
 
 As seen in Figure 5.17, the subsequent addition of succinic anhydride gave 
polyamide 9 in 87% yield over two steps. The final two transformations were the 
isoxazolidine-polyamide coupling and the subsequent acid deprotection of the tert-butyl 
group. The coupling step was somewhat problematic, as it is difficult to precisely measure 
stoichiometric quantities of each compound on such a small scale, and this reaction 
generally involved the formation of minor side products. A general procedure was 
developed to maximize product formation, but side-products have not been completely 
eliminated in this procedure. Finally, the tert-butyl group on the tail must be deprotected, 
and this step was also initially challenging. While different acid-catalyzed conditions 
(TFA/DCM, HCl/Ether, etc.) were attempted, decomposition of these polyamide-
isoxazolidine compounds was pervasive among all methods, and yields were extremely 
low. In order to limit the loss of invaluable isoxazolidine compounds, this reaction was 
performed on a very small scale, making it difficult to monitor. Compounding this issue 
was the need to purify the final conjugates via preparatory HPLC, often leading to an 
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additional significant reduction in yield. However, a milder deprotection procedure proved 
to be more successful, employing CeCl3 and NaI in refluxing acetonitrile. In general, this 
reaction minimized decomposition and significantly increased the overall yield. 
 
 
Figure 5.18: Polyamide-isoxazolidine coupling and final tert-butyl deprotection. Conditions: a) PyBOP, 
DIEA, DMF, RJC-6-X (see Figure 5.8), 60°, 3 hours; b) CeCl3•H2O, NaI, MeCN, 82°C, 1 hour, 21% yield 
over two steps. 
 
 Using this route, ATF-1, ATF-2, and ATF-4 were synthesized. Moderate 
quantities of ATF-1 and ATF-4 were synthesized, while a small amount of ATF-2 was 
also synthesized (Figure 5.19). With the excess of isoxazolidine compounds necessary for 
these coupling reactions, combined with the small amount of available isoxazolidine 
material, it was possible only to make usable quantities of ATF-1 and ATF-4. However, 
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these initial stocks allowed preliminary biological investigations to explore the gene 
activation potential of these conjugates (discussed below). 
 
Figure 5.19: Initial synthesized stock of proposed polyamide-isoxazolidine conjugate library. 
 
Linker Synthesis 
 After a second shipment of isoxazolidine compounds arrived from Mr. Casey in the 
Mapp laboratory, in somewhat larger quantities than before (Figure 5.20), optimization of 
the linker couplings was attempted at Caltech, due to low reported yields in previous 
procedures, which limited the amount of isoxazolidine that was sent.  
  
ATF-4: 
543nmol 
ATF-1 
352nmol 
ATF-2: 
26nmol 
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       RJC-6-1dep           RJC-6-3dep 
          24mg     70mg 
Figure 5.20: Second batch of isoxazolidines received from Mapp laboratory. 
 In considering the optimal route for attachment of a longer length linker, it was 
deemed that previous methods involving sequential attachment of two short PEG linkers 
were less than desirable, due to compounding low yield steps. In addition, the previous 
Fmoc-protected linkers yielded deprotection byproducts, which necessitated preparatory 
HPLC purification, further decreasing the yield. 
  
 
 
 
 
 
Figure 5.21: Routes for linker attachment (long linker variant). A) Previous strategy, involving sequential 
attachment of two short PEG linkers. B) Strategy utilizing a single longer linker, with a Boc protecting group. 
 
 As seen in Figure 5.21, another envisioned route was to use a single longer linker 
with a Boc protecting group. This procedure involved a single coupling, providing a 
relatively non-polar product, which can be purified by preparatory TLC. The linker-
isoxazolidine coupling reaction proceeded with relatively high yield. After Boc 
deprotection, this compound can be directly coupled to a polyamide (Figure 5.22). It was 
found that the previous CeCl3/NaI t-butyl deprotection procedure caused significant 
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decomposition in this route, so an improved 95% TFA/5% H2O protocol was developed 
allowing significantly improved yields. 
 
Figure 5.22: Synthesis of polyamide-isoxazolidine with longer linker. 
 
In Vivo Activation Studies 
 Concurrent with the synthesis of a polyamide-isoxazolidine with a longer linker, the 
initial completed compounds underwent pilot studies to assay for upregulation of 
transcription. Samples of ATF-1, ATF-2, and ATF-4 were sent to Michigan, along with 
parent polyamide 43 (an additional control) to be added to HeLa cells transfected with the 
pG5luc plasmid, the same system previously used in the Mapp laboratory.  
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Figure 5.23: Compounds used in initial luciferase assay by Mapp laboratory. 
 Additionally, a second plasmid containing a Renilla luciferase construct was used, 
thereby allowing a dual luciferase assay to be performed. Cells were plated, incubated f24 
hours, and dosed with polyamide-isoxazolidine conjugates for a 40 hour period. 
 
Figure 5.24: Initial results from Mapp laboratory: dual luciferase reporter assay in HeLa cells.  
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 In addition to the Renilla luciferase normalization, the fold activation is also 
normalized for  wells containing no synthetic conjugates, as well as for luciferase signal 
elicited by the parent polyamide, 43. At 10µM, significant cytotoxicity was observed, 
contributing to the large error. These initial results showed some promise, as there was a 
modest (~2-fold) increase in luciferase signal for cells treated with ATF-1 and ATF-2 at 
2.5µM. However, previous studies in the Mapp laboratory exhibited an 80-fold activation 
with a Gal4-based DBD.  
 In a later experiment, polyamide 44, containing a longer linker, was assayed by the 
Mapp laboratory in a similar dual luciferase reporter assay. 
 
Figure 5.25: Dual luciferase reporter assay for compound 44 in HeLa cells.  
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 As for the results of ATF-1 and ATF-2, no significant activation of luciferase 
activity was observed in this assay. 
 In addition to the experiments in HeLa cells run by the Mapp laboratory, 
experiments were performed at Caltech using the LNAR+ cell line. This cell line was 
developed by the Charles Sawyer laboratory at Sloan-Kettering. It consists of transformed 
LNCaP cells that have been stably transfected with a firefly luciferase reporter gene 
controlled by an Androgen Response Element (ARE) in the promoter region (which likely 
contains a GWWC sequence). Unfortunately, the sequence of this construct isn’t available. 
However, it was envisioned that this experiment would still be informative as to whether or 
not these polyamide-isoxazolidine conjugates are activating transcription.  
 In this experiment, polyamides at varying concentrations were added to cells in 
quadruplet, on a 96-well plate. Cells were plated at 50,000 cells/mL, incubated for 24 
hours, and treated with both active and inactive polyamide-isoxazolidine conjugates, as 
well as parent polyamide compounds as further controls. Positive and negative controls 
were set up by the presence and absence of induction by dihydrotestosterone (DHT), 
respectively. DHT is a potent agonist for androgen receptor activation, so cells induced by 
DHT should exhibit an increased luciferase signal. In addition to the luminescence assay 
that indicates firefly luciferase activity, a WST-1 cell proliferation assay was also 
performed to determine any cytotoxicity caused by the polyamides along the range of 
concentrations studied. This data can also be used to normalize the luciferase data, in that 
WST-1 assays provide an estimate of cell viability by measuring mitochondrial activity. 
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Figure 5.26: Experimental timeline. Cells are plated, incubated 24 hours, dosed with compounds, and 
incubated for 40 hours. A six-hour DHT induction was also performed in wells with no other added 
compounds. 
 
  After initial pilot studies were performed to optimize the assay (e.g. optimization of 
incubation time for the WST-1 assay, examination of a wide range of polyamide 
concentrations, etc.), an experiment consisting of four compounds, and ranging from 3nM 
to 10µM in concentration was conducted.  
  
Figure 5.27: Compounds used in LNAR+ assay. 
  
 Compounds 43 and 45 can be easily synthesized from intermediates in the solution-
phase route detailed above. After the luciferase assay was performed, the data was 
collected and normalized by subtracting out the background values of wells without any 
cells. As mentioned above, it was also normalized for WST-1 values, and the final values 
reported in Relative Luminescence Units (RLU). 
43 
 
45 
 
ATF-2 
 
ATF-1 
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   General Structure: 
 
 
 
 
 
 
Figure 5.28: LNAR+ assay. The structures of each of the polyamides is indicated below. Concentration is 
varied from 3nM to 10µM. Note: the y-axis is split.  
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Raw Luminescence 
       
 
Figure 5.29: LNAR+ assay raw data. It is notable that there is no significant decrease in WST-1 signal for 
any of the compounds. 
 
 The data seem to indicate that all four compounds cause an increase in luciferase 
signal to various degrees, which certainly was not anticipated. From this data, the 
succinylated polyamide 44 (listed as compound C in this study) actually seems to have the 
most drastic effect, followed by the active polyamide isoxazolidine, ATF-1 (compound A). 
At 10µM, however, all four compounds appear to elicit a significant increase in luciferase 
signal. 
 To investigate this system further, the concentration could be increased, to 
determine if the luciferase signal continues to increase, especially with no observable 
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toxicity via the WST-1 assay. However, an increase in concentration would require 
significantly more compound, necessitating the use of a sizeable portion of the relatively 
precious polyamide-isoxazolidine compounds. However, polyamide 43 (compound D) was 
available in large quantities, making it an ideal candidate to probe these results. 
 In the next experiment, the concentration of polyamide was varied from 100nM to 
50µM, and the procedure was repeated in the same manner as above. 
 
 
 
Normalized Luciferase Assay 
 
Concentration 
 
43 
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Figure 5.30: LNAR+ assay results for 43.  
  
 In this experiment, 43 elicited an extremely high luciferase signal, comparable to 
that of DHT at 50µM. In addition, there was observable cytotoxicity at this concentration. 
However, this polyamide has been previously shown to downregulate AR transcription,11 
so it seems unlikely that it would be directly activating transcription of the luciferase gene 
at the ARE. It is speculated that perhaps at these high concentrations there is some other 
global effect, causing downstream events that lead to activation of transcription at the ARE. 
This is speculation however, as there is no known process by which this occurs. Regardless 
Concentration 
 
Concentration 
 
Raw Luminescence 
 
WST-1 Cell Proliferation Assay 
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of the reason for this effect, it was determined that it was likely not possible to use this 
system to determine whether or not a polyamide-isoxazolidine conjugate is directly 
upregulating transcription, if a luciferase signal is elicited for all polyamide compounds 
tested.  
 In addition to the luciferase experiments outlined above, an alternative method to 
assay for transcriptional activation in an endogenous system was envisioned. In previous 
work by Muzikar et al.,31 Py-Im polyamides targeted to the glucocorticoid response 
element (GRE) have shown the ability to disrupt the binding of glucocorticoid receptor 
(GR) and inhibit expression of GR target genes such as glucocorticoid-induced leucine 
zipper (GILZ). 
 
Figure 5.31: Polyamide disruption of glucocorticoid receptor binding, and downregulation of dexamethasone-
induced GILZ transcription in A549 lung carcinoma cells. 
 
 Conversely, by using a polyamide-isoxazolidine conjugate targeting the same 
sequence of the GRE, it was envisioned that it might be possible to upregulate the 
transcription of GILZ. This experiment was performed under similar conditions to those 
used previously to assess inhibition of GR-mediated expression of GILZ, with 48 hour 
incubation of A549 cells with polyamide-isoxazolidine conjugates. The levels of GILZ 
mRNA for both dexamethasone induced and non-induced cells were determined using 
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quantitative real-time reverse transcriptase PCR relative to β-glucuronidase, an endogenous 
control, performed in collaboration with Katy Muzikar. 
 
Figure 5.32: Quantitative real-time reverse transcriptase PCR of A549 cells dosed with polyamide-
isoxazolidine compounds. 
 
 Based on these data, it appears that there is no significant increase in levels of GILZ 
mRNA in any of the compounds studied, including the polyamide-isoxazolidine 
conjugates.  For the non-induced systems, low levels of GILZ mRNA were seen across the 
panel of compounds, and for the dexamethasone-induced cells, GILZ mRNA levels were 
either low or decreased with increasing concentration of polyamide, consistent with 
polyamide-based disruption of the GR-DNA interface and concentration dependent 
repression of GILZ expression. 
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 Finally, a cell-free assay was envisioned as another route to determine if 
polyamide-isoxazolidine conjugates were able to activate transcription in vitro. Based on 
previous studies,13-15 the plasmid pMLΔ53, containing a g-less cassette reporter gene 
upstream of a TATA box and known ligation sites, was chosen and obtained via a generous 
gift of the laboratory of Cheng-Ming Chiang at the University of Texas Southwestern 
Medical Center. Following previous protocols, construction of a plasmid for gene 
activation experiments was attempted via insertion of a synthetic oligonucleotide 
containing the desired WGWWCW binding sites into a Bgl2 restriction site. After initial 
cloning attempts failed, subsequent sequencing results indicated there was no Bgl2 
restriction site in this plasmid, despite it bearing the same name as a previous plasmid with 
a known Bgl2 site. Another strategy was attempted via insertion of a synthetic 
oligonucleotide between EcoRI and XmaI restriction sites, which were identified via 
sequencing, and were upstream of the TATA box and g-less cassette. However, in all 
further attempts to assay in vitro transcription, even basal levels of transcription of the g-
less cassette were not observable as expected based on previous studies with the original 
pMLΔ53 plasmid. Further attempts to obtain the original plasmid with a Bgl2 restriction 
site were unsuccessful. 
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Conclusions 
 A general method for the synthesis of large quantities of polyamides functionalized 
for coupling to isoxazolidines has been accomplished. The entire solution-phase synthetic 
route is mapped out, and is likely applicable to other synthetic modulations for future 
studies (e.g. different polyamide core, alternative TADs, etc.). Conditions for attachment of 
various linkers and conjugation of several isoxazolidines moieties to polyamides have been 
optimized. However, based on multiple cell-culture assays, no significant levels of 
transcriptional upregulation have been observed to date. 
 While it is possible that the chosen geometry of the polyamide-isoxazolidine 
compounds is ineffective at activating transcription, a series of tail-conjugated polyamide-
isoxazolidine compounds have been synthesized and studied by Dr. Daniel Gubler. In 
similar cell culture studies, these compounds also failed to show any levels of 
transcriptional upregulation. It is currently not fully understood exactly why polyamide-
isoxazolidine conjugates were unsuccessful as artificial transcription factors, though it is 
speculated that the large size of these conjugates may be a negative determinant for cellular 
uptake, and this could mean that the levels of intracellular concentration are never high 
enough for significant effects to be observed. Other effects such as geometric constraints or 
protein binding may also be inhibiting the functionality of these compounds, and further 
studies will be necessary to deconvolute these various factors. 
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Section 5B: Synthesis of WM Conjugates 
Background 
 In addition to studying polyamide-isoxazolidine conjugates, another project 
involving transcriptional activation was also undertaken: a collaboration with Professor 
Aseem Ansari’s laboratory (University of Wisconsin). This involved the synthesis of a 
“WM” compound (so called because it contains tryptophan and methionine moieties) 
conjugated to a polyamide. These conjugates can facilitate Exd-DNA dimerization, 
analogous to the compound shown in Figure 5.3. 
 
 
Figure 5.33: The WM compound DCM-132 and control DCM-133 that were synthesized. DCM-132 
contains a natural methionine and a tryptophan with D stereochemistry. 
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 These compounds were previously synthesized by Dr. Ryan Stafford of the Dervan 
group, and were shipped to the Ansari laboratory. Using RLSiv-279A (Dr. Stafford’s 
version of DCM-132) in Jurkat cells, a reporter luciferase assay was used to assay for gene 
activation. This method indicated a 2-fold activation of transcription at 1µM. To determine 
whether this effect was concentration dependent, more material was necessary to allow 
higher concentrations to be assayed. However, the previously shipped material had nearly 
all been used in these initial experiments. Leslie Donato of Professor Ansari’s group asked 
if the Dervan laboratory could synthesize more of this compound, to be shipped to the 
Ansari laboratory. 
 Following Dr. Stafford’s protocol, these compounds were synthesized using Boc-
solid-phase polyamide synthesis, as mentioned previously. The synthesis of control 
compound DCM-133 was relatively straightforward: after cleavage from resin and 
preparatory HPLC purification, PyBOP coupling of isophthalic acid yielded the final 
product, which was again purified by preparatory HPLC. In the case of DCM-132, a 
phthalimide-protected amino group linked to a pyrrole was used as one of the monomers 
during the synthesis, to provide the handle for peptide conjugation as seen in Figure 5.34. 
In addition, after cleavage from resin, and preparatory HPLC purification, three more 
synthetic steps were required: coupling of the peptide fragment, deprotection of the Boc 
group on the tail, and isophthalic acid coupling. The final products were then purified via 
preparatory HPLC. 
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Figure 5.34: Synthesis of WM conjugate. 
 
 These compounds were synthesized in reasonable quantities (377nmol and 
519nmol for DCM-132 and DCM-133 respectively), with comparable yields to those 
previously reported. After their synthesis, these compounds were sent to the University of 
Wisconsin. Unfortunately, further luciferase assays employing increased concentrations did 
not increase the luciferase signal substantially. 
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Materials and Methods 
  Polyamides were synthesized using Kaiser oxime resin (0.56 mmol/g) and 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) from 
Novabiochem.  Z-ß-Dab(Boc)-OH was purchased from Peptides International.  Monomers 
and dimers for solid phase synthesis were synthesized using published protocols.24,32 N,N-
dimethylformamide (DMF), Dichloromethane (DCM), methanol (MeOH), trifluoroacetic 
acid (TFA), acetic anhydride, N,N-diisopropylethylamine (DIEA), 2.0M HCl in Ether, 
succinic anhydride, 1,4-dioxane, and diethyl ether were purchased from Aldrich.  1M 
aqueous NaOH, 1M aqueous HCl, solid sodium sulfate (Na2SO4), and solid sodium 
bicarbonate (NaHCO3) were purchased from EMD Chemicals. 
All NMR spectroscopy data was obtained on a 500MHz Varian instrument.  
Analytical high-pressure liquid chromatography (HPLC) was performed using a Beckman 
Gold system with a Phenomenex Gemini C18 column, using 0.1% TFA/water (A) and 
acetonitrile (B) solvent system.  Preparatory HPLC purification was performed using the 
same solvents on an Agilent Technologies 1200 Series system using a Phenomenex Gemini 
C18 column.  Matrix-assisted laser desportion/ionization time of flight mass spectrometry 
(MALDI-TOF) was performed on an Applied Biosystems Voyager DE Pro spectrometer.  
UV-vis were recorded in water and a minimum of acetonitrile using an Agilent 8453 
spectrophotometer. 
 Polyamide synthesis was performed as previously reported.24,25  Briefly, oxime 
resin was swelled by flushing with DMF in a peptide synthesis vessel containing a cap, 
stopcock, and frit.  Initial pyrrole loading of the resin occurred overnight (16 hrs) at 37° C.  
In general, couplings lasted 2 hours.  Boc-protecting groups were removed with 20% TFA 
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in DCM for 25 min at r.t. Carboxylic acids (3 eq) were preactivated with PyBOP (3.5 eq) 
and DIEA (5 eq) for 30 min in DMF.  Cleavage of the polyamide from resin was performed 
using 1 mL of triamine for 200 mg of resin, allowing the reaction to proceed at 55°C for 12 
hours.  Preparatory HPLC was used to purify polyamides after cleavage. Mono-tert-butyl 
isophthalic acid or isophthalic acid (10eq) were coupled to polyamide using PyBOP (3eq) 
and DIEA (5eq). 
 
Solution Phase Polyamide Synthesis 
(R)-tert-butyl 3-(3-((3-(4-(4-(4-(4-(3-(benzyloxycarbonylamino)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-
methyl-1H-imidazole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)propyl)-
(methyl)amino)propylcarbamoyl)benzoate (7).  To carboxylic acid 11 (310 mg, 0.255mmol) dissolved in 
1mL of DMF was added DIEA (178 µL, 1.02mmol) and PyBOP (265mg, 0.510mmol) and allowed to stir at 
room temperature for 30 minutes.  To this mixture was next transferred a solution of 10 (178mg, 0.510mmol) 
in 200µL DMF and DIEA (8µL, 2eq) and allowed to stir for 2 hours.  Reaction was monitored by HPLC. 
Upon completion, the reaction mixture was poured into 20mL of H2O, transferred to Eppendorf tubes, and 
centrifuged at 13,000rpm for 10 minutes. The tan solid was then washed twice more and centrifuged, 
providing 368mg of polyamide 7 (94% yield), which was 91% pure by HPLC; MALDI-TOF: Calc. Mass: 
1546.70 [M+H]+:1547.71, [M+Na] +:1570.53  
(R)-4-(4-(2-(5-(5-(5-(3-((3-(3-(tert-butoxycarbonyl)benzamido)propyl)(methyl)amino)-propylcarbamoyl)-1-
methyl-1H-pyrrol-3-ylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)-
1-methyl-1H-imidazol-4-ylamino)-1-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-4-
oxobutan-2-ylamino)-4-oxobutanoic acid (9).  To 4.9mg of Pd/C (1eq) in a glass vial fitted with a teflon 
septum was added Cbz-protected 7 (5 µmol, 1 eq) dissolved in 850µL of 1,4-Dioxane and 800µL of water.  
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To this mixture was added ammonium formate (31.5mg, 200eq), and the solution was stirred overnight at 60°.  
Reaction was monitored by analytical HPLC, and transferred to Eppendorf tubes.  After centrifugation at 
13,000rpm, supernatant was collected.  Pellet was washed twice with 4:1 1,4-dioxane:water, these samples 
were centrifuged and supernatants combined.  After a final centrifuge spin, supernatant was poured into a 
scintillation vial, and excess solvent was removed via rotary evaporation, then placed on the high vacuum line 
for 4 hours.  Next, 500µL of DMF were added along with DIEA (43.5µL, 50eq).  To this mixture was added 
succinic anhydride (2.5mg, 5eq), and stirred at room temperature for 1 hour.  Reaction was monitored via 
HPLC.  Preparatory HPLC purification yielded 3.0 mg of 9 (87%), which was 98% pure by HPLC; MALDI-
TOF: Calc. Mass:1512.68 [M+H] +:1513.69. 
Tert-butyl 3-(3-((3-aminopropyl)(methyl)amino)propylcarbamoyl)benzoate (10).  To a solution of 15 in 
15mL DCM was added HOBt (334mg, 1.1eq), then DCC (510mg, 1.1eq), and this solution was stirred for 1 
hr.  Solution filtered to remove urea byproduct, then diluted by the addition of 250mL DCM, and added to an 
addition funnel.  This was dripped into a solution of triamine 16 (7.25mL, 20eq) and 5mL DCM over 3.5 
hours.  Rotary evaporation, and extraction to remove excess 16, yielded 362mg of 10.  1H NMR [499.8 MHz, 
DMSO-d6]: δ 8.68 (t, 1H), 8.31 (s, 1H), 8.01 (m, 2H), 7.58 (dd, 1H), 3.28 (m, 2H), 2.32 (m, 4H), 2.05 (s, 3H), 
1.67 (m, 2H), 1.52 (s, 9H), 1.50 (m, 2H), 1.46 (m, 2H). ESI-MS: Calc. Mass: 349.2 [M+H]+:350.3. 
 (R)-4-(4-(4-(4-(3-(benzyloxycarbonylamino)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-
imidazole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-
1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylic acid (11).  To 50mg of 25 in a 
scintillation vial was added 1mL 1,4-dioxane, then 1mL 1N aqueous NaOH.  Solution was stirred at r.t. for 15 
hours, then poured into Falcon tube. 1N aqueous HCl was added until pH<4, and solid 11 precipitates to form 
a tan brown gel.  Centrifugation was performed, the supernatant poured off, and the solid was washed twice 
with cold water, each time centrifuging and removing supernatant.  Product was next lyophilized to yield 42 
mg of 11 (86%).  91% pure by HPLC.  MALDI-TOF: Calculated Mass: 1215.47 [M+H] +:1216.65 [M+Na] 
+:1238.63 [M+K] +:1254.59.  
1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-carboxamido)-1H-pyrrole-2-carboxamido)-
1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxylic acid (12).  See procedure for compound 11.  98% 
! 198 
yield.  1H NMR [499.8 MHz, DMSO-d6]: δ 10.47 (s, 1H), 9.97 (s, 1H), 9.92 (s, 1H), 7.45 (s, 1H), 7.40 (s, 
1H), 7.27 (s, 1H), 7.22 (s, 1H), 7.18 (s, 1H), 7.06 (s, 1H), 7.04 (s, 1H), 6.91 (s, 1H), 3.99 (s, 3H), 3.81 (s, 3H), 
3.79 (s, 3H). ESI-MS: Calc. Mass: 492.2 [M+H]+:493.2. 
((R)-ethyl 4-(4-(4-(4-(3-(benzyloxycarbonylamino)-4-(tert-butoxycarbonylamino)butanamido)-1-methyl-
1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxylate (24).  To a solution of Z-ß-Dab(Boc)-OH (350mg, 1.33eq) 
in 252µL DIEA (2eq) and 10mL DMF was added PyBOP (517mg, 1.33eq), and this solution was stirred for 
30 minutes.  A separate solution of 23 mixed with 252µL DIEA (2eq) and 5mL DMF was then added to the 
first solution.  Mixture was stirred at room temperature for 16 hours.  Rotary evaporation removed as much 
DMF as possible, and this viscous oil was purified using silica gel chromatography, eluted with 9:1 
EtOAc:Hexanes, yielding 506mg of 24 (78%).  1H NMR [499.8 MHz, DMSO-d6]: δ 10.19 (s, 1H), 10.02 (s, 
1H), 9.97 (s, 1H), 9.92 (s, 1H), 7.45 (s, 1H), 7.43 (s, 1H), 7.35-7.23 (m, 6H), 7.13 (s, 1H), 7.09-7.02 (m, 2H), 
6.90 (s, 1H), 4.98 (s, 2H), 4.20 (q, 2H), 3.96 (s, 3H), 3.89-3.80 (m, 9H), 3.05 (m, 2H), 2.47 (m, 2H), 1.37 (s, 
9H), 1.26 (t, 3H). ESI-MS: Calc. Mass: 869.4 [M+H]+:870.3. 
 (R)-ethyl 4-(4-(4-(4-(4-amino-3-(benzyloxycarbonylamino)butanamido)-1-methyl-1H-imidazole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-
pyrrole-2-carboxylate (13). To a stirred solution of 24 (274mg, 1eq) in DCM (5mL) was added 2M HCl in 
Et2O (5mL). The resulting suspension was stirred for 7 hours at room temperature.  Reaction mixture was 
concentrated via rotary evaporation, affording 251mg of 13 (99% yield).  1H NMR [499.8 MHz, DMSO-d6]: δ 
10.47 (s, 1H), 9.97 (s, 1H), 9.92 (s, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.27 (s, 1H), 7.22 (s, 1H), 7.18 (s, 1H), 
7.06 (s, 1H), 7.04 (s, 1H), 6.91 (s, 1H), 3.99 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H). ESI-MS: Calc. Mass: 769.3 
[M+H]+:770.1. 
3-(tert-butoxycarbonyl)benzoic acid (15) Compound was synthesized as reported in the literature.26 Briefly, 
to a solution of isophthaloylchloride (30g, 0.15mol) in 250mL of THF was added tert-butanol (13.8mL, 
0.15mol) and pyridine (26.3mL, 0.33mol), and this mixture was refluxed for 6 hours. Next, D.I. H2O was 
added, and the mixture was refluxed again for 6 hours. After quenching, extraction, and concentration, 
recrystallization from toluene yielded 16.6g of large needle like crystals. (52% yield).  1H NMR [499.8 MHz, 
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DMSO-d6]: δ 8.39 (s, 1H), 8.12 (m, 2H), 7.62 (dd, 1H), 1.54 (s, 9H). ESI-MS: Calc. Mass: 222.1 
[M+H]+:223.1. 
Ethyl 1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-carboxamido)-1H-pyrrole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxylate (21).  To trimer 20 (400mg, 1eq) in 
5mL DMF and 304µL of DIEA (2eq) was added Im-CCl3 (228mg, 0.95eq) dissolved in 5mL DMF and 
304µL of DIEA (2eq).  This solution was stirred 16 hours at room temperature.  Reaction mixture was added 
to 3.6mL 1M aqueous HCl (4eq) in 200mL of water, creating a dark brown precipitate.  Solid was filtered and 
washed with copious amounts of water.  Solid was transferred to a separatory funnel along with 80mL of 
1%MeOH in EtOAc.  Organic layer was washed with 20mL brine, dried over sodium sulfate, filtered, and the 
solvent  removed via rotary evaporation.  1H NMR [499.8 MHz, DMSO-d6]: δ 10.47 (s, 1H), 9.97 (s, 1H), 
9.92 (s, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.27 (s, 1H), 7.22 (s, 1H), 7.18 (s, 1H), 7.06 (s, 1H), 7.04 (s, 1H), 6.91 
(s, 1H), 4.39 (q, 2H), 3.99 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 1.27 (t, 3H). ESI-MS: Calc. Mass: 520.2 
[M+H]+:521.4. 
Ethyl 4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-
2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate (22). To a 
solution of Boc-Im-COOH (102.7mg, 0.95eq) dissolved in 4.5mL DMF and 152µL of DIEA (2eq) was added 
HBTU (162mg, 0.95eq).  Solution stirred at room temperature for 20 minutes.  This solution was added to 
trimer 20 (200mg, 1eq) in 3mL DMF and 152µL of DIEA (2eq).  This mixture was stirred 16 hours at room 
temperature.  Reaction mixture was added to 1.8mL 1M aqueous HCl (4eq) in 93mL of water, creating a dark 
brown precipitate.  Solid was filtered and washed with copious amounts of water.  Purified via silica gel 
chromatography, to yield 220mg of 22 (81%).  1H NMR [499.8 MHz, DMSO-d6]: δ 9.95 (s, 3H), 9.92 (s, 
1H), 7.43 (s, 1H), 7.27 (s, 1H), 7.24 (m, 2H), 7.14 (s, 1H), 7.08 (s, 1H), 6.94 (s, 1H), 4.20 (q, 2H), 3.93 (s, 
1H), 3.82 (m, 3H), 1.46 (s, 9H), 1.27 (t, 3H). ESI-MS: Calc. Mass: 635.3 [M+H]+:636.3. 
Ethyl 4-(4-(4-(4-amino-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate (20).  To Boc-protected compound 
22 (431mg, 0.678mmol) was added 2.5mL of 1,4-Dioxane.  This mixture was added to 40mL of 2.0M 
HCl/Et2O, forming a suspension, which was stirred for 3 hours.  Solid was collected via vacuum filtration and 
left under high vacuum to yield 376mg of 23 (97%).  1H NMR [499.8 MHz, DMSO-d6]: δ 9.95 (s, 3H), 7.43 
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(s, 1H), 7.27 (s, 1H), 7.24 (m, 2H), 7.14 (s, 1H), 7.08 (s, 1H), 6.94 (s, 1H), 4.20 (q, 2H), 3.93 (s, 1H), 3.82 (m, 
3H), 1.27 (t, 3H). ESI-MS: Calc. Mass: 448.2 [M+H]+:449.1. 
(R)-ethyl 4-(4-(4-(4-(3-(benzyloxycarbonylamino)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-
imidazole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-
1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate (25).  To carboxylic acid 12 
(35mg, 1eq) was added 500µL DMF, 25µL DIEA (4eq), and PyBOP (37mg, 1eq), and the mixture was stirred 
for 20 minutes.  To this a solution of 13 (58mg, 1eq) along with 500µL DMF and 25µL DIEA were added.  
Stirred at room temperature for 16 hours.  Reaction mixture poured into a solution of 0.58mL 1M HCl (8eq) 
in 20mL water.  A suspension formed, and the solid was centrifuged and lyophilized to yield 68mg of 25 
(76% yield).  Compound was 85% pure by HPLC.  MALDI-TOF: Calculated Mass: 1243.51, [M+H] 
+:1244.51, [M+Na] +:1266.49, [M+K] +:1282.46. 
 
Isoxazolidine Coupling Reactions 
Tert-butyl 3-(3-((3-(4-(4-(4-(4-((R)-3-(4-(((3S,5R)-3-allyl-2-benzyl-3-isobutylisoxazolidin-5-
yl)methylamino)-4-oxobutanamido)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-
1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propyl)(methyl)amino)propylcarbamoyl)benzoate (29).  To isoxazolidine RJC 6-1 (5.6mg, 
5eq) was added 100µL of DCM. 100µL of TFA was next added dropwise, and the resulting mixture was 
stirred for 5 minutes. After concentration via rotary evaporation, 100µL of DMF was added, followed by 
DIEA (2.25µL, 5eq). In a separate vial, 2.59µmol of polyamide 9 was dissolved in 200µL DMF, and DIEA 
(0.9µL, 2 eq) followed by PyBOP (2.7mg, 2eq) were added, and the mixture was stirred for 2 minutes. To this 
solution was added the solution of deprotected isoxazolidine, and the resulting mixture was stirred for 16 
hours at 23°C. After determination of completion by analytical HPLC, the solution was poured into 5mL H2O. 
This solution was poured into a Waters C18 Sep-Pak, and flushed with 10% acetonitrile in H2O with 0.1% 
TFA to remove any DMF and other highly polar contaminants. A 1:1 acetonitrile: H2O w/ 0.1% TFA wash 
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was then used to elute the desired product. The resulting solution was next lyophilized to dryness directly into 
a ½ dram glass vial, and the crude material was used directly in the following step. Crude 29 was 64% pure by 
HPLC, and was directly used in the following step. 
Tert-butyl 3-(3-((3-(4-(4-(4-(4-((R)-3-(4-(((3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-
yl)methylamino)-4-oxobutanamido)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-
1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propyl)(methyl)amino)propylcarbamoyl)benzoate (26). See procedure for compound 29. 
2.1µmol of 9 used, with 2.9 mg (3.5eq) of RJC 6-3 used. Crude material carried forward. 55% pure by HPLC. 
3-(3-((3-(4-(4-(4-(4-((R)-3-(4-(((3S,5R)-3-allyl-2-benzyl-3-isobutylisoxazolidin-5-yl)methylamino)-4-
oxobutanamido)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-carboxamido)-1H-
pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)butanamido)-1-methyl-
1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)propyl)(methyl)amino)propylcarbamoyl)benzoic acid 
(ATF-4). To crude 29 lyophilized in a glass vial was added acetonitrile (500µL) and the resulting suspension 
was stirred. To this suspension was added NaI (5.75mg, 15eq), followed by CeCl3•7H2O (29mg, 30eq). This 
solution was refluxed for 1 hour, at which point it was poured into 3mL H2O, and partially purified via Waters 
C18 Sep-Pak as in previous step. The resulting solution was concentrated to remove most of the acetonitrile, 
and taken up in 1:4 acetonitrile:H2O with 0.1% TFA, and purified via preparatory HPLC, yielding 543nmol 
(21% yield from 9) of ATF-4. MALDI-TOF: Calc. Mass: 1726.83, [M+H] +:1727.47. 99% pure by HPLC. 
3-(3-((3-(4-(4-(4-(4-((R)-3-(4-(((3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-
yl)methylamino)-4-oxobutanamido)-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
carboxamido)butanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-
1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propyl)(methyl)amino)propylcarbamoyl)benzoic acid (ATF-1). See procedure for synthesis of 
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ATF-4. Isolated 352nmol (17% yield from 9) MALDI-TOF: Calc. Mass: 1730.82, [M+H] +:1731.65. 99% 
pure by HPLC 
Tert-butyl 3-(3-((3-(4-(4-(4-(4-((R)-1-((3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-yl)-17-
((1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-carboxamido)-1H-pyrrole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)methyl)-3,12,15-trioxo-5,8-dioxa-
2,11,16-triazanonadecanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-
carboxamido)propyl)(methyl)amino)propylcarbamoyl)benzoate (27). See procedure for synthesis of 29. 
Used 482nmol of 9, and 0.32mg isoxazolidine (2eq). Crude material carried forward. 37% pure by HPLC. 
3-(3-((3-(4-(4-(4-(4-((R)-1-((3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-yl)-17-((1-methyl-
4-(1-methyl-4-(1-methyl-4-(1-methyl-1H-imidazole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)methyl)-3,12,15-trioxo-5,8-dioxa-2,11,16-
triazanonadecanamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)propyl)(methyl)amino) 
propylcarbamoyl)benzoic acid (ATF-2). To lyophilized 27 was added 100µL of 1:1 DCM:TFA. This solution 
was agitated for 10 minutes, then concentrated via rotary evaporation. To the resulting residue was added 1:4 
acetonitrile:H2O with 0.1% TFA, and preparatory HPLC chromatography afforded 26nmol of ATF-2 (6% 
yield from 9). MALDI-TOF: Calc. Mass:1875.90, [M+H] +:1877.17. 97% pure by HPLC. 
 
Isoxazolidine Scale-up 
tert-butyl hypochlorite (32).  A solution of commercial household bleach (500mL) was stirred at 0°C in a 
large Erlenmeyer flask. The flask was covered with aluminum foil and lights in the vicinity were turned off, 
while a solution of tert-butanol (37mL, .39mol) and glacial acetic acid (24.5mL, .43mol) was added in a 
single portion. This solution was stirred for 3 minutes, then washed with 10% NaHCO3 followed by water, 
and the organic layer was collected and dried over CaCl3, and used directly in subsequent steps without 
further purification, affording 30g of tert-butyl hypochlorite (71% yield). Prepared according to the method of 
Mintz and Walling.33 
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(E)-3-methylbutanal oxime (34). Followed procedure published by Kubanov et al.34 Briefly, aldehyde 33 
(20g, 0.23mol) was refluxed in 200mL Benzene, with hydroxylamine hydrochloride (16.9g, 0.244mol) and 
Na2CO3 (25.819g, 0.244mol) for 5 hours. After extraction, the residue was purified via fractional distillation 
to yield 11.2g of oxime 34 (48% yield). 1H NMR [499.8 MHz, CDCl3]: δ 7.45, 6.76 (t, 1H), 2.10 (dd, 2H), 
1.92-1.81 (m, 1H), 0.96 (m, 6H). 
(R)-(3-isobutyl-4,5-dihydroisoxazol-5-yl)methanol (35). To a stirring solution of oxime 34 (3g, 29.6 mmol) in 
60mL of toluene at -78°C was added 32 (3.35mL, 29.6mmol) drop wise and this mixture was stirred for 2 
hours. In a separate flask, allyl alcohol (2.62mL, 38.5mmol) was stirred at 0°C in 120mL of toluene. To this 
mixture was added tert-BuOH (9.27 mL, 97.7 mmol) followed by drop wise addition of a 3.0M solution of 
EtMgBr in Et2O (29.6 mL, 88.8mmol), and this mixture was stirred for 1 h. The solution of hydroximinoyl 
chloride was then transferred via cannula to the allylic alcohol solution and the mixture allowed to warm to 
room temperature and stirred for 15 h. After quenching with NH4Cl and H2O, The organic layer was washed 
with DCM (3X) and the combined organic extracts were combined, dried, concentrated, and purified via silica 
gel chromatography. This provided 3.58g of isoxazoline 35 (77% yield). 1H NMR [499.8 MHz, CDCl3]: δ 
4.62-4.68 (m, 1H), 3.76 (dd, 1H), 3.54 (dd, 1H), 2.93 (dd, 1H), 2.80 (dd, 1H), 2.21-2.19 (m, 2H), 1.92-1.86 
(m, 2H), 0.95 (d, 3H), 0.93 (d, 3H). 
 ((3S,5R)-3-allyl-3-isobutylisoxazolidin-5-yl)methanol (36). To a solution of isoxazoline 35 (200mg, 
1.27mmol) in 10mL of toluene cooled to -78°C was added BF3•OEt2 (484µL, 3.82mmol) drop wise, and the 
solution was stirred for 30 minutes.  A 2.0M solution of allylmagnesium chloride (4.45mL, 8.91mmol) was 
next added drop wise.  After stirring for 4 hours, saturated NaHCO3 was added, and the solution was extracted 
with EtOAc. The organic extracts were combined, washed with H2O and brine, dried over Na2SO4, 
concentrated, and purified via flash column chromatography, yielding 230mg of isoxazolidine 36 (91% yield). 
1H NMR [499.8 MHz, CDCl3]: δ 5.87-5.80 (m, 1H), 5.12-5.08 (m, 2H), 4.21-4.17 (m, 1H), 3.69 (dd, 1H), 
3.53 (dd, 1H), 2.36 (dd, 1H), 2.24-2.19 (m, 2H), 1.84-1.77 (m, 1H), 1.62 (dd, 1H), 1.44 (dd, 1H), 1.38 (dd, 
1H), 0.94 (d, 3H), 0.92 (d, 3H). ESI-MS: Calc. Mass: 199.2 [M+Na]+:222.2. 
(3S,5R)-3-allyl-5-((tert-butyldimethylsilyloxy)methyl)-3-isobutylisoxazolidine (37). To a solution of 
isoxazolidine 36 (170mg, 0.85mmol) in 50mL of THF at 0°C were added DMAP (5.3mg, 0.0427mmol) and 
Et3N (166 µL, 1.19mmol), followed by drop wise addition of TBSOTf (274µL, 1.19mmol). The mixture was 
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next warmed to room temperature, and stirred for 2 hours. It was next cooled to 0°C and quenched with 
saturated NH4Cl, and extracted with Et2O. The combined organic extracts were next washed with brine, dried, 
and concentrated via rotary evaporation. Silica gel chromatography yielded 251mg of 37 (94% yield). 1H 
NMR [499.8 MHz, CDCl3]: δ 4.63–4.59 (m, 1H), 3.69–3.62 (m, 2H), 3.56 (dd, 1H), 2.88 (d, 2H), 2.37–2.25 
(m, 2H), 1.14 (t, 3H), 0.88 (s, 9H), 0.85 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 (s, 3H), 0.04 (s, 3H). ESI-MS: 
Calc. Mass: 313.2 [M+H]+:314.2. 
((3S,5R)-3-allyl-2-benzyl-3-isobutylisoxazolidin-5-yl)methanol (38). To a solution of 37 (220mg, 
0.702mmol) in 2 mL of DMF was added DIEA (367µL, 2.10mmol) followed by BnBr (417µL, 3.508mmol). 
The solution was next irradiated in a 1000 W microwave (5 x 15 s) @ 30% power with mixing after each 
cycle.  The reaction was then diluted with H2O, and extracted with Et2O (3X).  The organic extracts were 
combined and washed with H2O and brine, dried over Na2SO4, filtered, and concentrated via rotary 
evaporation. The crude residue was next dissolved and stirred in 1mL THF, and a 1.0M solution of TBAF 
(1.05mL, 1.05mmol) was added drop wise. This solution was stirred for 4 hours, at which point H2O was 
added, and it was extracted with EtOAc (3X). The combined organic extracts were washed with brine, dried, 
and concentrated. Silica gel chromatography provided pure 166mg of pure 38 (82% yield over two steps). 1H 
NMR [499.8 MHz, CDCl3]: δ 7.40-7.20 (m, 5H), 5.98-5.88 (m, 1H), 5.09-5.13 (m, 2H), 4.02-4.10 (m, 1H), 
3.90 (d, 1H), 3.83 (d, 1H), 3.61-3.54 (m, 2H), 2.45 (dd, 1H), 2.28 (dd, 1H), 2.18-2.24 (br s, 1H), 2.01-2.08 (m, 
1H), 1.87-1.93 (m, 1H), 1.62 (dd, 1H), 1.39 (dd, 1H), 0.98 (d, 3H), 0.97 (d, 3H). ESI-MS: Calc. Mass: 289.2 
[M+H]+:290.1. 
 
Linker Synthesis 
2-(2-(2-aminoethoxy)ethoxy)-N-(((3S)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-
yl)methyl)acetamide (RJC-6-6). To a solution of Fmoc-AEEA-COOH (2.6mg, 6.7µmol) in 100µL DMF was 
added DIEA (3.4µL, 20µmol), followed by PyBOP (3.56mg, 6.8µmol), and this mixture was stirred for 30 
minutes at room temperature. Next, a solution of RJC-6-3dep (1mg, 3.4µmol) with DIEA (3.4µL, 20µmol) 
was added, and this mixture allowed to stir for 16 hours. This mixture was extracted with ethyl acetate, and 
organic fractions were concentrated. To this crude residue was added 300µL of 20% piperidine in DMF, and 
! 205 
the resulting solution stirred for 30 minutes. Next, the mixture was diluted with methanol, extracted with 
pentane, and concentrated, followed by preparatory HPLC purification, providing 0.4mg of RJC-6-6 (27% 
yield). 1H NMR [499.8 MHz, CD3OD]: 7.38-7.21 (m, 5H), 4.27-4.17 (m, 1H), 4.00-4.90 (m, 4H), 3.79-3.72 
(m, 3H), 3.61-3.43 (m, 6H), 3.37 (dd, 1H), 3.00 (t, 2H), 2.45 (dd, 1H), 2.07-1.98 (m, 1H), 1.90 (t, 2H), 1.85-
1.66 (m, 2H), 1.45 (dd, 1H), 1.0 (d, 3H), 0.96 (d, 3H). ESI-MS: Calc. Mass: 437.3 [M+H]+:438.3. 
tert-butyl 1-((3S)-2-benzyl-3-(2-hydroxyethyl)-3-isobutylisoxazolidin-5-yl)-3-oxo-6,9,12,15-tetraoxa-2-
azaheptadecan-17-ylcarbamate (41). To a solution of 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-
azaicosan-20-oic acid (12.5mg, 34.3µmol) in 300µL DMF was added DIEA (11.91µL, 68.4µmol) and PyBOP 
(18.2mg, 35.0µmol). This solution was stirred at 45°C for 30 minutes. Subsequently, a solution of RJC-6-3dep 
(5mg, 17µmol) with DIEA (5.96µL, 34.2µmol) was added to the activated PEG linker solution. This mixture 
was allowed to stir overnight. Water and brine were added, and the mixture was extracted with EtOAc (3X), 
dried, and concentrated. Purification via preparatory TLC afforded 8.1mg of the desired compound 41 (74% 
yield). 1H NMR [499.8 MHz, CDCl3]: 7.38-7.24 (m, 5H), 4.12-4.05 (s, 1H), 3.94-3.81 (m, 2H), 3.72-3.44 (m, 
8H), 3.41-3.30 (m, 2H), 3.28-3.20 (m, 1H), 2.46-2.19 (m, 4H), 1.93-1.80 (m, 2H), 1.68-1.59 (m, 1H), 1.44 (s, 
9H), 1.41-1.32 (m, 1H), 1.24 (s, 2H), 0.98 (t, 6H). ESI-MS: Calc. Mass: 639.4 [M+H]+:640.3 
 
Cell Culture 
 
 All cell lines were purchased from ATCC (Manassas, VA) and maintained in the 
following media: A549 cells (F-12K); LNAR+ (RPMI 1640); HCT-116 (McCoy’s 5a 
Medium Modified); MCF-7 (Eagle’s Minimum Essential Medium). All media were 
supplemented with 10% FBS and cultured at 37°C under 5% CO2. 
 
LNAR+ Luciferase Experiments 
 LNAR+ cells were plated in 96-well plates at a density of 50,000 cells per mL 
(5,000 cells/well) in RPMI 1640 medium (ATCC) supplemented with 10% FBS (Irvine 
Scientific, Santa Ana, CA) and 4 mM penicillin/streptomycin. After 24 h, the medium 
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was replaced with RPMI 1640 medium containing 10% charcoal-stripped FBS, 4 mM 
penicillin/streptomycin, and polyamides at varying concentrations in quadruplet. Cells 
were grown for an additional 34 h before treatment of induced wells with 1nM 
dihydrotestosterone (DHT) for 6 h. After 40 hours total polyamide treatment, 10µL WST-
1 reagent was added, and cells were incubated at 37°C with gentle shaking for 30 min, 
before measuring the absorbance at 450 nm. Next, cells were lysed by addition of 100µL 
of Glo Lysis Buffer (Promega), incubated 5 minutes, then 100µL of each well was added 
to a separate opaque-walled 96-well plate containing 100µL Bright-Glo™ reagent, mixed 
briefly and gently, and immediately imaged for luminescence. 
 
Measurement of dexamethasone-induced mRNA.  
 RNA isolation: A549 cells (ATCC) were plated in 24-well plates at a density of 
20-25 x 103 cells per well (40-50 x103 cells per mL) in F12-K medium (ATCC) 
supplemented with 10% FBS (Irvine Scientific, Santa Ana, CA) and 4 mM 
penicillin/streptomycin. After 24 h, the medium was replaced with F12-K containing 
10% charcoal-stripped FBS, 4 mM penicillin/streptomycin, and polyamides or 
mifepristone at the designated concentrations. Cells were grown for an additional 48 h 
and then treated with 100 nM dexamethasone for 6 hours. The medium was removed, 
cells were washed with ice-cold PBS and immediately lysed with RLT buffer from an 
RNeasy kit (Qiagen). Further RNA isolation was carried out with the RNeasy kit as 
described in the manufacturer’s manual. The isolated total RNA was quantified. The 
yields were 12-15 µg per well.  
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 Reverse transcription: A 2.5 µg sample of total RNA was used to reverse 
transcribe cDNA using Superscript II reverse transcriptase (Invitrogen) according to the 
manufacturer’s protocol. Random hexamers were used as primers. The total volume for 
each RT reaction was 20 µL.  
 Real-time quantitative RT-PCR: Analysis was performed using the GILZ gene 
primers described below, purchased from Integrated DNA Technologies Quantitative 
real-time RT-PCR was performed with SYBR 66 Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) following the manufacturer’s suggested protocol. 
Temperature cycling and detection of the SYBR Green emission were performed with an 
ABI 7300 real-time instrument using Applied Biosystems Sequence Detection System 
version 1.2. Statistical analysis was performed on three independent experiments. mRNA 
of the genes of interest were measured relative to β-glucuronidase as an endogenous 
control. Primer sequences were designed using Primer3.  
 To amplify the 97-bp fragment from the 3’-translated region of GILZ:  
Forward primer: 5’- CTCCCCGTTTGTTTTTCTCA -3’  
Reverse primer: 5’- TGCTCCTTCAGGATCTCCAC -3’  
 To amplify the β-glucuronidase gene as an endogenous control:  
Forward primer: 5’- CTCATT TGGAATTTTGCCGATT -3’  
Reverse primer: 5’- CCGAGTGAAGATCCCCTTTTTA -3’ 
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